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 ABSTRACT 
 
CT Perfusion (CTP) provides measurement of perfusion at the capillary level which can 
be used to characterize tissue viability, and blood-brain-barrier (BBB) compromise. Using 
CTP, the goals of this research are to: 1) select patients that will benefit from acute stroke 
treatment, and 2) determine if pre-stroke neuroprotection reduces stroke severity.   
 Chapter two investigates the cerebral blood volume (CBV) parameter in a small 
acute ischemic stroke (AIS) patient set. Overestimation of the acute CBV defect is caused 
by incomplete wash-out of the CT contrast due to a shortened CTP acquisition time 
(“truncation artifact”).   
 In chapter three we examine the prognostic reliability of the acute CBV defect to 
predict infarct core and penumbra in AIS. We determine that hypervolemia, the 
“truncation artifact” and recanalization are all important variables which affect the 
relationship between the acute CBV defect volume and the final infarct volume.  
 Chapter four implements a novel porcine model of ischemic stroke using the 
transient vasoconstrictor, endothelin-1. Using this model, we show that the CTP-cerebral 
blood flow (CBF) parameter is as good as MR-DWI for acute infarct core delineation, 
and the CBF/CBV mismatch may not indicate penumbral tissue in the acute stroke 
setting.  
  In Chapter five, it we show that vascular integrity measured with the CTP-BBB 
permeability surface area product (PS) is a strong predictor of sub-acute bleeding in the 
brain (hemorrhagic transformation).  
 Chapter six shows that different rates of CT contrast extravasation exist for 
primary intracerebral hemorrhage (ICH) patients with/without the CTA-Spot Sign and/or 
  
iii 
 
post-contrast leakage. Furthermore, early rates of extravasation are correlated with sub-
acute hematoma expansion.  
 Chapter seven describes the development of an improved, reproducible and 
survivable rabbit large clot embolic model (RLCEM) of cerebral ischemia for testing 
treatment options for AIS. We demonstrate that pre-stroke treatment with dipyridamole 
provides a neurovascular advantage post stroke onset.  
 In summary, the current uses of CTP imaging in acute stroke include: 1) 
quantifying ischemia to define infarct core and penumbra in AIS, 2) predicting 
hemorrhagic transformation of AIS, 3) predicting hematoma expansion in primary ICH, 
and 4) assessing treatment response in animal models of stroke to facilitate new drug 
development.  
 
 
 
 
 
 
 
Keywords: 
Stroke, CT Perfusion, cerebral ischemia, primary cerebral hemorrhage, secondary 
hemorrhagic transformation, cerebral blood flow, cerebral blood volume, infarction, 
hematoma expansion, animal stroke model, primary stroke treatment, tPA 
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CHAPTER 1  
 
1.1 INTRODUCTION 
According to the World Health Organization (WHO), stroke is the world leading cause of 
long-term morbidity, and the third leading cause of death in developed countries
1
. Over 
the past two decades, there has been an overall reduction in stroke-related deaths in North 
America; however, within certain racial groups and gender cohorts, stroke incidence and 
severity has worsened during this time
2-6
. Over the next 40 years, the number of incident 
strokes will more than double, with the majority of the increase occurring in individuals 
age 75 and older
7
. Although prevention is the most effective method for mitigating stroke 
burden, acute treatment and long-term care remains the current focus for improving 
stroke outcome. The expected number of stroke survivors living with permanent disability 
will rise dramatically if acute treatment strategies are not improved; the degree of 
disability is linked to early treatment response. Further, as long term care remains the 
dominant cost for all stroke patients, effective acute treatment could minimize the social 
and economic burden of cerebrovascular disease in the future
8
.  
 
1.2 STROKE PATHOPHYSIOLOGY 
Stroke is caused by variable disturbances in blood flow to intracranial brain tissue due to 
blockage of supplying vessels and/or leakage of blood from damaged vessels. These 
cerebrovascular accidents can result in transient or long term neurological deficit, 
depending on the ictus duration and the area of affected brain. The WHO determined that 
the global incidence of stroke is ~200 per 100,000 people
9
. Ischemic stroke accounts for 
2 
 
 
 
~87% of strokes in North American, while primary intracerebral hemorrhage (ICH) 
accounts for ~13%
10
. Of the people who suffer an ischemic stroke, approximately 20% 
will die, and 55% will be left with some form of disability that does not permit 
independent living
11
. For patients with primary ICH, the 30 day mortality rate ranges 
from 40% to 50%, with some form of  long term morbidity present in almost all 
survivors
12
.  
 
1.2.1 Cerebral ischemia 
Cerebral ischemia is a sudden decrease in brain blood flow, resulting in the alteration of 
cellular function. With interruption of oxygen and glucose rich arterial flow, electrically 
active neurons and supporting glial cells are unable to maintain basal functions needed to 
stay alive
13
.  
 Cerebral ischemia has various arterial etiologies. The most common of which is 
thrombosis, the formation of a blood clot secondary to general endothelial injury or 
rupture of an atherosclerotic plaque
14
. Occasionally breaking away from the site of 
thrombosis, single or multiple thromboemboli can travel to the brain causing focal 
ischemia; clot consistency (variations of fibrin-platelet bridging and red blood cell 
adherence) will affect response to acute treatment and overall stroke severity
15
. The heart 
is also a major source of cerebral emboli, produced by the left atrium in patients with 
atrial-fibrillation (blood becomes static due to weak, irregular heartbeats) or recent 
cardiac surgery (clots may form via the external coagulation cascade around the surgical 
site). Moreover, systemic hypoperfusion, as a result of a general decrease in mean arterial 
pressure caused by any myocardial dysfunction, can lead to ischemia in the distal 
territories of the cerebral arterial tree, known as watershed stroke
16
. The Trial of Org 
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10172 in Acute Stroke Treatment (TOAST) criteria allows investigators to report 
responses to treatment among important sub-groups of patients with ischemic stroke. The 
TOAST classification denotes four subtypes of ischemic stroke: large-artery 
atherosclerosis, cardio-embolism, small-vessel occlusion, and stroke of other 
determined/undetermined etiology
17
. Regardless of the cause, a reduction in blood supply 
to the brain creates a homeostatic imbalance in pH, temperature, overall nutrition, and 
waste removal, the first steps towards cellular dysfunction
18
. 
More than 70% of all energy use in the brain is to maintain the neuronal 
membrane voltage gradient via active, facilitated transport of Na
+
/K
+
. This gradient is 
fundamental for electrical and chemical signaling via action potential propagation. During 
ischemia, if cellular respiration is no longer capable of adequate ATP production, 
intracellular ATP is depleted within minutes due to this energy-consuming process. This 
first stage of the “ischemic cascade” causes neuronal depolarization, due to the influx of 
Ca
2+
 and Na
+   
ions, and the efflux of K
+
 ions
19
. The increase in intracellular Ca
2+
 triggers 
the release of glutamate, an excitatory neurotransmitter, which activates several enzymes 
involved in the lysis of proteins, lipids and nucleic acids. Moreover, sustained 
depolarization of neighbouring neurons, called spreading depression, is enhanced with the 
failure of glutamate re-uptake, and further Ca
2+
 influx
20
. This state of cellular excitation 
leads to neuronal apoptosis or necrosis, which depends on the damage intensity caused by 
an onslaught of increasing inflammatory, oxidative and nitrative stressors
21
. 
The understanding of the ischemic cascade brought forth distinct definitions of 
tissue status during hyper-acute cerebral ischemia. Within the most hypoperfused 
territory, called the ischemic or infarct core, cells are irreversibly damaged; even upon 
reperfusion, these cells are no longer viable
22
. Across species, the threshold for 
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irreversible neuronal death has been identified as a CBF value of approximately 8-10 
ml·min
-1
·(100g)
-1 23-27
. The infarct core, consisting of apoptotic/necrotic tissue, is 
surrounded by a variably sized tissue region with blood flow above the threshold to 
induce immediate infarction – the ischemic penumbra. The original definition of this 
tissue state is based on the absence of electroencephalography (EEG) signals and sensory 
evoked potentials with maintenance of membrane pump function and ionic gradients 
retained at near normal levels
28, 29
. Due to this electrical silence (neurons are unable to 
transmit signals), clinical symptoms relating to the affected tissue region are apparent; 
therefore, it is impossible to discern the amount of viable penumbral tissue based on 
clinical symptoms alone. The survival of penumbral tissue on the border zone of 
infarction is largely dependent on leptomeningeal collateral supply, as well the degree of 
peri-infarct depolarization
30
. If blood flow is not restored promptly, the viable ischemic 
penumbra invariably progresses to infarction; however, with reperfusion in a timely 
manner, this tissue will fully recover, along with clinical function –  the so-called “time is 
brain” paradigm31. Depending on the technique for measuring CBF, the upper threshold 
for electrical silence and neuronal dysfunction occurs at a CBF of 22-25 ml·min
-1
·(100g)
-
1 26
. The duration of ischemia will determine tissue fate below this threshold
32
. A third 
tissue state is described as having a CBF above the upper threshold for neuronal 
dysfunction, but lower than normal CBF values, called benign oligemia. Regardless of the 
duration of ischemia, this tissue does not progress to infarction and maintains normal 
cellular function, in spite of slight hypoperfusion
33
.  
The cerebrum is composed of two distinct tissue types, gray and white matter
34
. 
Gray matter predominates in the cortex and deep nuclei of the brain, composed of 
unmyelinated axons, neuronal cell bodies, dendrites and glial cells
35
. White matter 
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consists of mainly of glial cells and myelinated axonal tracts, which allow neural signals 
to travel quickly between the cerebrum and other brain regions
34
. In resting gray matter, 
average CBF values are approximately 50-60 ml·min
-1
·(100g)
-1
, whereas white matter 
values are closer to 20-25 ml·min
-1
·(100g)
-1 36
. This substantial discrepancy in flow 
values is mainly because white matter synapse activity consumes ≤ 0.5% of the energy of 
gray matter synapses
34
. It follows that white matter may be more tolerant to ischemia than 
gray matter, as there is a greater relative decrease in CBF from normal in gray matter than 
in white matter
37
. Further, since gray matter has a higher metabolic demand, it can be 
expected that the damage would occur earlier and be more severe than white matter for a 
given CBF. At the cellular level, the ischemic cascade also differs between gray and 
white matter. Gray matter infarction is facilitated primarily through glutamate 
excitotoxicity, as described in the previous section. White matter is deficient in glutamate 
receptors, and Ca
2+
 enters the cell through a reversal of the Ca
2+
 -Na
+
 ion exchanger
25, 38
. 
This disparity could affect the efficacy of therapeutic strategies targeting the ischemic 
cascade, depending on what region of the brain is affected. A recent study has shown that 
ischemic vulnerability is location-specific; a 60% reduction in rCBF within highly 
vulnerable locations (the putamen, frontal gyri, and insular ribbon) distinguishes infarct 
core, whereas an 85% reduction in rCBF distinguishes infarct core in the remainder of the 
brain
39
. 
The first perfusion thresholds to define infarct and penumbral tissue focused 
mainly on gray matter because animal stroke models were used; lower rodents, typical of 
many stroke studies, have a much lower white/gray matter ratio compared to humans and 
higher primates
40
. Further, thresholds originating from humans frequently use regions 
with combined gray and white matter, which could lead to under/overestimation of 
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infarcted tissue in subsequent prospective studies. Since gray and white matter have very 
different basal perfusion and thresholds for damage to occur, both pre-clinical and clinical 
studies on ischemic damage should define separate thresholds for gray and white matter.  
 
1.2.2 Hemorrhagic transformation of cerebral ischemia 
Hemorrhage occurs when blood is abnormally present in brain parenchyma or cerebral 
spinal fluid. This may occur due to a number of vasculopathies associated with trauma, 
vascular abnormalities, tumours or impaired coagulation; however, several studies have 
demonstrated the tendency of embolic ischemia to undergo hemorrhagic transformation
41-
44
. Hemorrhage in an area of ischemia occurs when blood extravasates through vessel 
walls with compromised integrity and increased permeability, commonly caused by the 
restoration of perfusion to the site of ischemic injury. The risk of hemorrhage secondary 
to acute ischemic stroke (AIS) occurs in 2.2%–44.0% of patients, and is the single most 
important risk factor to consider in deciding whether thrombolytic therapy should be 
given
11, 45-47
. AIS-related hemorrhage is divided into parenchymal hemorrhage (PH) and 
hemorrhagic infarction (HI), the former increasing mortality risk by 10-fold
48
. While 
more severe hemorrhage is undoubtedly associated with worse outcome, there is 
controversy whether less severe forms of hemorrhage are clinically important, indicative 
of successful reperfusion
48-52
. Some investigators believe non-PH hemorrhagic 
transformation may represent a clinically irrelevant epiphenomenon, with different 
pathogenesis
53
. If this is the case, the ability to predict PH, the symptomatic hemorrhage 
sub-type, at the acute stroke phase is critical to guide early treatment. Several groups have 
explored the use of biomarkers, as well as CT and MRI imaging in an attempt to predict 
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secondary hemorrhage; however, low sensitivity and specificity have limited their use in 
acute triage
43, 54-59
.  
 
1.2.3 Primary intra-cerebral hemorrhage 
ICH is an extravasation of blood into the brain parenchyma originating from the 
spontaneous rupture of small vessels damaged by chronic hypertension, amyloid 
angiopathy, or iatrogenic causes. The primary injury occurs within minutes of bleeding 
and is largely the result of mechanical damage associated with edema and subsequent 
mass effect.  After the initial rupture, the hematoma can continue to expand over several 
hours through the primary arterial leakage or mechanically injured surrounding vessels; 
there is an exponential increase in mortality when the hematoma volume exceeds 30 
milliliters
60
. The cause of early hematoma expansion is unknown, but secondary vessel 
injury and peri-hematomal ischemia have been implicated
61
. The degree of expansion is 
related to both acute hypertension and the innate coagulation efficiency
62
. Pro-thrombin 
cleavage, an essential step in the coagulation cascade, evokes a local inflammatory 
reaction responsible for brain swelling and clinical deterioration
63
. Thrombin has been 
shown to be neurotoxic via glutamate-mediated excitotoxicity, causing spreading 
depression and overall disruption of the blood–brain barrier and neuronal death64. Further, 
red blood cell breakdown products, hemoglobin and the iron constituent, are cytotoxic via 
the generation of free radicals causing oxidative damage to enzymes, nucleic acids, and 
lipids within cells of the neurovascular unit
65
. During the sub-acute stage, these 
mechanisms may also contribute to secondary ischemic injury, leading to the 
development of a peri-hematomal ischemic penumbra, especially in patients with 
therapeutically reduced blood pressure to treat the initial ICH episode
66
. Investigators 
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have confirmed the existence of this penumbra after ICH; however, contrary to the 
definition of penumbral tissue, recent imaging studies have shown that this delayed 
hypoperfusion is accompanied by a decrease in metabolic demand and lowered, not 
elevated, oxygen extraction fraction
67, 68
. Nonetheless, peri-hematomal ischemia may still 
represent a therapeutic target for patients with ICH.  
 
1.3 STROKE TREATMENT 
Only in the last couple of decades, treatment of stroke has progressed from basic life 
support at the time of onset, to administration of advanced neuroprotective therapies. For 
both thromboembolic cerebral ischemia and ICH, protecting and salvaging brain tissue 
during the acute stroke setting is vital to regulate stroke severity. The acute imaging 
assessment, typically a CT scan, informs clinicians on the appropriate treatment course, 
depending on stroke etiology (ischemic or hemorrhagic) and whether prior stroke has 
occurred. Identical treatment regimens may be beneficial for one stroke sub-type, while 
detrimental for another. Even individuals with similar stroke etiologies may also respond 
differently to the same treatment. Therefore, establishing individualized approaches to 
acute stroke management will improve outcome.    
 
1.3.1 Ischemic stroke  
The identification of reversibly damaged tissue during the acute stroke setting has led to 
several early treatment strategies aimed to slow the progression of compromised tissue 
towards infarction. Although prompt treatment is beneficial, it is currently known that the 
penumbra can remain viable for up to 12 hours or more in some patients
69
. Therefore, 
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strategies to return blood flow during the first few hours of onset, as well as to preserve 
neuronal integrity during the sub-acute stroke setting are imperative. 
 Early restoration of blood flow using thrombolytic therapy is an effective way to 
reverse ischemic stroke. Thrombolytic agents (mainly fibrinolytic enzymes) activate the 
endogenous protein plasminogen to breakdown fibrin, the structural scaffold of most 
blood clots. However, the negative pleiotropic effects of these agents may increase the 
probability of hemorrhage through the degradation of important clotting factors, and 
disruption of the blood-brain barrier
70
. Nonetheless, evidence from the National Institute 
of Neurological Disorders and Stroke (NINDS) tissue plasminogen activator (tPA) study, 
showed that tPA administered within the first three hours after stroke  significantly 
improved the average neurological outcomes in a large cohort of patients; this result was 
sufficient for the Food and Drug Administration (FDA) of the United States to approval 
tPA in 1996
11
. Patients treated with intravenous (IV) tPA up to 3 hours post ictus were 
30% more likely to have minimal or no disability compared to those receiving placebo. 
However, this strict time constraint has limited the use of tPA in less than 7% of AIS 
patients, as the risk of hemorrhagic transformation outweighed the clinical benefit beyond 
the 3-hour treatment window
71, 72
. Several important studies have investigated the use of 
tPA beyond the 3 hour treatment window, namely: the 2008 European Cooperative Acute 
Stroke Study (ECASS) III, followed by a similar study in 2009 examining a broad range 
of sub-groups of patients, both comparing groups given alteplase or placebo 3 hours post 
ictus
73
; observational studies investigating the Safe Implementation of Treatments in 
Stroke (SITS) through an internet-based audit of the International Stroke Thrombolysis 
Registry (ISTR), and the Canadian Alteplase for Stroke Effectiveness Study (CASES), 
both comparing patients receiving alteplase before and after the 3 hour window 
44, 73-75
. 
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Consensus was that IV-tPA has proven benefits if administered up to 4.5 hours from 
stroke onset. Only recently, the IV- tPA therapeutic window was extended to 4.5 hours 
from stroke onset
45, 76
. Nonetheless, the ECASS III study did report a significant 
difference in intracranial hemorrhage for patients given alteplase, yet mortality did not 
differ between the treated and the placebo group
75
. The Simplified Management of Acute 
Stroke Using Revised Treatment (SMART) criteria study is ongoing, including all stroke 
patients for thrombolysis in a time window up to 4.5 hours, with hemorrhage being the 
only exclusion criterion
77
.  
 Intra-arterial (IA) delivery of tPA to the site of occlusion (as opposed to a 
systemic IV delivery) has also been shown to be beneficial
78
. An advantage of IA-tPA 
treatment is the reduced systemic exposure, which allows for a higher concentration of 
tPA at the site of occlusion. Early studies showed that IA-tPA may be beneficial up to six 
hours after stroke onset, resulting in increased recanalization rates, and no increase in 
mortality, compared with controls
79
. Combining IV and IA-tPA has also been tested, with 
moderate improvement in clinical outcome
79
.   
Current alternatives to thrombolysis are the Mechanical Embolus Removal in 
Cerebral Ischemia (MERCI) device and Penumbra clot retrieval device, which are 
approved  to be used up to 8 hours post stroke onset, and are the only treatments available 
after the 4.5 hour IV-tPA treatment window
80, 81
. These devices mechanically remove the 
thrombus/embolus from the involved vessel, a process known as thrombectomy or 
embolectomy. Both devices have high reperfusion rates and low rates of secondary 
intracranial hemorrhage; however, sample sizes of those trials were small
82
.  
A second approach for improving neurological outcome following ischemic stroke 
is to use agents which interfere with the ischemic cascade, with the goal of slowing, or 
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even stopping the progression of penumbra to infarction. Many of these drugs were 
successful when applied to animal models, but failed in the clinical arena, resulting in 
skepticism to further research and development in this domain
83
. Pre-clinical studies 
assessing possible neuroprotectants often used young, healthy animals, whereas clinical 
subjects are typically over the age of 60 and may present with a number of confounding 
conditions such as atherosclerosis, hypertension, small vessel disease, diabetes and other 
neurovascular disorders. Further, different proportions of gray and white matter between 
humans and animals may further contribute to the lack of efficacy in humans trials, as 
both tissue types have different responses to ischemia, as described in a previous section. 
 One drug which actually showed promise in the clinical setting came out of the 
SAINT-1 trial, which investigated the free-radical trapping agent NXY-059
84
. A 72-hour 
infusion of NXY-059 significantly reduced disability 3 months later, and showed a 
reduction in the rate of secondary intracerebral hemorrhage when compared to patients 
given placebo. However, an attempt to repeat these promising results in a phase III trial 
indicated no significant benefit in neurological outcome.  Another recent neuroprotectant 
tested in the Evaluating Neuroprotection in Aneurysm Coiling Therapy (ENACT) trial, 
NA-1, has been successful for reducing the volume of strokes after middle cerebral artery 
occlusion in non-human primates
85
. In a randomized control trial of 197 patients, NA-1 
reduced the number of peri-procedural ischemic strokes, as detected by MR imaging, in 
patients undergoing endovascular repair of intracranial aneurysms
86
.     
Pre-morbid use of antiplatelet drugs may also offer a neuroprotective benefit via 
antithrombotic and anti-inflammatory pleiotropic mechanisms during the acute stroke 
setting
87
. Well-established in their ability to prevent impending stroke, the effectiveness 
of pre-morbid administration to reduce stroke severity is still debated
88
. Discrepancies 
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between studies can be attributed to inadequate outcome measurements, small sample 
sizes, and variable baseline characteristics between patients, including inconsistent dosing 
regimens
89
. Therefore, controlled experiments are needed to determine the relationship of 
anti-platelet drugs on stroke outcome.  
  Without the need to administer therapeutic agents, cooling the body by ~3-5 
degrees Celsius after stroke onset has been shown to be beneficial in animal models and 
clinical studies
90, 91
. Hypothermia decreases the cellular metabolic rate in both gray and 
white matter, which coincides in a reduction in free radical formation and suppression of 
elevated intracellular calcium – these mechanisms slow the cytotoxic cascade90. 
Nonetheless, hypothermia in the acute stroke setting is logistically difficult to achieve and 
sustain. Improvements in cooling techniques continue to be made
92
.  
Regardless of the potential of various ischemic stroke therapies, improved 
functional outcome can only be achieved if treated patients have the necessary 
prerequisites for improvement. That is, the presence of a substantial volume of reversibly 
damaged penumbra. Without a relative abundance of salvageable tissue, acute stroke 
treatment is futile, and may at times be more detrimental to patient outcome.   
 
1.3.2 Primary intracerebral hemorrhage  
Although the pathologic progression of primary ICH is distinct from thromboembolism 
induced ischemia, the “time is brain” paradigm still applies with respect to acute 
treatment. Systolic hypertension, greater than 140 mm Hg, and increases in intracranial 
pressure (ICP) after ICH may be associated with hematoma expansion and has been 
shown to double the risk of dependency and death
93
. Therefore, aggressive blood pressure 
(BP) reduction, via the combination of hyperventilation and mannitol infusion has been 
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employed clinically. Hypertension, causing a decrease in blood carbon dioxide tension 
initiating vasoconstriction, decreases the volume of blood within the rigid cranial cavity, 
while mannitol elevates plasma osmolarity, pulling water (brain edema) into the 
vasculature for clearance – both strategies directly decrease ICP94, 95. Nonetheless, 
clinicians are cautious not to be overaggressive with BP treatment as secondary ischemic 
injury caused by a global decrease in cerebral perfusion pressure is possible
96
.  
 In 2005, a phase II study showed that treatment with a powerful hemostatic agent, 
recombinant factor VII, within 4 hours of ICH significantly lessened hematoma 
expansion, reducing mortality and improving functional outcome at 3 months; although 
there was a small increase in thromboembolic complications with incremental doses
97
. In 
spite of these early positive results, the phase III trial (Factor VII for Acute Hemorrhagic 
Stroke) failed to show improvement in severe disability and mortality rates within the 
treated cohort
98
.  
 Current research on neurosurgical interventions focuses on minimally invasive 
surgery and intra-ventricular clot fibrinolysis to mitigate hematoma expansion and 
improve clinical symptoms have been promising; however, results from studies 
examining the benefit of hematoma evacuation and clot aspiration were contradictory in 
terms of functional outcome improvement
99-101
. The randomized Surgical Trial in Lobar 
Intracerebral Hemorrhage (STICH) trial found that early surgery is ineffective 
corroborating other reports which suggested craniotomy and clot evacuation lead to 
higher re-bleeding rates
102, 103
. Consequently, the STICH II-trial set out to establish 
whether earlier surgical evacuation of the hematoma in patients with spontaneous lobar 
ICH would improve outcome compared to initial conservative treatment – recruitment for 
this trial is underway
100
. Clearly, controlled randomized trials are needed to further 
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explore and develop therapies to minimize hematoma expansion, peri-hematomal 
edema/ischemia and secondary neuronal damage.  
 
1.4 MEDICAL IMAGING IN STROKE 
In the past 40 years, the use of medical imaging to distinguish stroke sub-types has 
become a mainstay at almost all medical institutions, revolutionizing acute diagnosis and 
treatment, as well as improving prediction of long term patient outcome. For both clinical 
and experimental stroke, details of the anatomical structure and function of the brain are 
currently possible with multi-modal imaging. Computed tomography (CT), magnetic 
resonance imaging (MRI), and positron emission tomography (PET) have helped guide 
acute stroke triage and advanced our knowledge of pathophysiological mechanisms 
guiding stroke treatment strategies. 
 
1.4.1 Positron emission tomography  
PET imaging provides functional, metabolic and molecular information at the cellular 
level, and is the current clinical gold standard for measurement of cerebral hemodynamics 
and metabolism. As a highly sensitive imaging modality, localization of nanomolar 
concentrations of a radioactively labeled biological molecule, called tracers, is achieved 
through the coincident detection of gamma rays resulting from positron annihilation. 
These tracers can be used to measure various hemodynamic and metabolic processes of 
interest to diagnosis of stroke, including cerebral blood flow (CBF), cerebral blood 
volume (CBV), and cerebral metabolic rate of oxygen (CMRO2). Acute tissue states 
defined by these PET parameters have been well established. A matched decrease in CBF 
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and CMRO2, measured with 
15
O-labeled water and oxygen, respectively, represents non-
viable tissue
104
. Penumbra is tissue with maintained CMRO2, with CBF below the 
threshold needed for basal neuronal function, a phenomenon termed ‘misery 
perfusion’105. Measuring the cerebral metabolic rate of glucose with 18F-2-fluoro-2-
deoxy-d-glucose (
18
F-FDG) has been shown to discern between viable and non-viable 
tissue during the acute stroke setting
106
. Moreover, monitoring glucose metabolism yields 
information about the degree of glycolysis, discerning between aerobic and anaerobic cell 
states. Even with these well-established definitions for tissue status, several drawbacks 
exist when using these PET parameters, mainly the need for a PET scanner with a 
cyclotron close by (the half-life of 
15
O is ~2 minutes), rapid arterial sampling to obtain 
accurate quantitative values, and the overall poor resolution which affects infarct volume 
measures and tissue segmentation.  These requirements make it difficult to compare CBF 
and CMRO2 values, derived from PET, with values from other imaging modalities.   
More recently, tracers have been developed to target cell surface receptors on 
neurons, inflammatory cells, and the blood-brain-barrier allowing for specific pathways 
and physiological states to be examined. One such tracer, 
18
F-labeled Flumazenil (
18
F-
FMZ), binds to a subunit of the central benzodiazepine GABA receptor on healthy 
neurons; however, these receptors are only present in cortical gray matter, limiting its 
effectiveness to discriminate white matter lesions. Another tracer, 
18
F-labeled 
fluoromisonidazole (
18
F-MISO), has been shown to identify hypoxic tissue, and 
independently delineate ischemic penumbra
107
. Inflammation during the sub-acute stroke 
setting can also be observed using 
11
C-PK11195, which binds to activated microglial cells 
within the brain
108
. A possible relationship between neuroinflammatory reaction and 
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integrity of white matter tracts has recently been investigated by combining microglia 
PET with diffusion tensor imaging
109
.  
 PET imaging in acute stroke remains limited to research studies in academic 
centers due to its cost, and logistical/technical complexities. PET tracers and scanners will 
continue to evolve, but it is unlikely that PET will see widespread clinical use for acute 
stroke patients in the near future. Nonetheless, PET will remain instrumental in the 
validation of other imaging techniques and the understanding of the pathophysiology of 
stroke. 
 
1.4.2 Magnetic resonance imaging 
MRI is a multi-faceted imaging modality used frequently for acute stroke diagnosis and 
prognosis. Recent studies indicate that MRI, particularly diffusion-weighted imaging 
(DWI) and gradient-recalled echo (GRE) sequences are as sensitive as CT for detecting 
ICH in the acute setting
110
. The DWI sequence has also been shown to have a greater 
sensitivity for detecting acute ischemic changes, especially in patients with transient 
ischemic attack
111
. Further, magnetic resonance angiography (MRA) can be used to 
assess intra- and extra-cranial vessel patency, while perfusion-weighted imaging (PWI) 
can describe the cerebral hemodynamics in all stroke sub-types
112
.   
DWI is one of the most sensitive methods for identifying very early ischemic 
changes. The hyperintense lesion is caused by reduced brownian motion (diffusion 
restriction) of water molecules as a result of swollen, edematous cells caused by 
cytotoxicity
113
. This defect is a downstream effect of hemodynamic dysfunction, and 
cellular ion pump failure, one of the final steps towards irreversible tissue damage. 
Nonetheless, recent reports have shown complete reversal and recovery of tissue that was 
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initially hyperintense on acute DWI
114, 115
. Moreover, DWI abnormalities have been 
shown to disappear then recur within hours and days following and ischemic episode in 
both animal and clinical studies
113, 114, 116
. In spite of these inconsistencies, the DWI 
sequence remains an important imaging modality to define hyper-acute and sub-acute 
ischemic changes. 
To complement the DWI sequence, the PWI acquisition requires the intravenous 
injection of the paramagnetic contrast agent, gadolinium-DTPA. This dynamic sequence 
provides functional maps for relative cerebral blood flow (rCBF), cerebral blood volume 
(CBV), and time to peak (TTP)
117, 118
. PWI cannot provide accurate absolute CBF values 
due to the non-linear relationship between signal intensity and contrast concentration and 
difficulties in obtaining accurate artery input function
119
. Thresholds of TTP and rCBF 
have been shown to discriminate tissue at risk of infarction, though there is no consensus 
on the optimal parameter or threshold
27, 37, 117, 120-123
. By combining the PWI and DWI 
images, the PWI/DWI mismatch is also a commonly used working definition of the 
ischemic penumbra by identifying the difference between viable tissue at risk and tissue 
that is irreversibly damaged, given by the DWI lesion; however, recent studies have 
shown that milder perfusion defects are experiencing benign oligemia, insufficient to 
produce infarction
124
.  
MR imaging of blood-brain-barrier permeability has also become an important 
tool for prediction of hemorrhagic transformation of ischemic stroke. Several MR-
permeability studies have shown that increased permeability at admission is associated 
with hemorrhage at later times secondary to ischemia
118, 125, 126
.  
Compared to PET imaging, MRI is more readily available in the setting of acute 
stroke and does not require a radioactive substance to be injected. Further, most 
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sequences, unlike CT, are able to cover both supra- and infra-tentorial brain regions, 
allowing a more robust diagnostic imaging window and increased prognostic sensitivity. 
In terms of patient throughput, individuals who are claustrophobic, or have metal 
implants and pacemakers are excluded from MR imaging. Further, MRI scanners have 
limited availability, primarily accessible at large city hospitals or academic centers. 
Nonetheless, the absence of harmful ionizing radiation and the ability to discern very 
early ischemic changes makes the MR imaging an important modality in acute stroke 
triage.  
 
1.4.3 Computed tomography imaging 
CT imaging is a diagnostic tool that is widely available, relatively inexpensive compared 
to its MRI counterpart, non-invasive and fast. The acute CT imaging stroke series 
generally consists of a non-contrast CT (NCCT), followed by CT angiography (CTA), for 
patients with stroke symptoms.  
 
1.4.3.1 Non-contrast CT 
Improvements in the quality of the CT images and further experience in NCCT images 
currently allow for a number of subtle changes to be appreciated prior to complete 
infarction, as well as reliable diagnosis of ICH. Petechial hemorrhage, the loss of gray-
white matter differentiation, cortical swelling, and obscuration of the insular ribbon, basal 
ganglia, and internal capsule can be seen within a few hours of stroke onset
127, 128
. 
Hypoattenuation, including loss of gray-white differentiation and delineation of brain 
structures on NCCT have also been recognized as specific for irreversible infarction
129, 
130
. Further, the change in hypoattenuation over time could be used to indicate time of 
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stroke onset
131
. In patients with ICH, a single NCCT scan at onset has been shown to 
predict morbidity and mortality at 30 days
132
.  
 Currently, the NCCT acquisition is the most common imaging modality used to 
make tPA administration decisions for patients with ischemic stroke. Contraindications 
for tPA, as observed on NCCT, are: 1) ICH, and 2) any region of hypointensity, which 
likely reflects non-viable tissue, greater than 1/3 of the middle cerebral artery (MCA) 
territory
133, 134
. Notwithstanding general acceptance of the above criteria, inter-observer 
agreement for the criterion of 1/3 MCA territory involvement is rather poor
133
. A more 
recent scoring system, The Alberta Stroke Program Early CT Score (ASPECTS) is a ten 
point rating system for assessing the extent of early ischemic changes on NCCT
135
. It is 
easy to implement, using two representative slices from the admission NCCT, and 
provides valuable information for predicting patient outcome after thrombolysis. When 
compared with the 1/3 MCA rule, ASPECTS has been shown to have an improved 
reliability and inter-observer concurrence in identifying stroke patients unlikely to make 
an independent recovery despite thrombolytic treatment
134-136
.  
 
1.4.3.1 CT angiography 
CTA requires the intravenous injection of iodinated contrast agent followed by rapid 
helical scanning during the peak intravascular contrast enhancement.  Various techniques 
can be applied to interpret the acquired images, including direct viewing of source 
images, three-dimensional reconstructions, and maximum intensity projections (MIP).  
Although all three techniques are utilized, MIPs are the most common, with three-
dimensional reconstructions requiring extra post-processing time.  Source images are 
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important for examining the information in detail, and are often used to confirm occlusion 
or stenosis seen on the reformatted MIP images.  
For patients with ICH, 40-50% has contrast extravasation on acute CTA and post-
contrast CT (PCCT), which is associated with hematoma expansion and increased 
mortality
137-141
.  
For patients with ischemic stroke, the CTA based Clot Burden Score and the 
Boston Acute Stroke Imaging Scale are also used for the successful assessment of EIC, 
and can determine radiological and clinical outcomes
142, 143
.  
   
1.4.4.2 CT Perfusion  
In a few added minutes, further assessment of cerebral hemodynamics with CT perfusion 
(CTP) can give insight into early ischemic changes (EIC), tissue states, and blood-brain 
barrier disturbances, unseen on NCCT/CTA. Moreover, due to optimized scanning 
protocols, the added radiation dose is minimized.  
Although CTP imaging is rarely used for acute diagnosis of ICH, recent perfusion 
studies have attempted to find secondary ischemic changes in surrounding tissue, leading 
to edema and possibly worsening clinical outcome
96, 144-146
. Briefly, Rosand et al. (2002) 
revealed a gradient of peri-hematomal hypoperfusion, which may have been associated 
with ischemic changes
145
. Subsequent findings by Fainardi et al. (2008) demonstrated that 
this centrifugal CBF distribution around the hematoma was not suggestive of ischemic 
penumbra destined to survive, but rather indicative of edema formation, a potential 
confounding factor in hematoma growth
144
. During the first 3 hours of symptom onset, 
early hematoma growth is seen in 18-38% of patients with ICH, reducing to 11% 
thereafter
62, 65
. Mitigating secondary bleeding is imperative when dealing with ICH.  
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In the setting of ischemic stroke, hemodynamic thresholds from multiple 
parameters could be utilized to define the acute infarct core
147
. Since absolute CTP 
parameter values may depend on the details of the processing algorithm, using relative 
thresholds have been proposed as an alternative. Schaefer et al. (2006) had success with 
defining infarction using normalized (to contralateral hemisphere) CTP-CBF values
148
. It 
is critical that the contralateral region of interest (ROI) contains a similar distribution of 
gray and white matter, as both tissue types have different CBF and CBV values
149
. 
Similarly, absolute thresholds obtained from ROIs with a mix of gray and white matter 
tissue may present a problem, as both tissue types have different CBF and CBV, as 
described in a previous section. To circumvent this issue, efforts to determine individual 
gray and white matter threshold values for infarct core and penumbra have been carried 
out, with varying results
150-154
.  
Depending on the clinical symptoms, the imaged volume is selected at the level of 
the basal ganglia, which includes posterior, anterior, and middle cerebral arteries. CTP 
derived CBF and CBV describes hemodynamics within the entire vasculature including 
large arteries, arterioles, capillary beds, venules, and veins. As an intravascular contrast 
bolus passes through a mass of brain tissue, the signal intensity of each voxel within a CT 
image will change over time. The intensity of the CT image, expressed in Hounsfield 
Units (HU), is linearly proportional to the efficiency with which x-rays are attenuated. 
For each pixel, its time-density (attenuation) curve (TDC)  is used to quantify several 
perfusion parameters: cerebral blood flow (CBF), the volume rate of blood moving 
though the mass of tissue [ml·min
-1
·(100g)
-1
]; cerebral blood volume (CBV), the total 
volume of moving blood in the mass of tissue [(ml·(100g)
-1
]; the time-to-peak of the pixel 
TDC corrected for the dispersion in the artery TDC (Tmax) or the time-to-maximum of the 
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tissue residue function, and a new parameter used in the acute stroke setting, the 
permeability surface area product (PS) of the blood-brain-barrier, the rate of contrast 
extravasation from intra- to extravascular compartments through a damaged barrier 
[ml·min
-1
·(100g)
-1
]. 
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Figure 1.1 – Sample CBF, CBV, Tmax , and PS CTP functional maps for patient with 
ischemic stroke 
 
Colour coded functional maps of cerebral blood flow (CBF), cerebral blood volume 
(CBV), time-to-peak of tissue-residue-function (Tmax), and permeability surface area 
product (PS) calculated using CT Perfusion software (GE Healthcare).  CBF is expressed 
in units of ml∙(100g)-1∙min-1, CBV in ml∙(100g)-1, Tmax in seconds, and PS in ml∙(100g)
-
1∙min-1.  
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With current CT perfusion software (GE Healthcare), post-processing of 
hemodynamic functional maps is practically automated. The operator needs only to select 
an arterial input function (AIF-TDC) and a venous output function (VOF-TDC). The AIF 
is selected from within a large artery (usually the anterior cerebral artery), preferably at a 
location along the artery where it is orthogonal to the scan plane to limit partial volume 
averaging (PVA) – this ‘dilution’ effect will become apparent when comparing the peak 
enhancement (increase of attenuation above baseline) of arteries of different sizes. The 
VOF is selected from a large vein, usually the superior sagittal sinus, to minimize the 
effect of PVA on its accurate measurement. As such, the underestimation of the AIF from 
PVA can be corrected by normalizing the area of the AIF with that of the VOF
155
. 
Deconvolution and non-deconvolution based models are used to calculate 
perfusion parameters. The work contained in this thesis uses the deconvolution process. 
Although physiologically more appropriate, deconvolution models involve complex 
algorithms and require more time for the calculation, whereas the simplicity of non-
deconvolution models stems from their simplified assumptions about hemodynamics in 
the brain that may not hold true in general. Deconvolution methods correct for the 
inability to deliver a contrast bolus directly into the supplying artery of a tissue of interest 
– the bolus introduced at a peripheral vein  undergoes ‘delay’ and ‘dispersion’ prior to its 
arrival at the artery to become the AIF or the TDC of the artery. Deconvolution corrects 
for this by calculating an impulse residue function [IRF or R(t)], which simulates the 
tissue TDC obtained under the ideal injection condition (Figure 1.2).  
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Figure 1.2 – Sample IRF 
 
 
 
 
 
 
 
 
 
 
 
 
The impulse residue function (IRF) can be viewed as the fraction of contrast medium that 
remains in the tissue as time evolves following a bolus injection into the arterial input. 
Beyond the minimum transit time (the duration of the plateau), the difference of R(t + Δt) 
and R(t) is the fraction of contrast medium that has a transit time of t. This difference is 
the height of the strip with a transit time of t. Further, the area of each of the horizontal 
strips is the product of the transit time and the fraction of contrast medium having that 
transit time. It follows that the area of all the horizontal strips, that is, the area under the 
curve (AUC) of R(t), is the mean transit time (MTT). Alternatively, as the Central 
Volume Principle states that the product of CBF and MTT is CBV, the AUC of CBF∙R(t) 
is the CBV. The Tmax parameter is the time to peak of the IRF.  For the case when the 
IRF has a flat ‘top’ as shown, without loss of generality, Tmax can be taken as the half-
way time point of the flat ‘top’. 
 
R(t) 
R(t+t) 
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Limited axial coverage of the whole brain and use of ionizing radiation are current 
limitations of CT perfusion. The volume of brain tissue which can be imaged in one CTP 
acquisition is limited in the craniocaudal direction (z-axis for all scanners) by the number 
of detector rows in a CT scanner (4-12 cm).Coverage in this direction can be doubled (to 
include two adjacent sections of the brain) using shuttle mode or two separate boluses
156, 
157
. The shuttle technique can have two variations, step and shoot (axial shuttle) between 
two sections or continuous table translation back and forth (helical shuttle). Axial shuttle 
mode generally has less motion artifact than helical shuttle mode as images are acquired 
with the patient table (brain) stationary. Also, the image interval of all slices in axial 
shuttle mode is uniform (2-3 seconds), while the helical shuttle mode is non-uniform for 
the cranial and caudal slices – the image intervals for slices in the centre of the two-
section volume will be roughly uniform at 2-3 seconds, and those for the more cranial and 
caudal slices of that volume can vary from 1-2 to 4-5 seconds. The two injections 
technique requires double the dosage of iodinated contrast increasing the risk of contrast 
induced nephrotoxicity (CIN). However, a recent multicenter study has shown that the 
incidence of CIN was low ~2.6% among at-risk patients undergoing contrast enhanced 
CT scans in a “real world” clinical setting, where guideline-recommended strategies for 
CIN prevention may not be consistently followed
158
. 
Although a 60-70 second imaging protocol is sufficient for a perfusion only study, 
acquisitions of 90-180 second durations have been advocated for combined perfusion and 
blood-brain barrier permeability studies
76, 159-161
. To minimize radiation exposure from the 
lengthened scan time required for blood-brain permeability measurement, temporal 
sampling is decreased to one image every 10-15 seconds after the first phase
160
.  The total 
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effective dose from a multimodal CT stroke study, for a 64-row detector CT, is ~7mSv,  
which is double the average annual background radiation
162
. Radiation-dose reduction 
strategies, such as the Adaptive Statistical Iterative Reconstruction, can maintain image 
quality while reducing effective dose by > 25%
163
. Also, radiation dose could be reduced 
by two thirds, without compromising the accuracy of the CTP functional maps, by 
increasing the sampling interval from 1 second to 3 seconds in the first phase of a CTP 
study
156
.  Other limitations of perfusion, across all modalities, including MRI, CT and 
PET are: the lack of standardized image acquisition protocols; post-processing tools in the 
experimental and clinical settings and total perfusion imaging time, which could take up 
to 30 minutes from entering the imaging suite to making a treatment decision. Even with 
these drawbacks, the role of perfusion imaging in the setting of acute stroke continues to 
progress.   
 
1.5 ANIMAL MODELS OF STROKE 
Several animal models have been developed over the last four decades to explore global 
and focal permanent and transient cerebral ischemia, as well as primary and secondary 
hemorrhage. Current stroke models are divided into two categories: 1) non-induced, 
spontaneous vascular insults, and 2) artificially induced vascular insults. These models 
contribute to our overall understanding of stroke sub-type etiology, while developing 
primary treatment and secondary prevention strategies, in a controlled environment. 
Furthermore, the development of new imaging techniques and the establishment of 
imaging thresholds have become important research goals in the pre-clinical setting, with 
obvious clinical translation. Typically, rodent models of stroke have been developed due 
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to their cost-effectiveness, high throughput, reproducibility, and their genome is easily 
manipulated to form transgenic strains; however, the anatomical, and possible 
pathophysiological differences between the rodent and human brain remains a limitation 
– rat brains are lissencephalic (smooth brain surface lacking gyri and sulci), and possess 
very little white matter compared with humans. Therefore, rabbits, pigs, dogs and even 
primates have also been utilized over the years as they more closely resemble humans, 
including a gyroencephalic brain structure and  similar proportions of gray and white 
matter. Disadvantages of using higher animals for stroke research are their higher cost 
and ethical concerns.  
The use of animal models tends to eliminate confounding factors pertinent in the 
clinical setting (vascular cognitive impairment, small vessel disease, diabetes etc.). This is 
especially important when determining drug efficacies. However, no animal model 
completely recapitulates the complicated processes of ischemic or hemorrhagic stroke in 
humans, a factor which should be considered translating animal model results to the 
clinical arena. 
 
1.5.1 Global ischemia 
Global ischemia is achieved in a four vessel occlusion model where temporary ligation of 
two vertebral and two common carotid arteries results in a reduction in blood flow to the 
entire brain. These models, primarily developed in rats, are used to study the 
hemodynamic changes that occur during cardiac arrest, as well delayed neuronal death of 
the pyramidal cells in the CA1 region of the hippocampus
164, 165
.  
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1.5.2 Focal ischemia 
 The alternative to global ischemia is focal ischemia, which attempts to mimic the 
majority of ischemic stroke cases, in which the occlusion of the middle cerebral artery 
occurs. A common model of focal ischemia is the intraluminal filament procedure, which 
attempts to preserve blood flow through the internal carotid artery (ICA)
166
. This 
technique involves the insertion of a filament of surgical suture anterograde into the ICA, 
which is then advanced to block the MCA origin; however, significant mechanical 
abrasion may result in endothelial damage and even hemorrhage. If done correctly, this 
model is relatively easy to implement, produces consistent results between animals and 
removal of the filament can mimic a reperfusion scenario. Other models of focal ischemia 
are photothrombosis, endothelin-1, and the Tamura method (transection of the MCA), all 
of which create an occlusion of the MCA
167-169
.  
 To investigate thrombolysis and tPA therapy, an autologous blood clot can useful. 
The rabbit small/large clot embolic stroke model (RCEM), which involves an injection of 
autologous blood clots into the internal carotid artery, causing occlusion of the MCA
170
. 
This model was utilized in the original study that showed the beneficial effect of tPA and 
also in the development of the first neuroprotectant to show efficacy in clinical trials
171, 
172
. Advantages of the RCEM include a similar vascular anatomy to humans, formation of 
thrombus following occlusion, and the similarity of the embolic material in both the 
animal model and human disease. The similarities between human stroke and this 
embolic stroke model make it suitable for testing future therapies, especially those being 
tested in combination with tPA to achieve reperfusion. Nonetheless, the ligation of the 
30 
 
 
 
external carotid artery, prior to insertion of the clot, makes longitudinal studies difficult as 
extra-cranial structures, including mastication muscles, are damaged.  
A number of rare forms of stroke occur in humans as a result of single gene 
disorders. The most common of these is cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leucoencephalopathy, resulting from mutations in the Notch3 
gene
173
. With the introduction of transgenic animals, many spontaneous stroke models 
have been developed with small rodents to cause spontaneous vascular pathologies, as 
observed in the clinical setting
174
. Though, due to inter-strain variations of the vascular 
territories and incomplete posterior communicating arteries, careful selection is required 
to minimize these effects. The spontaneously hypertensive stroke-prone rat is commonly 
used to mimic clinical case of hypertension, used for producing large MCA infarcts
175
. 
This model closely resembles older individuals who typically have underlying vascular 
pathologies.   
 
1.5.3 Intracerebral hemorrhage 
Intracerebral injection of blood or bacterial collagenase, as well as mechanically induced 
vessel rupture mimics the pathophysiology of spontaneous primary and secondary forms 
of ICH in humans. These models can also be used to determine the effects of hemostatic 
agents on edema formation and hematoma expansion. Genetically engineered mice are 
valuable in determining the mechanisms of injury following ICH
176
. Several groups have 
recently used transgenic mice to study the role of factors that may contribute to ICH-
induced injury, identifying therapeutic targets. Furthermore, they can be used to 
corroborate the gene expression profile in peri-hematomal tissue after ICH in humans
177
.   
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Despite the setbacks in translating experimental results to the clinical setting, 
animal models provide a necessary step for testing potential strategies to improve 
treatment of acute stroke. 
 
1.6 FUTURE STROKE DIAGNOSIS & TREATMENT 
Stroke diagnosis, prognosis and treatment planning has come a long way in the last four 
decades. Currently, one of the major limiting factors in the acute setting is whether 
treatment, either surgical or pharmacological, will improve or worsen outcome. 
Neuroimaging is at the forefront of establishing a more individualized approach to stroke 
treatment, which emphasizes the physiological condition of the brain tissue, rather than a 
strict reliance on time from ictus. Development of this comprehensive diagnostic work-up 
makes use of both MRI and CT imaging. MRI and CT can both be used to determine 
vessel status (MRA and CTA) while perfusion-weighted imaging (PWI) and CTP 
imaging can provide comparable information on the hemodynamic parameters. PWI is 
advantageous since it provides greater anatomical coverage than CT and does not involve 
ionizing radiation; however, CTP has the benefit of providing quantitative values, 
acquisition speed is faster, and is more frequently available at most hospitals. Further, 
absolute measurement of vascular integrity in terms of permeability surface area product 
during the first few hours of stroke onset is possible. The addition of CTA and CTP to the 
standard NCCT adds minimal time to the acute stroke triage, and all studies can be 
performed within the same scanner. Using these three CT protocols, development of a 
patient-specific treatment plan has the ability to significantly advance stroke treatment by 
assessing the relative risks and benefits of early therapy on a patient by patient basis. 
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Additionally, these techniques may provide the necessary information to exclude patients 
at high risk of hematoma expansion and hemorrhagic transformation in primary and 
secondary hemorrhage cases.  
   
 
1.7 RESEARCH OBJECTIVES 
 
The main objective of the work contained in this thesis is to use the CT perfusion imaging 
modality to reduce the average rate of neuronal loss during the acute stroke setting by 
guiding acute treatment and determining the efficacy of pre-stroke neuroprotective 
strategies.  
 
This work is divided into the following projects: 
1)  Determine the prognostic reliability of the cerebral blood volume parameter in acute 
ischemic stroke.  
2)  In a porcine model of ischemic stroke, correlate the optimal CT perfusion 
parameter/thresholds for acute infarct core delineation in gray and white matter with 
the imaging and histological gold standards.  
3)  Determine whether early blood-brain-barrier integrity, as measured by the CT 
perfusion derived permeability surface area product, is associated with both 
radiological and clinical outcomes in primary and secondary intracerebral 
hemorrhage. 
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4) Development of a longitudinal animal model of middle cerebral artery embolic 
occlusion (rabbit) to explore the neuroprotective effect of dipyridamole, an anti-
platelet drug, in embolic cerebral ischemia. 
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CHAPTER 2 
The Evolution of the Cerebral Blood Volume Abnormality in Patients 
with Ischemic Stroke 
The contents of this chapter have been adapted from the paper entitled “The evolution of 
the cerebral blood volume abnormality in patients with ischemic stroke: a CT perfusion 
study”, published in Acta Radiologica 2012;53(4):461-7 by C.D. d’Esterre, R.I. Aviv, and 
T.Y. Lee.  
 
2.1 INTRODUCTION 
When a cerebrovascular accident of thromboembolic origin occurs, the primary objective 
is to salvage tissue at-risk (penumbra) by limiting infarct expansion. Treatment with 
tissue plasminogen activator (tPA) up to 4.5 hours post stroke onset has shown to be 
clinically effective in this regard
1
. Yet, the triggering of clinically adverse events, such as 
hemorrhagic transformation, remains a concern anytime thrombolysis treatment is given
2
. 
Recent studies have shown that hemorrhage risk post revascularization and clinical 
outcome are highly correlated with final infarct volume and acute (< 6 hours post ictus) 
infarct volume, respectively
3, 4
. In conjunction with the admission National Institutes of 
Health Stroke Scale (NIHSS) score, the acute infarct core could be used to indicate the 
amount of tissue at-risk – presumably, a small infarct core at onset combined with a high 
NIHSS score suggests there is a substantial amount of electrically silent but viable tissue. 
Therefore, acute infarct core quantification during the acute stroke setting bears high 
clinical significance, potentially guiding acute stroke treatment.   
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Numerous attempts to identify admission imaging thresholds for delineation of non-viable 
cerebral tissue have been extensive, resulting in a wide range of values
5-10
. One modality, 
magnetic resonance (MR) diffusion weighted imaging (DWI), has the capability to detect 
cerebral infarction within hours of stroke onset with high sensitivity, and is correlated 
with clinical outcome days later
11-13
. Nonetheless, there are instances where DWI 
hyperintensities have been shown to reverse following successful thrombolysis
14-17
. This 
overestimation of acute infarct volume may falsely exclude patients from receiving 
thrombolytic therapy
17, 18
. Further, the limited availability of MR imaging during the 
acute stroke setting promotes the use of other imaging modalities. 
              Due to its accessibility and simplicity, computed tomography (CT) is suitable for 
diagnosis ischemic stroke. Although the Alberta Stroke Program Early CT Score 
(ASPECTS) has proven to be a reliable indicator of early ischemic change using only a 
standard CT examination, irreversibly damaged tissue and/or tissue at risk of progression 
to infarction may still exist within normal appearing regions on hyper-acute non-contrast 
CT (NCCT)
19, 20
. CT perfusion (CTP) ASPECTS has been shown to provide some 
advantage over NCCT for clinical outcome prediction, and detecting reversible 
ischemia
21
. Specifically, the CBV-ASPECTS emerged as the best predictor of fatal stroke 
in the hyperacute state
22
; however, due to high correlation between predicted  infarct 
volumes defined by DWI- and CBV-defects, speculation concerning the evolution of 
CBV within critically hypoperfused tissue is vindicated 
23, 24
. Therefore, we sought to 
examine: (1) the temporal profile of CTP-derived CBV within tissue that progresses to 
infarction (CBVI) at admission, 24 hours and 5-7 days post stroke onset to determine if 
CBVI, like DWI defects, can normalize, and (2) the possible overestimation of predicted 
infarct volume as defined by the CBV abnormality.  
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2.2 MATERIALS & METHODS 
2.2.1 Participants and study design 
Ethics approval was obtained from both participating institutions
+
. Informed consent was 
obtained from patients and family members. Patients were eligible for inclusion in the 
study if they: showed signs and symptoms of middle cerebral artery occlusion, had CTA 
confirmed recanalization, presented at the hospital < 6 hours post symptom onset, had no 
previous stroke, NIHSS > 4, had a CT perfusion (CTP) scan at admission, 24 hour and 5-
7 post ictus, and had a delayed non-contrast CT (NCCT) to quantify final infarct size. 
Exclusion criteria were as follows: evidence of brain stem infarct, prior stroke with 
residual deficit intracranial hemorrhage, minor stroke symptoms (NIHSS score < 4), 
clinically significant hyperglycemia, impaired renal function and/or known allergy to 
contrast media; pregnancy, and age less than 18 years. Patients were enrolled regardless 
of therapy, and results of the CT perfusion study performed at admission did not 
influence treatment decisions (patients and family members providing informed consent 
were aware of this). 
 
 
 
 
 
 
_______________________________ 
+
 Appendix A – Human Ethics Approval Form 
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2.2.2 CT imaging procedures 
Imaging was performed on a Lightspeed CT scanner (GE Healthcare, Milwaukee, WI, 
USA) at Sunnybrook Health Sciences Center, Toronto Canada. Thirteen patients had a 
non-contrast CT (NCCT), CT angiography (CTA), and CT perfusion (CTP) scan at 
admission and 24 hours, and NCCT and CTP 5-7 days post admission. Thirty-two 
patients had a NCCT, CTA, and CTP scan at admission, and NCCT/CTA and 5-7 days 
post admission. NCCT scans were performed using the following parameters: 120 kVp, 
340 mA, 4 x 5 mm collimation, 1 second/rotation. CTA scan covered from the carotid 
bifurcation through to the vertex and was acquired using 0.7 ml/kg contrast agent, at 120 
kVp and 270 mA, 1 sec/rotation, 1.25 mm thick slices, and pitch of 0.75. Recanalization 
was characterized as no visible narrowing of the vessel, while occlusion was 
characterized by the absence of contrast material distal to the thrombus on the CTA, 
based on an adaptation of the thrombolysis in myocardial infarction criteria
25
. CTP 
images were collected from the basal ganglia to the lateral ventricles, with 4 x 5 mm thick 
slices acquired at 80 kVp and 190 mAs for 60 seconds. Iodinated contrast agent, 
Omnipaque (300 mg iodine per milliliter; Iohexol; GE Healthcare, Mississauga, Ontario, 
Canada) was injected (0.5 ml/kg) at a rate of 4 ml/sec.  
 An overview of the CTP image processing was provided in Chapter 1. Briefly, 
each CTP imaging study was analyzed using commercially available CT perfusion, delay-
insensitive software (version 4, GE Healthcare, Milwaukee, WI, USA). For each CTP 
scan, time-density curves (TDC) for the arterial input function (AIF) and venous output 
functions (VOF) were obtained from the anterior cerebral artery and superior sagittal 
sinus, respectively. The AIF was corrected for partial volume averaging by scaling its 
area relative to that of the VOF-TDC; partial volume averaging effects are minimal in the 
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sagittal sinus
26
. Parametric maps of cerebral blood flow [CBF; ml·min
-1
·(100g)
-1
] and 
cerebral blood volume [CBV; ml·(100g)
-1
] were calculated by deconvolution of tissue 
TDCs and the AIF; these values have been validated by using microspheres in animal 
studies and positron emission tomography (PET) in humans
27, 28
. Perfusion weighted 
maps were created by averaging the cine CTP images over the duration of the first pass of 
contrast. 
 
2.2.3 CTP image analysis 
Custom software (IDL, version 6.2, RSI, Boulder, Colorado) was used for all post 
processing analysis. Analysis was performed while blinded to results from imaging at 
each time point, as well as to clinical outcomes.  
 
2.2.3.1 The 5-7 day evolution of CBV within tissue destined to infarct  
Group A was used for this analysis (Table 2.1). Delayed NCCT images were registered 
with admission, 24 hour and 5-7 post admission parametric maps by adjusting for in-
plane rotational changes. Final infarct regions of interest (ROI), as defined by areas of 
hypoattenuation, were traced onto the delayed NCCT images by an experienced 
neuroradiologist of 5 years. These ROIs were superimposed onto CBF and CBV 
parametric maps at each time point, avoiding cerebrospinal fluid, and skull bones. 
Perfusion weighted maps were used to produce a gray and white matter anatomical mask 
based on the Hounsfield Unit differences between the two tissue types. CBV values from 
within superimposed infarct ROIs (CBVI) for gray and white matter were calculated from 
all ROIs for each patient, at each time point. These values were weighted according to the 
size of the ROI for each slice. Further, patients were dichotomized based on whether the 
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TDC, taken from the ischemic defect (TDCi), was truncated or non-truncated; truncation 
was defined as the absence of the lower 50% of the TDC trailing slope (contrast wash out 
phase). An overall average CBVI using all patients was calculated at each time point. 
Pixels with a CBF > 100 ml·min
-1
·(100g)
-1
 or CBV > 8 ml·(100g)
-1
 were excluded from 
the average calculation, a technique used to eliminate large vessel hemodynamic values, 
focusing on parenchymal perfusion
28
.  
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Table 2.1 Demographics for Group A, N = 13 ischemic stroke patients. 
Patient Age Gender 
Onset to 
Imaging 
(minutes) 
Admission 
NIHSS 
tPA 
Recanalization 
@ 24 hours 
TDCi 
truncation 
1 54 M 73 18 IV Partial No 
2 60 M 135 8 IV+IA 
IA 
Partial No 
3 62 F 78 21 IV+IA 
IA 
Partial Yes 
4 56 F 75 8 IV Partial Yes 
5 78 M 286 25 None No No 
6 72 M 126 13 IV No No 
7 64 M 175 19 IV No No 
8 90 F 427 19 None No No 
9 72 F 394 19 None No No 
10 67 M 169 12 IV No Yes 
11 53 M 300 22 None No Yes 
12 92 F 107 24 None No No 
13 57 M 225 
 
17 IV+IA No No 
 67±13 8M,5F 197±120 17.3±5.5 8/13 
tPA 
 4/13 
 
NIHSS = National Institutes of Health Stroke Scale, M = Male, F = Female, tPA = tissue 
plasminogen activator, IA = intra-arterial, TDCi = time density curve from tissue destined 
to infarct. Data presented as mean ± standard deviation. 
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2.2.3.2 Determining CBV defect overestimation  
In part 1 of this analysis, Group B was used to obtain admission CBV thresholds for 
infarction in gray and white matter, respectively. Patients were included if they had full 
recanalization and were classified as ITDC truncation negative. Of the 32 patients with 
imaging, 13 contributed data for this analysis (Table 2.2). This was carried out as follows: 
the perfusion weighted map was used to segment gray and white matter on the basis of 
Hounsfield unit thresholds to produce a gray/white matter mask. This ROI mask was then 
applied to the admission CBF and CBV maps. The admission perfusion-weighted, CBF, 
and CBV maps were automatically co-registered as they came from the same CT 
perfusion study. Delayed NCCT images were registered to the admission images using 
custom software (IDL, version 6.0, RSI, Boulder, Colorado). The final infarct was outlined 
by an experienced neuroradiologist of 5 years. The final infarct ROI was then 
superimposed onto the admission CBF and CBV functional maps, and the gray/white 
matter ROI mask was applied within the infarct ROI. CBV values from within the 
superimposed ROI were obtained for gray and white matter, respectively. These values 
represent the acute infarction thresholds. To be certain penumbral tissue pixels were not 
incorporated, we set an upper threshold for CBV for each patient using the mirror 
contralateral hemisphere ROI – this upper threshold was defined as the mean CBV 
subtract one standard deviation.  
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Table 2.2 Demographics for Group B, N = 13 ischemic stroke patients. 
Patient Age Gender 
Onset to 
Imaging 
(minutes) 
Admission 
NIHSS 
tPA 
Recanaliza- 
tion @ 24 
hours 
TDCi 
Trunc
-ation 
14 44 F 280 10 IA Complete No 
15 77 F 163 6 IA Complete No 
16 81 F 147 26 None Complete No 
17 75 M 168 4 None Complete No 
18 82 F 178 23 None Complete No 
19 89 F 133 18 None Complete No 
20 54 F 129 9 IV Complete No 
21 77 F 82 10 IV Complete No 
22 78 M 157 9 None Complete No 
23 60 F 64 11 IV+IA 
IA 
Complete No 
24 67 F 130 13 IV+IA Complete No 
25 57 F 137 14 None Complete No 
26 82 M 122 
 
11 IV Complete No 
 71±
13 
3M,10F 145±51 12.3±6.3 7/13 
tPA 
 0/13 
 
 
NIHSS = National Institutes of Health Stroke Scale, M = Male, F = Female, tPA = tissue 
plasminogen activator, IA = intra-arterial, TDCi = time density curve from tissue destined 
to infarct. Data presented as mean ± standard deviation. 
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In part 2 of this analysis, the CBV values obtained in part 1 were applied to all 
CTP time points for patients in Group A. This was carried out as follows: peri-infarct 
hypoperfusion was outlined at CBF < 25 ml·min
-1
·(100g)
-1
 
29
. Within this hypoperfused 
region, gray and white matter tissue was flooded with their respective CBV infarct 
thresholds obtained in part 1. Patients with peri-infarct tissue regions with a CBV below 
these determined thresholds were classified as having an overestimation of the CBV 
defect (ie. the final infarct volume at 5-7 days, defined on NCCT, was smaller than the 
admission and/or 24 hour infarct volume predicted by the CBV infarct thresholds).  
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Figure 2.1 - Study design flow chart 
 
Number of patients assigned to each of the study groups (solid boxes), and analysis 
procedure performed on each group (dashed boxes). 
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2.2.4 Statistical analysis 
Results are reported as mean ± standard deviation, unless stated otherwise. An unpaired t-
test was used to examine significant differences in overall average CBVI between time 
points, for both cerebral tissue types. Within truncated and non-truncated TDCi groups, 
CBVI values were analyzed by repeated measures ANOVA to identify significance over 
time. All statistical analyses were performed by using software (SPSS, version 16 for 
Windows; SPSS, Chicago, IL, USA). 
 
2.3 RESULTS 
2.3.1 The 5-7 day evolution of CBV within tissue destined to infarct  
Gray matter infarct regions were present in 11 patients, while white matter infarct regions 
were present in 9 patients. Three patients did not have CTP data at 24 hours. CBVI 
[ml·(100g)
-1
 ; mean ± stdev] values for gray and white matter at admission, 24 hours and 
5-7 days were 1.82 ± 0.56, 1.56 ± 0.42, 1.75 ± 0.31 and 1.38 ± 0.65, 1.13 ± 0.31, 1.32 ± 
0.44, respectively when averaged over all patients (Figure 2.2). There were no significant 
differences in mean CBVI between time points for both brain tissue types (p > 0.05). 
TDCi truncation was present in 4/13 (30%): Two patients had TDCi truncation at 
admission only, while two others had TDCi truncation at admission and 24 hours. For 
these four patients, mean CBVI [ml·(100g)
-1
; mean ± stdev] values for gray and white 
matter at admission, 24 hours and 5-7 days were 1.24 ± 0.17, 1.22 ± 0.20, 1.70 ± 0.9, and 
1.05 ± 0.36, 1.13 ± 0.37, 1.51 ± 0.32, respectively. Significant CBVI increases occurred at 
the 5-7 day time point within gray matter only (p < 0.05); white matter values were not 
significant, but showed a similar trend. For patients without TDCi truncation, 9/13 (70%), 
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mean CBVI [ml·(100g)
-1
; mean ± stdev] values for gray and white matter at admission, 24 
hours and 5-7 days were 2.15 ± 0.41, 1.90 ± 0.21, 1.79 ± 0.38, and 1.64 ± 0.75, 1.13 ± 
0.28, 1.18 ± 0.32, respectively. There were no significant CBVI increases at 24 hours or 
5-7 days compared to admission for this group. 
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Figure 2.2 Cerebral blood volume within tissue destined to infarct 
 
Mean ± stdev CBVI [ml·(100g)
-1
] for gray matter (A) and white matter (B) at admission, 
24 hours and 5-7 days post stroke onset for all patients (open circles). Box plots represent 
patients with and without TDCi. In each box, median (solid line), mean (dotted line), first 
and third quartile values are illustrated. A significant increase in gray matter CBVI was 
observed at 5-7 days for the truncated group (*p < 0.05). 
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2.3.2 Determining acute CBV defect overestimation  
In part 1, CBV [ml·(100g)
-1
; mean ± stdev] values to define infarction, obtained from 13 
patients (group B) with confirmed recanalization/reperfusion and no ITDC truncation, 
were 1.10 and 0.75 for gray and white matter, respectively. In part 2, overestimation of 
the final infarct volume, as defined by the CBV thresholds in part 1, was present at 
admission in 3/4 (75%) and 1/9 (11%) of patients who were TDCi truncation positive and 
negative, respectively. Final infarct volume overestimation was absent at both 24 hour 
and 5-7 day CTP imaging time points (Figure 2.3).  
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 Figure 2.3 Example of truncation artifact and CBV defect overestimation  
 
 
 
Patient 10, CTP-derived contrast enhanced image, CBF [scale 0-150 ml·min
-1
·(100g)
-1
] 
and CBV [scale 0-8 ml·(100g)
-1
] functional maps (i-iii) at admission, 24 hours, and 7 
days post stroke onset (A-C). NCCT from 7 days post stroke shows outlined infarct 
region (iv). Corresponding time-density curves (Hounsfield units versus time) were taken 
at each time point. Confluent areas outside of superimposed infarct ROI showing CBV 
defect overestimation (dashed arrows); at this time, TDCi truncation is apparent. CBVI 
reversibility is observed at 24 hours and 7 days, compared to admission, for this patient.  
 
 
 
 
 
67 
 
 
 
2.4 DISCUSSION 
To our knowledge, progression of CTP-derived CBV defect has never been realized 
beyond the acute stroke stage. This study examines CBV changes within gray and white 
matter cerebral tissue destined to infarct, as well as determines the final infarct volume 
overestimation as defined by the CBV abnormality. Previous studies have shown the 
ability of acute CTP-derived CBV defects (ie. CBV close to zero) to predict non-viable 
ischemic tissue
9, 30
. Briefly, a decrease in cerebral perfusion pressure leads to the eventual 
loss of cerebrovascular autoregulation in very hypoperfused tissue, followed by a 
permanent, focal decrease in CBV; however, this mechanism is not yet fully understood
31-
33
. We observe CBVI reversibility out to 7 days post admission in several patients; 
however, this reversal is more common in patients with an incomplete (truncated) tissue 
TDCi at admission and/or 24 hours post stroke ictus. We also observe CBV defect 
overestimation (very low CBV outside of superimposed final infarct volume) at 
admission in 75% and 11% of patients with and without TDCi truncation, respectively. 
Figure 2.3 illustrates CBV overestimation in a patient with TDCi truncation at admission. 
These findings highlight the importance of acquiring a complete tissue TDC for the 
accurate calculation of the impulse residue function, H(t), by the CT perfusion software 
(GE Healthcare). This function describes the amount of contrast remaining in the tissue 
over time. In short, the adiabatic approximation to the Johnson and Wilson model 
describes the impulse residue function as
34
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where Tc 
is the capillary mean transit time and F is CBF. Therefore, according to the 
central volume principle, CBV is F · Tc. E is the contrast extraction fraction, and Vc is the 
contrast agent distribution volume in the extra-vascular space (EVS). The measured tissue 
TDC, Q(t), can be calculated by the convolution of the arterial input, Ca(t) and H(t): 
 
Q(t) = F ∙ [Ca(t) * H (t –To)]    (2) 
 
where * is the convolution operator and T0 is the tracer arrival time relative to the arterial 
input. After measuring Q(t) and Ca(t) using the CTP study, CBV and CBF are calculated 
by iteratively changing their values until an optimum fit to Q(t) is achieved by means of 
Equations (1)-(2). The initial height of the function H(t) is equal to CBF in ml·min
-
1
·(100g)
-1
 and the area under this function gives CBV in ml·(100g)
-1
. Therefore, when the 
tissue TDC is truncated, CBV is underestimated as a consequence. 
In the present study, there were four instances where the admission CTP-CBV 
defined defect volumes extended beyond the superimposed final infarct ROI. One of 
these patients did not have TDCi truncation, and was therefore considered to have ‘true 
CBV reversibility’. This reversibility may be caused by a failure of contrast to access the 
ischemic tissue even though blood filled capillaries may still be present before and/or 
after the short imaging time window
35
. Endothelial swelling (cytotoxic edema) and 
inflammatory mechanisms, such as platelet aggregation and leukocyte adhesion in 
capillaries of ischemic tissue, known as capillary plugging, may play a role
36
. Moreover, 
early reperfusion could allow recovery of cellular membrane ion pumps, instigating 
metabolic resurgence in clusters of cells within the periphery of CBV-predicted infarction 
– this is especially true during instances when spontaneous partial/full reperfusion occurs 
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around the time of image acquisition
37
. In similar work by Silvennoinen et al., 4/45(9%) 
of tPA treated patients had CBV defect volumes that were larger than final infarct 
volumes. However, the CTP software (CTP version 3, GE Healthcare) used to produce 
these hemodynamic parametric maps uses a singular value decomposition algorithm 
which does not have delay correction optimization. To help compensate for the late tracer 
bolus to the affected area, the newest version of CT perfusion (CTP version 4, GE 
Healthcare) “delay optimized” algorithm shifts the tissue TDC baseline to match the 
arterial input function. Making use if this optimized delay correction CTP software (CTP 
version 4, GE Healthcare), Schaefer et al. observed CBV defect reversibility in 2/11 
(18%) patients post endovascular induced recanalization
38
. The small decreases in initial 
defect size were also considered ‘true CBV reversibility’ as TDCi truncation was reported 
not to affect CBV computation.  
The use of CTP imaging to define non-viable tissue during the acute stroke setting 
is possible if technical aspects are considered. Several institutes continue to use a CTP 
acquisition less than 50 seconds when examining acute stroke
39-42
. By incorporating a 
two-phase CTP imaging protocol, TDCi truncation can be prevented. Following the initial 
50-60 second cine scan, sampling every 15 seconds for an additional 90 seconds can 
minimize radiation dose while obtaining the data required for an accurate CBV 
calculation
43
. The second phase data can also be used to evaluate blood brain barrier 
permeability, further guiding thrombolysis treatment
43
. In addition to the lengthened scan 
time, newest versions of the CT Perfusion functional map processing software (GE 
Healthcare), with the delay correction algorithm, should always be utilized; however, this 
correction may not always be sufficient, especially when the peak contrast enhancement 
of the TDC is never reached during the CTP acquisition. Endogenous characteristics 
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which may contribute to the late arrival time of the CT contrast include: atrial fibrillation, 
internal carotid stenosis, inadequate blood supply from collaterals and congestive heart 
failure. To improve arrival time of contrast, a higher injection rate (6-8 ml/sec) is needed. 
In the study by Silvennoinen et al. a rate of 7 ml/sec was used which would shorten the 
contrast bolus, and thus the width of the measured TDC. They reported a much lower 
incidence of TDC truncation, in contrary to the results herein.  
This study is not without its limitations. First, improvement on the small sample 
size of 13 patients with CTP imaging out to 5-7 days or more is needed. Second, defining 
infarcted tissue at 5-7 days post stroke could result in over/underestimation of final infarct 
volume as penumbral tissue remains in a transient state of viability past one week
8
. An 
NCCT with a DWI scan several weeks after stroke onset would be more suitable. Third, 
since slice location varied slightly between time points, image registration was not always 
exact. Accordingly, an ROI analysis comparing the entire 20 mm slab was performed 
(weighted average of 4 slices), instead of a pixel-by-pixel analysis. Fourth, only a 2 cm 
slab of tissue was imaged during the CTP acquisition, which could have missed part of 
the infarct volume. Also of note, the validation of CTP-CBV has yet to be demonstrated 
in any clinical study, and only CTP-CBF has been formally validated
44
.  
 
2.5 CONCLUSION 
This study describes changes in the CBV abnormality from the first few hours of 
ischemic stroke onset.  The acute CBV abnormality is shown to be a reliable indicator of 
impending infarction when the CT contrast wash out phase within ischemic tissue is 
71 
 
 
 
completed within the CTP imaging time frame. Further investigation is needed to 
determine the effects of this truncation artifact on other CTP parameters.  
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CHAPTER 3 
Reliability of the CT Perfusion Cerebral Blood Volume Parameter in 
Ischemic Stroke 
The contents of this chapter have been adapted from the paper entitled “Reliability of the 
cerebral blood volume parameter in ischemic stroke”, has been reviewed and re-submitted 
to the journal Neuroradiology, by C.D. d’Esterre, T.Y. Lee, S. Ceruti, G. Roversi, A. 
Saletti, E. Fainardi. 
 
3.1 INTRODUCTION 
Thromboembolic cerebral ischemia makes up 87% of all stroke sub-types
1
. Early 
restoration of blood flow using thrombolytic therapy is the most effective way to reverse 
stroke symptoms, improving clinical outcome
2
. The intravenous (IV) tissue plasminogen 
activator (tPA) therapeutic window is limited to 4.5 hours post stroke onset
3, 4
. This time 
constraint has limited its use in less than 7% of acute ischemic stroke (AIS) patients as the 
risk of hemorrhagic transformation outweighed the clinical benefit beyond the treatment 
window
5, 6
. A major goal of acute neuroimaging in AIS is to eliminate this rigid temporal 
criterion used to decide if thrombolytic therapy is appropriate. Instead, a patient specific 
approach, based on tissue viability at the time of onset, is currently being explored by 
many investigators, using both computed tomography (CT) and magnetic resonance (MR) 
imaging
7-14
.  
CT imaging remains the modality of choice for AIS for its widespread 
availability, acquisition speed and limited invasiveness. The initial non-contrast CT 
(NCCT) scan is used for detection of stroke mimics, intracranial hemorrhage, infarct 
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delineation, and remains the imaging modality needed to administer tissue plasminogen 
activator (tPA)
15
. Nonetheless, a current widespread method to detect early ischemic 
changes (EIC), the Alberta Stroke Program Early CT Score (ASPECTS), provides only 
subtle indication of EIS along with broad inter-subject variability, especially during the 
first few hours from ictus
16, 17
. Consequently, there have been many attempts to 
standardize perfusion parameters to determine cerebral tissue viability during the acute 
stroke setting
18-24
. A complete reduction in CBV was suggested as the hemodynamic 
indicator to discriminate between viable and non-viable tissue states
25, 26
. The rationale is 
that a decrease in cerebral perfusion pressure in severely hypoperfused tissue leads to 
cerebrovascular autoregulatory failure followed by a supposedly permanent, focal 
decrease in CBV
27
. Conversely, an acute increase in cerebral blood volume (CBV) was 
proposed to have a protective effect on perfusion compromised, yet viable tissue; the so-
called “penumbral hypothesis” 10, 28. Recently, when comparing perfusion parameters to 
the AIS imaging gold standard, the MR-diffusion weighted (DWI) sequence, several 
studies suggest that the CBV parameter is unreliable in the accurate delineation of the 
acute infarct core
22, 23, 29
. Specifically, Campbell et al. (2011) and Kamalian et al. (2011) 
both demonstrated that absolute and relative (to contralateral hemisphere) CBF parameter  
approximate better the DWI-defined infarct core than CBV and MTT parameters 
22, 23
; 
however, both studies used shortened CT Perfusion (CTP) scan times, which may under- 
and overestimate CBV and MTT, respectively
30
. Further, acute DWI defects may not be 
truly representative of non-viable tissue, as partial/full reversal has been shown in 7%-
85% of patients
31, 32
. Therefore, the CBV parameter may still have its place in AIS 
imaging triage. Accordingly, using the newest CTP software from GE Healthcare, which 
incorporates a delay-insensitive deconvolution algorithm, we address the physiological 
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and technical variables which affect the CBV parameter during the acute and sub-acute 
stroke period by comparing the acute CBV defect (CBVD) with the fully evolved infarct, 
defined on the 3 month NCCT, and examining perfusion values, CBV and CBF, within 
tissue destined to infarct at admission, 24 hours, 7 days and 3 months.  
 
3.2 MATERIALS & METHODS 
3.2.1 Patient selection 
The study was approved by the research ethics board of the institution
+
. Informed 
consents were obtained from patient and/or their legal representative. Sixty-four 
consecutively screened acute ischemic stroke patients were enrolled over a two year 
period (between February 2009 and July 2011). Patients were included if they: presented 
at the hospital < 6 hours post symptom onset, had no previous stroke and showed signs 
and symptoms of middle cerebral artery occlusion, had a CT angiography (CTA) at 
baseline and 24 hours for recanalization status, and were able to complete CTP studies at 
all four time points. Exclusion criteria included: evidence of brain stem infarct, prior 
stroke with residual deficit, intracranial hemorrhage, minor stroke symptoms [onset 
National Institutes of Health Stroke Scale (NIHSS) score < 4], clinically significant 
hyperglycemia, impaired renal function and/or known allergy to contrast media; 
pregnancy, and age less than 18 years. Of the 64 patients enrolled, 55 contributed data for 
this study, while 9 were excluded for the following reasons: onset NIHSS score < 4 (n=5), 
no perfusion deficit at onset (n=4). Results of the CTP study performed at admission did  
 
____________________________________ 
+
 Appendix B – Human Ethics Approval form  
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not influence treatment decisions (patients and/or legal representatives providing 
informed consent were aware of this). Patients were enrolled regardless of therapy. An 
experienced neurologist (G.R.) assessed clinical outcome for all patients using the NIHSS 
and at admission, 24 hour, one week, and 3 months, as well as modified Rankin Scoring 
(mRS) 3 months post stroke onset. 
 
3.2.2 Imaging protocol 
Imaging was performed at four time points post stroke onset. Patients underwent a 
NCCT, CTA and CTP at admission (< 6 hours post ictus), 24 hours, 7 days and at 3 
months. Imaging was conducted on a 64–slice Lightspeed VCT scanner (GE Healthcare, 
Waukesha, WI, USA). The CTP scanning protocol consisted of a continuous 50 second 
scan using 80 kV, 100 mA and 1 second rotation time while the couch remained 
stationary. Seven-hundred ninety two 512 × 512 images were reconstructed with a 25 cm 
field-of-view at 0.5 second intervals for each of the eight 5 mm thick slice locations. Five 
seconds before the start of scanning, a 40 ml bolus of iodinated contrast agent (Iomeron 
300 mg/ml, Bracco Imaging SpA, Milan, Italy) was injected at a rate of 4 ml/second into 
an antecubital vein with an automatic injector (Medrad, Indianola, PA). The gantry was 
tilted to parallel the supraorbito-meatal line to avoid irradiation of eye lenses. NCCT 
helical scans were performed from the skull base to the vertex using the following 
imaging parameters: 120 kV, 340 mA, 4x5-mm collimation, 1 second/rotation, and table 
speed of 15 mm/rotation. CTA was performed as follows: 0.7 mL/kg contrast (maximum 
90 mL), 5- to 10-second delay from injection to scanning, 120 kV, 270 mA, 1 
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second/rotation, 1.25-mm thick slices, and table speed 3.75 mm/rotation. CTA covered 
from the carotid bifurcation to vertex.  
 
3.2.3 CTP functional maps 
For consistency, each CTP imaging study was analyzed using a commercially available 
delay-insensitive deconvolution software (CT Perfusion 4D, GE Healthcare, Waukesha, 
WI). For each CTP scan, time-density curves (TDC) for the arterial input function (AIF) 
and venous output functions (VOF) were obtained from the anterior cerebral artery and 
superior sagittal sinus, respectively. The AIF was corrected for partial volume averaging 
using the VOF-TDC. Functional maps of cerebral blood flow [CBF; ml·min
-1
·(100g)
-1
] 
and cerebral blood volume [CBV; ml·(100g)
-1
] were calculated by deconvolution of tissue 
TDCs and the AIF. Perfusion weighted maps were created by averaging the cine CTP 
images over the duration of the first pass of contrast. A functional map was also created 
representing the percentage of TDC truncation (incomplete imaging of the contrast wash-
out phase) for each tissue voxel, defined as: the ratio of the increase in Hounsfield Unit 
(HU) value at the end of the CTP acquisition relative to that of the peak HU above 
baseline.  
 
3.2.4 CTP, CTA, and NCCT image analysis 
One author performed all analysis on CTP maps using custom software (IDL, version 6.2, 
RSI, Boulder, Colorado). For all perfusion studies, perfusion weighted maps were used to 
exclude cerebrospinal fluid (CSF) and cranium from analysis as well as to produce a gray 
and white matter anatomical mask based on the HU differences between the two tissue 
types. All CTP and NCCT scans were co-registered. The admission CBVD volumes were 
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outlined on all CBV functional maps (8 x 5mm) using previously established gray and 
white matter CBV thresholds for infarct core, derived from maps generated by delay-
insensitive deconvolution software (GE Healthcare)
30
. This was performed separately by 
two observers with the final result arrived at by consensus. For each patient, the total 
CBVD size (gray plus white matter volumes) was determined and compared with 
corresponding 3 month post ictus NCCT images. Two neuroradiologist, traced a region of 
interest (ROI) around the hypodense area of the 3 month NCCT (NCCTD) as the final 
infarct ROI. All CBVD and NCCTD areas from each involved slice were multiplied by the 
section thickness and summed to obtain the final defect volume in cubic centimeters.  
To examine perfusion states within the tissue destined to infarct over time, the 
final infarct ROI, from the 3 month NCCT, was superimposed onto the CBV and CBF 
functional maps at all four time points. This ROI was mirrored in the contralateral 
hemisphere. Large vessels within the infarct and contralateral ROIs were excluded from 
the calculation of the mean tissue perfusion parameters
33
.  
Recanalization was classified using CTA at 24 hours post as complete, partial, or 
absent by an experienced neuroradiologist based on an adaptation of the thrombolysis in 
myocardial infarction (TIMI) criteria
34
. Complete occlusion was characterized by the 
absence of CT contrast distal to the thrombus, while full recanalization was characterized 
by no visible narrowing of the involved vessel seen at baseline CTA. Partial 
recanalization was defined as a narrowing of the vessel at the site of occlusion with 
contrast distal to the thrombus.  
The 24 hour and 7 day NCCT was used to categorize hemorrhagic transformation 
(HT), if present, according to the European Cooperative Acute Stroke Study II criteria
35
: 
hemorrhagic infarction (HI-1,2) or parenchymal hematoma (PH-1,2). Symptomatic 
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intracerebral hemorrhage (sICH) was identified as PH with worsening of neurological 
deficit ≥ 4 points on the NIHSS between admission and 24 hours.  
 
3.2.5 Patient groupings and statistical analysis 
One author performed all statistical analysis (SPSS, version 16 for Windows; SPSS, 
Chicago, IL, USA) and results were verified by all co-authors. All data sets were checked 
for normality with the Shapiro-Wilk test prior to analysis with the appropriate parametric 
or non-parameteric tests. 
In some CTP studies, the 50 second acquisition led to truncation of ischemic 
tissue time density curves (TDCi) before the washout phase was completed 
underestimating the area under the TDCi. Therefore, patients were divided into TDCi   
truncation positive (n=24) and negative (n=31) sets, based on the average (values from 
both gray and white matter tissue) TDCi truncation. An TDCi with an average truncation 
value of 50% or greater was deemed truncation positive (Table 3.1 and 3.2). For both 
sets, the mean and standard deviation for age, time from ictus, treatment status with tPA, 
recanalization status at 24-hours, NIHSS (admission, 24 hours, 7 days and 3 months), 3 
month modified Rankin Score (mRS)  and severity of HT were listed .  
The agreement between the admission CBVD volume and NCCTD volume was 
assessed with Bland-Altman analysis for recanalization positive (n=32) and negative 
groups (n=23), and sub-groups based on TDCi truncation and hypervolemia status at 
admission (Table 3.3). Agreement between CBVD and NCCTD volume was evaluated by 
95% limits of agreement, defined as the bias ± 1.96 times the standard deviation of the 
differences
36
. As a secondary analysis, all CBVD volumes were plotted against NCCTD 
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volumes for linear regression analysis. The Pearson correlation coefficient and slope of 
the regression line was calculated for both groups and sub-groups as listed in table 3.3. 
To examine perfusion states within gray and white matter destined to infarct over 
time, admission CBF and CBV were compared with 24 hour, 7 day, and 3 month 
perfusion values using Mann-Whitney Rank Sum Tests for all patients, recanalization 
positive and negative groups. Significant differences were defined as p < 0.05.   
For this study, we define hypervolemia and hyperperfusion as CBV and CBF, 
from within the superimposed final infarct ROI, greater than the average plus one 
standard deviation of the CBV and CBF values obtained from the contralateral mirrored 
ROI, respectively, for each patient. The fractions of patients with hypervolemia and 
hyperperfusion along with the clinical improvement, as given by the average ± standard 
deviation of the difference of the NIHSS from admission for all patients, were determined 
at admission, 24 hours, 7 days and 3 months post stroke. At each of the four time points, 
Fisher Exact Tests were used to investigate: 1) whether the fractions of patients with 
hypervolemia or hyperperfusion between the recanalization positive and negative groups 
and 2) the difference in clinical improvement from admission, as defined by a decrease in 
the NIHSS of ≥4 points, between the recanalization positive and negative groups were 
significantly different. 
  Patients were also dichotomized into hypervolemia positive (n=25) and 
hypervolemia unknown (n=30). Comparing both groups, Fisher Exact Tests were used to 
investigate: 1) the difference in clinical improvement from admission, as defined by a 
decrease in the NIHSS of ≥ 4 points and 2) the fraction of patients with HT.  
 Average gray and white matter admission CBV and CBF values from within 
tissue destined to infarct were determined for each HT type and compared with Student-t 
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tests. Also, for patients with a CBVD at admission (n=30) average CBVD volume (cm
3
) 
for patients with HI, PH and non-HT were compared using student t-tests, to examine the 
effect of admission infarct core size on HT severity.  
 
3.3 RESULTS 
Fifty-five patients (23 females, 32 males) were included in this study, and their 
demographics are shown in tables 3.1 and 3.2. A summary for all patients is as follows 
[mean (range; SD)]: Age was 67 (42 to 82; 11 years), stroke onset to CTP time 155 (50 to 
345; 90 minutes), NIHSS 12 (4 to 25; 6), 24 hour NIHSS 9 (1 to 22; 6), 7 day NIHSS 6 (1 
to 22; 6), 3 month NIHSS 5 (1 to 21; 6), 3 month modified Rankin Score 2 (1 to 5; 1). 
Twenty-seven patients were treated with intra-venous (IV) tPA, 7 with intra-arterial (IA) 
tPA, 1 with both IV and IA tPA, and 20 were not treated with thrombolytic agents. 
Locations of occlusions were as follows: 27 M1 only occlusions, 6 proximal ICA + M1 
occlusions, 16 M2 only occlusions, 6 M3 only occlusions.  
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Table 3.1 Demographics for patients with truncation of the ischemic time-density 
curve at admission. 
 
NIHSS = National institute of health stroke scale, tPA = tissue plasminogen activator, i.v. 
= intra-venous, i.a. = intra-arterial, M = male, F = female, mRS = modified Rankin Score, 
HT = hemorrhagic, HI = hemorrhagic infarction, PH = parenchymal hematoma. 
 
 
 
 
 
 
Patient Age Gender 
Recan. at 
24 hrs 
Onset 
NIHSS 
24hrs 
NIHSS 
7day 
NIHSS 
3month 
NIHSS 
3month 
mRS 
HT 
 
1 65 F No 12 6 1 1 1 None 
2 78 M No 13 4 4 1 1 None 
3 67 F Yes 5 10 5 1 2 None 
4 50 F No 10 4 3 1 1 HI-1 
5 72 F Yes 4 3 2 1 1 None 
6 73 F No 22 8 3 2 1 None 
7 43 F No 4 4 2 2 1 None 
8 73 F Yes 20 9 4 3 1 HI-2 
9 56 M Yes 8 3 2 2 1 None 
10 51 M Yes 9 9 7 5 2 HI-1 
11 57 M No 9 6 4 2 1 None 
12 74 F Yes 14 9 9 5 2 None 
13 69 F No 24 22 22 20 4 None 
14 69 M No 13 13 10 15 4 HI-1 
15 65 M Yes 4 1 1 1 1 None 
16 50 F No 13 13 2 1 1 None 
17 69 M Yes 16 11 4 3 1 HI-1 
18 42 M Yes 13 3 1 0 0 None 
19 76 M Yes 4 4 4 6 1 None 
20 66 M Yes 7 3 3 3 1 PH-2 
21 78 M Yes 7 6 3 2 1 None 
22 77 F Yes 4 4 4 2 1 None 
23 76 M Yes 4 8 2 2 1 None 
24 82 F Yes 12 2 2 4 2 None 
N=24 65±11 12F,12M  10.7±5.7 6.9±4.7 4.3±4.4 3.5±4.6 1.5±1.2  
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Table 3.2 Demographics for patients without truncation of the ischemic time-density 
curve at admission. 
 
NIHSS = National institute of health stroke scale, tPA = tissue plasminogen activator, i.v. 
= intra-venous, i.a. = intra-arterial, M = male, F = female, mRS = modified Rankin Score, 
HT = hemorrhagic, HI = hemorrhagic infarction, PH = parenchymal hematoma. 
 
 
Patient Age Gender 
Recan. at 
24 hrs 
Onset 
NIHSS 
24hrs 
NIHSS 
7day 
NIHSS 
3month 
NIHSS 
3month 
mRS 
HT 
 
25 70 M No 17 17 17 3 1 HI-1 
26 61 M Yes 12 10 6 6 3 PH-1 
27 55 M No 22 16 9 18 3 None 
28 55 M Yes 9 6 3 2 1 None 
29 47 F Yes 14 7 2 1 1 None 
30 56 M Yes 20 15 15 12 4 PH-1 
31 56 M No 8 3 2 2 1 None 
32 80 F No 16 13 10 14 3 HI-1 
33 69 M No 25 21 19 12 4 HI-1 
34 67 F No 9 9 4 3 1 HI-1 
35 69 M Yes 16 11 4 3 1 HI-1 
36 80 F No 6 6 1 1 1 None 
37 67 M Yes 8 6 3 2 1 None 
38 42 M No 12 17 14 11 3 HI-2 
39 65 M Yes 13 15 8 3 2 None 
40 81 M No 4 18 18 15 3 PH-1 
41 77 F No 18 17 17 5 1 None 
42 65 M Yes 9 7 3 1 1 None 
43 80 F Yes 11 3 1 0 0 None 
44 67 M Yes 5 1 1 1 1 None 
45 76 F No 18 18 17 17 5 PH-2 
46 76 M No 8 6 5 4 2 PH-1 
47 82 F Yes 8 0 0 0 0 None 
48 78 F Yes 8 1 1 1 1 None 
49 59 M Yes 7 13 13 6 3 PH-1 
50 78 M Yes 10 3 1 1 1 None 
51 81 M Yes 10 5 2 1 1 None 
52 58 F Yes 4 1 1 1 1 None 
53 70 M No 19 17 9 4 2 HI-1 
54 79 F Yes 20 16 11 3 1 PH-2 
55 80 M No 21 21 18 21 5 HI-2 
          
N=31 68±11 11F,20M  12.5±5.7 10.0±6.6 7.6±6.5 5.6±6.0 1.9±1.3  
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Table 3.3 contains the results for the Bland-Altman analysis, as well as the 
Pearson correlation for the CBVD volume versus final infarct volume, measured on the 3-
month NCCT.  The 95% limits of agreement from the Bland-Altman analysis were widest 
for the recanalization negative group and its sub-groups, compared with the 
recanalization positive group and its sub-groups. The recanalization positive and 
truncation negative group had the highest Pearson correlation coefficient (R = 0.81) and 
slope of the regression line closest to unity (slope = 0.80). The regression line slopes for 
both hypervolemia positive sub-groups were negative and closest to zero.  
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Table 3.3 Bland-Altman and linear regression results for the admission CBV defect 
volume versus the final infarct volume at 3 months  
 
 
95% Limits of 
Agreement 
(mean difference 
± 2*SD) 
Pearson 
Correlation 
Coefficient, 
R (P value) 
Slope of 
Regression 
Line 
Recanalization Positive (n=32) [-48.3,29.1] 0.78 ( 0.08) 0.64 
  Truncation negative (n=17) [-8.4,16.0] 0.81 (0.19) 0.80 
  Truncation positive (n=15) [-40.5,30.3] 0.61 (0.11) 0.46 
  Hypervolemia unknown (n=17) [-51.9,38.2] 0.80 (0.04) 0.57 
  Hypervolemia positive (n=15) [-37.6,16.1] 0.22 (0.79) -0.04 
Recanalization Negative (n=23) [-86.2,51.1] 0.57 (0.03) 0.42 
  Truncation negative (n=14) [-85.9,68.3] 0.15 (0.74) 0.14 
  Truncation positive (n=9) [-69.9,36.9] 0.71 (0.04) 0.62 
  Hypervolemia unknown (n=13) [-96.9,61.3] 0.68 (0.10) 0.37 
  Hypervolemia positive (n=10) [-56.9,19.2] 0.39 (0.22) -0.13 
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Tables 3.4, 3.5 and 3.6 give CBF [ml·min
-1
·(100g)
-1
] and CBV [ml·(100g)
-1
] 
values from within the superimposed final infarct volume for all patients, the 
recanalization positive group and negative group, respectively, at each time point. CBF 
and CBV were highest at day 7 for both tissue types; gray matter CBF was significantly 
higher than the admission CBF value (p < 0.05). For both gray and white matter, there 
were no significant differences between admission and 3 month CBF and CBV values (p 
> 0.05).  Also shown are the fractions of patients with hypervolemia or hyperperfusion at 
each time point, and the NIHSS improvement relative to the admission NIHSS. The 
recanalization positive group had a higher fraction of patients with hypervolemia at 
admission, 24 hours, 7 days, and hyperperfusion at 24 hours and 7 days than the 
recanalization negative group (p = 0.054 to 0.067). There were trends in clinical 
improvement from admission in patients who recanalized, but the changes in NIHSS 
scores were not significantly different from the non-recanalized group (p > 0.05).  
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Table 3.4 All patients (n=55): CBF and CBV values at four time points from within 
superimposed final infarct volumes. Also shown are the fractions of patients with 
hypervolemia and hyperperfusion, along with change in NIHSS.  
 
 
 
 
Table 3.5 Recanalization positive group (n=32): CBF and CBV values at four time 
points from within superimposed final infarct volumes. Also shown are the fractions 
of patients with hypervolemia and hyperperfusion, along with change in NIHSS.  
 
γ
Significantly different (p < 0.05) from admission gray matter CBF.     
                    
 
 
 
Table 3.6 Recanalization negative group (n=23): CBF and CBV values at four time 
points from within superimposed final infarct volumes. Also shown are the fractions 
of patients with hypervolemia and hyperperfusion, along with change in NIHSS.  
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Table 3.7 shows the NIHSS improvement from admission throughout the 3 
months in patients with/without hypervolemia at admission, and the HT percentage for 
both groups. Comparing the NIHSS improvement among the three time points, there were 
no significant differences (p > 0.05). However, admission hypervolemia was associated 
with a significantly higher incidence of HT (p = 0.048), but this group also had a non-
significantly higher incidence of recanalization relative to hypervolemia negative 
patients.  
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Table 3.7 Clinical outcome and hemorrhage rates for patients with/without 
admission hypervolemia. 
 
 Improvement in NIHSS from admission HT 
Hypervolemia at 
admission 
24 hours 7 days 3 months  
Positive (n=25) 2.2±4.5 4.8±5.1 6.4±5.5 52%* 
Unknown (n=30) 2.6±4.5 5.2±5.4 6.7±5.7 26% 
 
* Percentage of patients with hemorrhagic transformation (HT) was significantly  higher 
(p = 0.0478) when hypervolemia was confirmed at admission.  
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The relationship between admission CBVD and final infarct size is affected by the 
following technical and physiological conditions: truncation of TDCi, recanalization 
status within 24 hours of the admission CTP study and hypervolemia during the 
admission CTP study.  Using the scores 1, 0 and -1 to denote admission CBV defect is 
larger than, equal to and smaller than final infarct size, respectively, table 3.8 evaluates 
the effect of the presence or absence of each of the confounding factors on the size of 
admission CBV defect size relative to the final infarct size. While TDCi truncation and 
recanalization can be determined by analysis of the TDCi and CTA/CTP-CBF images, 
respectively, hypervolemia cannot be determined with certainty, except for the case when 
the admission CBV is higher than contralateral normal brain. In cases where ipsilateral 
CBV is equal to or lower than contralateral CBV, hypervolemia status is unknown 
because of one or more of the following reasons: the TDCi is truncated, hypervolemia is 
heterogeneous and does not happen uniformly throughout the CBVD, or it may have 
occurred before or after the admission CTP study. In these instances, if we assume the 
proportion of hypervolemia positive and negative cases are equal, table 3.8 contracts to 
table 3.9. Therefore, this heuristic model predicts that the admission CBVD will 
overestimate the final infarct size for truncation positive/recanalization positive cases, and 
underestimate the final infarct size for all other cases (Table 3.9). Table 3.10 shows the 
measured admission CBVD as a percentage of the final infarct volume, under different 
conditions of TDCi truncation and recanalization. The proposed heuristic model was able 
to demonstrate the trend in the dis/agreement between admission CBVD and the final 
infarct size, though no significance of the dis/agreement was observed in any of the 
groups (p > 0.05).  
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Table 3.8  Model to describe the relationship between admission CBVD and final 
infarct size from 3 month NCCT. 
Hyper (-) 0 Hyper (-) 0 Hyper (-) 0 Hyper (-) 0 
Truncat (+) 1 Truncat (+) 1 Truncat (-) 0 Truncat (-) 0 
Recan(+) 0 Recan(-) -1 Recan(+) 0 Recan(-) -1 
Sum 1 Sum 0 Sum 0 Sum -1 
Hyper (+) -1 Hyper (+) -1 Hyper (+) -1 Hyper (+) -1 
Truncat (+) 1 Truncat (+) 1 Truncat (-) 0 Truncat (-) 0 
Recan(+) 0 Recan(-) -1 Recan(+) 0 Recan(-) -1 
Sum 0 Sum -1 Sum -1 Sum -2 
 
 
Table 3.9. Predicted baseline CBVD size relative to final infarct size among the four 
cases of TDCi truncation and recanalization status when prevalence of hypervolemia 
is 50%. 
 Recanalization (+) Recanalization (-) 
Truncation (+) 0.5 -0.5 
Truncation (-) -0.5 -1.5 
 
 
Table 3.10 Measured baseline CBV defect size as a percentage of the final infarct size 
among the four cases of TDCi truncation and recanalization status when prevalence 
of hypervolemia is 50%. 
 Recanalization (+) Recanalization (-) 
Truncation (+) 111.1 ± 94.1 64.9 ± 50.2 
Truncation (-) 83.4 ± 78.2 74.4 ± 99.2 
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Hemorrhagic transformation (HT) was observed in 21/55 patients: 13 HI, 8 PH 
(Tables 3.1 and 3.2). HT was present in 10/32 and 11/23 patients in the recanalization 
positive and negative groups, respectively. Figure 3.1 and 3.2 depict box plots for 
admission gray and white matter CBV and CBF values for patients with PH, HI and 
without HT. For both cerebral tissue types, mean CBV and CBF values, from within 
tissue destined to infarct, in non-HT patients were significantly different than values from 
patients with PH (p < 0.05). Average CBVD volumes (cm
3
) for non-HT, HI, and PH and 
groups were 39.9 ± 32.3, 53.1 ± 28.9 and 102.3 ± 43.0, respectively (Figure 3.3). Average 
admission CBVD volume for patients with PH was significantly higher than the CBVD 
volume for patients without HT (p < 0.05).   
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Figure 3.1 Admission gray matter CBV and CBF from within the superimposed 
final infarct ROI 
 
 
Box plots for admission gray matter CBV [ml·(100g)
-1
; blue boxes] and CBF [ml·min
-1
· 
(100g)
-1
; gray boxes] from within the superimposed final infarct ROI. Patients were 
separated into non-hemorrhagic transformation (HT), hemorrhagic infarction (HI), and 
parenchymal hematoma (PH). Median and mean are given as solid and dashed lines, 
respectively. Mean CBV (*) and CBF (#) values for the non-HT group were both 
significantly different (p < 0.05) than the mean CBV and CBF values for the PH group.  
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Figure 3.2 Admission white matter CBV and CBF from within the superimposed 
final infarct ROI 
 
 
 
Box plots for admission white matter CBV [ml·(100g)
-1
; blue boxes] and CBF [ml·min
-1
· 
(100g)
-1
; gray boxes] from within the superimposed final infarct. Patients were separated 
into non-hemorrhagic transformation (HT), hemorrhagic infarction (HI), and 
parenchymal hematoma (PH). Median and mean are given as solid and dashed lines, 
respectively. Mean CBV (*) and CBF (#) values for the non-HT group were both 
significantly different (p < 0.05) than the mean CBV and CBF values for the PH group.  
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Figure 3.3 CBV defect volume for non-HT and HT sub-groups 
 
 
 
Average ± standard deviation admission CBVD volume (cm
3
) for patients with a CBV 
defect present at admission for patients with no hemorrhagic transformation (n=17), 
hemorrhagic infarction (HI; n=9) and parenchymal hematoma (PH; n=5). Median and 
mean are given as solid and dashed lines, respectively (*) denotes significantly different 
from non-HT patients (p < 0.05)  
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3.4 DISCUSSION 
This AIS study explores technical and physiological processes which affect the CBV 
parameter: 1) TDCi truncation, 2) nutritive and non-nutritive hypervolemia, and 3) 
recanalization status. As a secondary analysis, we describe acute and sub-acute perfusion 
states (CBV and CBF values) within gray and white matter that progresses to infarction, 
and association with hemorrhagic transformation (HT). The volume of infarct core, as 
defined by the CBV parameter, is associated with the severity of HT. Further, very low 
CBF and CBV values, within tissue that progresses to infarction, were also indicative of 
HT severity. A three month NCCT was used to define the final infarct volume to allow 
for edema reduction and infarct maturation. 
 The CBV parameter continues to be an important parameter to distinguish tissue 
viability states in the setting of ischemic stroke. A substantial reduction in CBV during 
the acute stroke setting is presumed to be a physiological surrogate for infarction, due to 
the irreversible loss of vascular smooth muscle autoregulatory capacity
37
. Conversely, an 
increase in CBV in an area of hypoperfusion has been suggested to represent electrically 
silent, yet viable tissue
38
. Still, there remains a lack of standardization for CBV thresholds 
to define tissue viability, and with its poor correlation with the acute DWI hyperintensity, 
the reliability of the CBV parameter are increasingly being questioned
29
. Although 
diffusion-weighted imaging (DWI) hyperintensities are commonly described as non-
viable tissue, a recent study showed that reversal can occur in > 50% of patients
31
. PET 
imaging of the central benzodiazepine receptor with 
18
F-flumazenil, is the only method to 
truly define infarct core, but this technique is not practicable within the setting of acute 
stroke
39
. The results herein show that the best correlation between CBVD versus the final 
infarct volume occurs in patients who recanalize within 24 hours. This makes intuitive 
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sense, as the infarct core will minimally expand into the surrounding penumbra once 
recanalization is achieved. Moreover, TDCi truncation has a differing effect on 
recanalization positive and negative groups, as shown in table 3.3. In patients who do not 
recanalize and have truncation of the TDCi, the acute CBVD volume closely matches the 
final infarct volume because truncation at admission artificially lowers CBV, 
overestimating the predicted infarct core. This could lead to an inaccurate estimate of the 
CBV threshold for infarction in retrospective studies.  Conversely, in patients who 
recanalize, the overestimation of the infarct core at admission, caused by truncation of the 
TDCi, could lead to the paradoxical phenomenon of reversal of infarct define with CBV 
threshold
30, 40
. 
 In determining whether truncation of the TDCi is present, it is important to note 
that complete wash-in and wash-out of the arterial input function and/or venous output 
function do not mean the ischemic tissue TDC is free of the artifact. Conditions which 
may lead to the late arrival time of the CT contrast and truncation of the TDCi include 
internal carotid artery stenosis, atrial fibrillation, insufficient blood supply from 
collaterals and congestive heart failure. An effective way to prevent truncation of TDCi 
from late arrival of contrast is to use an extended second phase perfusion imaging 
protocol. Following the initial 45-50 second cine scan, sampling every 15 seconds for an 
additional 90 seconds can minimize radiation dose while obtaining the data required for 
an accurate CBV calculation 
41
. The second phase data can also be used to evaluate blood 
brain barrier permeability, further guiding thrombolysis administration decisions
41
.  The 
total effective dose from a multimodal CT stroke study, for a 64-row detector CT, is 
~7mSv, double the annual background radiation dose
42
. Radiation-dose reduction 
strategies, such as the Adaptive Statistical Iterative Reconstruction (ASIR) (GE 
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Healthcare), can maintain image quality while reducing effective dose by > 25%
43
. Also, 
radiation dose could be reduced by two thirds, without compromising the accuracy of the 
CTP functional maps, by increasing the sampling interval from 1 s to 3 seconds in the 
first phase of a CTP study
44
.   
The physiological state of hypervolemia, defined as an increase in CBV, or the 
increase in the amount of blood in tissue, relative to the mirror region of the contralateral 
hemisphere, may also impact both prospective clinical decisions as well as characterizing 
perfusion thresholds experimentally. Irrespective of recanalization, the CBVD volume had 
the poorest correlation with final infarct volume in patients with admission hypervolemia. 
This transient perfusion state is observed in regions with increased, decreased or normal 
CBF at any time during infarct maturation
45
. The hypervolemic response can be promoted 
by embolic migration, therapeutic dissolution, and/or release of vasolidatory- and 
inflammatory-mediators
45
.  
Chronic, non-nutritive hypervolemia and hyperperfusion can induce blood-brain 
barrier breakdown, enhancing the risk of HT, edema formation and release of 
inflammatory-related mediators (reperfusion injury) potentially worsening clinical 
outcome, as shown in figure 3.4
45, 46
. Here, a matched decrease in CBF and CBV is 
apparent at onset within the hypodense region, indicative of cortical swelling, on the 
corresponding admission NCCT. After CTA confirmed recanalization, hyperperfusion 
and hypervolemia are seen at 24 hours and 7 days post stroke onset, the so-called “luxury 
perfusion syndrome”47. Nonetheless, this non-nutritive hypervolemic/hyperperfusion 
response was associated with only a short-term decline in clinical outcome. When 
examining all patients at 24 hours, 7 days and 3 months, an increase in CBV was present 
in 33%, 40% and 0% of patients, respectively, which was not associated with an average 
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overall worsening of the NIHSS score at any time point, compared to the patients without 
hypervolemia at onset. This finding is consistent with a study by Kidwell et al. (2001) 
who found that hyperperfusion occurred in 50% of AIS patients by day 7; correlating 
perfusion images with diffusion weighted MR images, this hyperperfusion occurred 
mainly in regions that went on to infarction and was not associated with clinical outcome 
48
. Examining 9 patients with AIS, Hatazawa et al. (2011) demonstrated that variable 
states of hypervolemia, as shown by increased, decreased and unchanged CBV, depended 
on the severity of hypoperfusion. The results herein showed that early hypervolemia was 
associated with low CBF, and late hypervolemia was associated with low, normal or high 
CBF within tissue progressing to infarction. 
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Figure 3.4 Example of acute matched decrease in CBF and CBV, and sub-acute 
hypervolemia and hyperperfusion  
 
CT perfusion studies at admission, 24 hours, 7 days, and 3 months post ictus for AIS 
patient 3, with confirmed recanalization at 24 hours. NCCT, CBV and CBF maps are 
shown in rows 1, 2 and 3, respectively. A matched decrease in CBV and CBF is visible at 
onset, corresponding to the slightly hypodense area on the NCCT. At 24 hours and 7 
days, a matched increase in CBV and CBF, within the tissue destined to infarct, is 
indicative of hyperperfusion and hypervolemia responses, respectively. NIHSS scores for 
this patient were 5, 10, 5, 1 for onset, 24 hours, 7 days and 3 months, respectively, with 
modified Rankin score of 2, at 3 months  
 
 
Onset 24 hours 7 days                3 months
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Overall, incidences of hypervolemia and hyperperfusion were highest at 7 days in both 
gray and white matter tissue and more pronounced in patients who recanalized. During 
this sub-acute stroke stage, the occurrence could mask late, evolving infarction, but does 
not seem to have a long term effect on clinical outcome. During the hyper-acute stroke 
stage (< 6 hours), increased CBV within hypoperfused tissue has been used to detect 
potentially salvageable tissue, the so called “penumbral hypothesis”. Contrary to sub-
acute hypervolemia, the hyper-acute (< 6 hours) increase in pooled blood may offer 
improved nutrition and act as a buffer for acid metabolites, protecting against pH 
changes; however these hypervolemic regions may not be distinguished from potentially 
malignant, non-nutritional hypervolemia within already evolving infarction. Figure 3.5 
shows a patient with a CBF/CBV mismatch at admission with little evidence of early 
ischemic change on the corresponding NCCT. Even with confirmed 
recanalization/reperfusion at 24 hours, portions of the supposedly viable hypervolemic 
tissue at admission still progressed to infarction. For the entire patient cohort, this 
admission CBF/CBV mismatch within areas of little or no early ischemic change 
discerned on contemporaneous NCCT images was observed in 38% (12/32) of patients 
with confirmed recanalization at 24 hours. Of this sub-group, 83% (10/12) of patients had 
hypervolemic tissue at admission (the CBF/CBV mismatch) and 24 hours (either a 
matched increase, or mismatch in CBF/CBV), that went on to infarction. Also, the same 
10/12 patients had full or partial hyperperfusion at 24 hours within areas of NCCT 
hypoattenuation at 3 months.  Moreover, incidence of HT was higher in patients with 
admission hypervolemia, but this group also had a higher incidence of recanalization; 
however, just 17% of patients with HT had hypervolemia out to 7 days.  
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Figure 3.5 Example of acute mismatch CBF/CBV, and sub-acute hypervolemia and 
hyperperfusion  
 
CT perfusion studies at admission, 24 hours, 7 days, and 3 months post ictus for AIS 
patient 29, with confirmed recanalization at 24 hours. NCCT, CBV and CBF maps are 
shown in rows 1, 2 and 3, respectively. A mismatch between CBF and CBV is apparent at 
onset. At 24 hours, CBF returns to normal, while a slight decrease in CBV was visible. At 
7 days, the CBF defect matched the area of hypoattenuation on the NCCT, while CBV 
remained high within the region of hypoperfusion. At 3 months, both the CBV and CBF 
defects matched the final infarct volume. NIHSS scores for this patient were 14, 7, 2, 1 
for onset, 24 hours, 7 days and 3 months, respectively, with modified Rankin score of 1 at 
3 months. 
 
Onset 24 hours 7 days             3 months
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We speculate that acute and sub-acute collateral recruitment and vasodilatory 
effort of relatively (compared to neurons) ischemic resistant endothelial cells is one of 
futility, as neurons have already begun their slow progression towards apoptotic/necrotic 
cell death, a process which could last out to 7 days post ictus; neurons are more 
vulnerable to ischemic injury than any other type of cell in the brain (except immature 
oligodendrocytes)
49-51
. Hypervolemia and hyperperfusion during the acute and sub-acute 
stages can also result from the opening of arteriovenous shunts (anastomoses) and 
subsequent increase in venous volume, a feature independent of the particular injury 
process, within the infarct zone
52
. Figure 3.6 depicts a scanning electron micrograph of 
the gerbil microvascular architecture in a control animal and papaverine pre-treated 
animal, injected with acrylic resin causing parenchymal herniation from brain swelling. In 
response to the increased intra-cranial pressure, development of direct arteriovenous  
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Figure 3.6 Example of arteriovenous shunting  
 
 
 
 
        
 
Scanning electron micrograph of the gerbil microvascular architecture in a control animal 
(A) and papaverine pre-treated animal (B), injected with acrylic resin causing 
parenchymal herniation from brain swelling. Arteriovenous shunting, venous filling, and 
capillary compression are evident. Adapted from Cererbral Hyperemia and Ischemia: 
From the Standpoint of Cerebral Blood Volume (p. 19), by M. Tomita et. al., 1987, 
Osaka, Japan: Elsevier Science Publishers. Adapted and Reprinted with permission 
 
 
 
 
 
 
 
 
 
 
A B 
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shunting via thoroughfare channels, venous distension, and compressed capillaries is 
evident.  In stroke, similar pathological mechanisms, as shown in Figure 3.6, likely 
characterize the transition from nutritive to non-nutritive hypervolemia as cytotoxic 
and/or vasogenic edema increases in conjunction with the loss of endothelial cell smooth 
muscle regulation, and capillary compression. Therefore, we hypothesize that a hyper-
acute CBF/CBV mismatch is not always indicative of viable tissue (penumbra), an 
important consideration when defining the infarct core. This is further validated by the 
fact that the degree of clinical improvement was not higher in patients with an acute 
CBF/CBV mismatch, compared to patients with a matched decrease in CBF/CBV (Table 
3.7). Nonetheless, the transition from nutritive to malignant hypervolemia is time 
dependent and differs between individuals.  
When implementing brain perfusion thresholds it’s also important to separate gray 
and white matter. In resting gray matter, average CBF values are approximately 50-60 
ml·min
-1
·(100g)
-1
, whereas white matter values are closer to 20-25 ml·min
-1
·(100g)
-1
. 
This substantial discrepancy in flow values is mainly because white matter synapses 
consume ≤ 0.5% of the energy of gray matter synapses53. It follows that white matter may 
be more tolerant to ischemia than gray matter, as there is a greater relative decrease in 
CBF from normal in gray matter than in white matter
54
. Further, since gray matter has a 
greater metabolic demand for maintenance of cell structure integrity, it can be expected 
that the damage would occur earlier and be more severe than white matter for a given 
CBF. Thresholds originating from human studies frequently use regions with combined 
gray and white matter, which could lead to under/overestimation of infarcted tissue in 
follow-up prospective studies. Since we know gray and white matter have very different 
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basal and pathological perfusion thresholds, current studies need to define separate 
thresholds for gray and white matter.  
This study is not without its limitations. First, use of the 3 month NCCT to 
determine final infarction volume could be affected by infarct shrinkage and secondary 
vascular injury, potentially causing under- and overestimation of final infarct volume, 
respectively. Second, only a 2cm slab of tissue was imaged during the CTP acquisition, 
which could have missed part of the infarct volume and hypervolemic states. Further, 
recanalization and reperfusion are defined using the 24 hour CTA and CTP-CBF images, 
respectively.  
In summary, the reliability of the admission CBV defect to define infarct is 
affected by the physiological factors of recanalization and hypervolemia, and the 
technical factor of TDCi truncation. When determining an optimal threshold to define 
acute tissue viability, patients should be dichotomized into recanalization positive and 
negative groups, due to potential differences in infarct expansion. The truncation artifact 
can cause varying degrees of artificial CBV reduction, potentially overestimating the 
acute infarct core. We observed varying perfusion states within evolving infarction, both 
acutely and sub-acutely. Late hypervolemia and hyperperfusion measures were not 
associated with clinical decline or HT, but could mask late evolving infarction if CBV 
thresholds were used to define infarct size. We speculate that early hypervolemia, as seen 
in the CBF/CBV mismatch, could contain ‘hidden infarction’ due to opening of non-
nutritive arteriovenous shunts, causing venous filling. This could affect both thrombolytic 
treatment decisions as well as the validity of CBV thresholds obtained from retrospective 
studies. At admission, the size of the CBVD volume in patients without admission 
hypervolemia, and lower CBF and CBV values were associated with HT development.  
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Although use of CBV thresholds may miss infarction present in ~80% of 
CBF/CBV mismatch,  we conclude that very low CBV, or a matched decrease in 
CBF/CBV, is a valuable predictor of infarct core, and potentially HT when the acquisition 
of TDCi data is complete and recanalization does not occur. Therefore, CBV thresholds 
for acute infarct core should be obtained from this sub-set of patients, and may be used to 
guide thrombolysis treatment.  
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CHAPTER 4  
Multi-modality Neuroimaging in a Porcine Model of Endothelin-1 
Induced Cerebral Ischemia: Defining the Acute Infarct Core 
 
The contents of this chapter have been adapted from the paper entitled “Multi-modality 
neuroimaging in a porcine model of endothelin-1 induced cerebral ischemia: defining the 
acute infarct core”, was submitted to Stroke in April, 2013 by: C.D. d’Esterre, U. 
Anazodo, K. St. Lawrence, L. Morrison, T.Y. Lee, E. Fainardi. 
 
4.1 INTRODUCTION 
As discussed in Chapters 2 and 3, delineation of irreversibly injured tissue that cannot be 
salvaged, even with reperfusion, in patients with anterior large vessel occlusion has 
important implications for recanalization decisions, hemorrhagic transformation 
prognosis, and long-term clinical outcome. Patients with a small infarct core volume, 
confirmed with neuroimaging techniques, and a high NIHSS will likely benefit from 
reperfusion therapy, less than 4.5 hours post ictus; however, consensus on the optimal 
imaging parameter to delineate hyper-acute infarct core remains uncertain
1-4
.  
There remains conflicting evidence concerning the reliability of the acute MR-
diffusion weighted imaging (DWI) defect, as permanent hyperintensity reversal is 
prevalent in both temporary artery occlusion models, and human stroke; however, the 
causal relationship between DWI defect reversal and improved clinical outcome remains 
uncertain
5, 6
. Due to the impracticality of the MRI modality during the acute stroke 
setting, much effort has been put forth to determine CT perfusion (CTP)-derived 
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hemodynamic thresholds to define acute tissue states - CT imaging is fast, non-invasive, 
and with new dose-saving techniques, relatively safe
7, 8
. Taking into account certain 
caveats which affect the prognostic ability of the cerebral blood volume (CBV) 
parameter, namely reactive hypervolemia, truncation of the ischemic time density curve, 
and recanalization status, reversibility of very low CBV is uncommon, as loss of vascular 
autoregulation likely represents non-viable tissue
9, 10
. In contrast, normal or elevated CBV 
is suspected to represent either nutritive or non-nutritive hypervolemia, within electrically 
silent yet viable tissue (penumbra) and infarct core, respectively, as discussed in Chapter 
3. As such, recent reports suggest a cerebral blood flow (CBF) threshold is optimal to 
separate infarct from penumbra, prior to reperfusion efforts
1, 2, 11
. It has been shown in 
animal stroke studies that the threshold for pan-necrosis is between 0.17 and 0.24 ml·min
-
1
·g
-1 
with persistent occlusion
12
. This threshold decreases to 0.12 ml·min
-1
·g
-1
 when 
ischemia is limited to a few hours
13
.  However, the threshold of infarction (pan-necrosis) 
for ischemia lasting less than an hour, which is becoming more relevant in the era of rapid 
revascularization, is unknown.   
Due to the assortment of different perfusion post-processing algorithms, and 
consequent lack of standardized perfusion thresholds, CTP has yet to fully breakthrough 
into the clinical setting
4, 11, 14
. Further, many CTP thresholds are commonly compared to 
the final infarct volume derived from delayed imaging at 24 hours or 5-7 days post ictus, 
which may under/overestimate the final infarct volume, depending on time of 
recanalization
15, 16
. PET imaging with 
18
F-flumazenil, the imaging gold standard for 
infarction, or histology are not feasible in the clinical setting
17, 18
. Therefore, stroke 
models continue to be valuable for defining and assessing perfusion thresholds for acute 
tissue status. The use of endothelin-1 (ET-1) to cause transient cerebral ischemia has been 
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well established in rodents and lower primates
19, 20
. As a potent vasoconstrictor, ET-1 
causes a dose-dependent focal CBF decrease through G-protein coupled contraction of 
smooth muscle, adjacent to endothelium
21
. Appearance of infarction, with minimal tissue 
edema, occurs within an hour of ET-1 administration, mimicking ischemic progression 
similar to that of humans
22
. This characteristic makes the ET-1 stroke model useful for 
tracking changes in vascular/tissue pathophysiology during the early stages of stroke 
onset
23
. 
This hyper-acute ischemic stroke study sought to determine: 1) whether the 
predicted infarct volume (PIV) described by CTP parameters and contemporaneous DWI 
imaging correlates with true infarct volume (TIV) defined by 2,3,5-tetrazolium chloride 
(TTC) histology;  2) the distribution of 
18
F-FDG uptake (glucose metabolism) within the 
TIV and peri-TIV; 3) CTP-CBF and CBV values within superimposed TIV regions of 
interest.  
 
4.2 MATERIALS & METHODS 
4.2.1 Study design 
 Animal experiments were conducted following the guidelines of the Canadian Council 
on Animal Care and approved by the Animal Use Subcommittee at the University of 
Western Ontario
+
.  Duroc-cross pigs (n = 10) were obtained from a local supplier, housed 
and allowed to grow to a desired weight of 45 ± 10 kg.  Anesthesia was induced with an 
intra-muscular injection of telazol (100 mg/ml, 1 ml/20 kg).  A 22 gauge catheter was  
 
_____________________________________ 
+
 Appendix C – Human Ethics Approval form  
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placed in the ear vein for single bolus of propofol (10 mg/ml, 2-5 mg/kg) to maintain 
anaesthesia during intubation.  Animals were mechanically ventilated with an 
oxygen/medical air mixture and surgical anesthesia was maintained with inhaled 
isoflurane at 2-4%.  A 22 gauge catheter was placed in the cephalic vein for imaging 
contrast injections. A femoral artery was also catheterized (24 or 22 gauge) to monitor 
heart rate and mean arterial blood pressure as well as to intermittently collect arterial 
blood samples for blood gas measurements. Heart rate, end tidal CO2, arterial O₂ 
saturation, respiration rate, blood pressure and temperature were monitored continuously.  
Rectal temperature was maintained between 37.5 and 39.5 ◦C at all times throughout 
surgery and imaging, using a whole-body water blanket. The animals were placed in a 
prone position, an incision was made above the parietal bone, mid-way between the left 
ear and eye, and the skin and periosteum were separated from the skull bone. A 2 mm 
diameter hole was drilled into the parietal bone through the incision site, using a dremel 
rotary hand tool. A 27 gauge, 1 ¼ inch needle and PE20 polyethylene tubing was used to 
inject 25µg of ET-1 (human/porcine, Sigma Chemical Company, St. Louis, MO, USA) in 
150 µL of sterile water, at a rate of 50µL/minute (NE-100 single syringe pump, New Era 
Pump Systems Inc., Farmingdale, NY). Careful placement of the needle into the left 
striatum, avoiding ventricles, was confirmed with a non-contrast CT (NCCT) scan prior 
to ET-1 infusion. Two equal doses of ET-1 were given 2 hours apart with monitoring of 
ischemic progression using CT perfusion imaging after each infusion. An experimental 
timeline is shown in figure 1. Throughout all imaging anesthesia was maintained with 2-
3% isoflurane. 
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Figure 4.1 Timeline for the experimental protocol 
 
 
 
Mean ± standard deviation acquisition time for post 3 hour contemporaneous MR, CTP 
and PET imaging was 2hrs21min ± 18min. CTP = CT perfusion, ET-1 = endothelin-1, 
18
FDG = glucose analog radiotracer, MR-DWI = magnetic resonance diffusion weighted 
imaging, PET = positron emission tomography, TTC = tetrazolium chloride stain 
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4.2.2 Computed tomography perfusion imaging  
Each CT acquisition was performed with a Discovery LS PET/CT hybrid scanner (GE 
Healthcare, Waukesha, WI). A preliminary axial CT scan was used to localize 16 x 2.5 
mm-thick slices in the territory of the ET-1 injection. For CT perfusion (CTP) imaging, a 
contrast-enhanced cine continuous scan was performed where the couch remained 
stationary while the gantry rotated continuously, acquiring images simultaneously from 
sixteen different (contiguous) slice locations. A 40 ml bolus of 370 mg·ml
-1
 non-ionic, 
iodinated contrast (Isovue®-300, Bracco Diagnostics, Princeton, NJ) was injected (1.5 
ml•s-1) into a saphenous vein  5 seconds after the start of the CTP acquisition. The head 
was continuously scanned at 120 kVp, 200 mA and 1second rotation period for 120 
seconds, to avoid any truncation artifact. From the acquired data, 512 x 512 images were 
reconstructed at 0.5 second intervals and 15 cm FOV.  CTP scans were performed at 
baseline (pre-ET-1) and every 30 minutes post-ET-1 to monitor its effect on tissue 
perfusion. A second dose of ET-1 was given around 2 hours after the first dose – the 
second dose was given when the CBF defect started to normalize, as observed on the 
CTP-CBF functional maps (ie. any shrinkage of the initial CBF defect observed after the 
first ET-1 infusion). ‘Severe’ ischemia (adequate to cause infarction) was confirmed with 
CTP imaging immediately following the infusion. The final CTP acquisition was 
performed within 10 minutes of the completion of MR imaging (see below).  
 
4.2.3 Magnetic resonance imaging  
MR imaging was performed on a Siemens 3T BIOGRAPH mMR (Erlangen, Germany) 
with software syngo VB 18P.  Heart rate and O2 saturation were monitored by an MR 
compatible pulse oximeter (8604F0 Pulse Oximeter, Nonin Medical, Plymouth, MN).  
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Animals were imaged supine using a 15 channel phase array transmit/receive extremity 
coil. Diffusion imaging was performed parallel to collosal line as determined from 
acquisition of 3D high resolution anatomical scan (MPRAGE T1, 1 mm x 1 mm x 1 mm 
resolution).  Echo Planar DWI was acquired with the following parameters:  TR 
(repetition time) 3500 ms, TE (echo time) 95 ms, FOV (field of view) 220 mm, spectral 
fat saturation, 16 interleaved slices 5 mm thick with no gap, matrix 128 x 128, in-plane 
resolution 1.7 mm x 1.7 mm, acceleration GRAPPA 2, b-values 0 and 1000 s/mm
2
, 20 
diffusion gradient directions, 6 signal averages and bandwidth 1446 Hz/pixel.  Time for 
DWI acquisition 7:46 min. 20 diffusion directions were applied to avoid anisotropy 
effects and allow signal averaging to generate high quality apparent diffusion coefficient 
(ADC) maps from the DWI data. Median (range) time (minutes) of MR imaging relative 
to the second ET-1 infusion was 57 (49-68).  
 
4.2.4 
18
F-FDG Positron emission tomography imaging  
Thirty minutes after the second injection of ET-1, a dose of the glucose analog, fluorine-
18 labeled fluorodeoxyglucose (
18
F-FDG, 300-380MBq), was administered via ear vein. 
PET imaging commenced within 15 minutes of completing the MR imaging (3 minutes 
after completion of the last CTP scan), 40-60 minutes after 
18
F-FDG injection.  Prior to 
acquisition of the PET raw data, a CT-based attenuation correction was performed. PET 
emission data was collected on a Discovery LS PET/CT hybrid scanner (GE Healthcare) 
in 2D mode, with a photopeak window of 280-700keV for 20 minutes. Data were 
acquired in a 128 × 128 matrix with pixel widths of 0.478 mm and slice thickness of 3.3 
mm. Image sets were reconstructed, using the iterative reconstruction software available 
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on the commercial system (GE Medical Systems software) including attenuation and 
random correction. 
 
4.2.5 Histology 
Following imaging, the whole brain was carefully excised and cut into coronal sections 
corresponding to the CT-perfusion weighted images (PWI) scan slice locations. To 
identify infarcted tissue, each slice was stained with TTC to quantify the extent of dead 
tissue, and fixed in 10% formalin. TTC, which is colorless in solution, is reduced to a 
deep red formazan by dehydrogenase enzymes of functioning mitochondria, while 
infarcted brain regions do not convert TTC and remain unstained. Digital images were 
acquired with a desktop colour scanner (Brother DCP-7040, Bridgewater, NJ).  Image J 
(Image J, Bethesda, MD) software was used to determine the TIV (cm
3
) as described 
previously
24
. Briefly, to determine infarct volume by manual measurement, a calibration 
factor was derived by scanning a ruler alongside the brain slices, and determining the 
number of pixels per mm. For each animal, this calibration factor was entered into ImageJ 
to convert pixel area measures to mm
2
. The outlined infarct area for each slice was 
multiplied by 5 mm (thickness of each section) and the volumes summed to get the true 
infarct volume (cm
3
). 
 
4.2.6 Image analysis 
For consistency, functional maps of cerebral blood flow [CBF; ml·min
-1
·(100g)
-1
] 
cerebral blood volume [CBV; ml·(100g)
-1
] and time-to-maximum (Tmax; seconds) were 
calculated by one author using a commercially available delay-insensitive deconvolution 
software (CT Perfusion 4D, GE Healthcare, Waukesha, WI). A 2 × 2 pixel region of 
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interest was placed in the right common carotid artery to obtain the arterial input function 
(AIF). The AIF was deconvolved with each tissue time density curve using a method 
described previously
25, 26. After functional map processing, a CBF•CBV product map was 
also calculated by multiplying matching voxels from the CBF and CBV functional maps. 
PWIs were created by averaging the cine CTP images over the duration of the first pass of 
CT contrast.  
Custom software (IDL, version 6.2, RSI, Boulder, Colorado) was used for all 
image post processing analysis. The ~3 hour post (final CTP acquisition) CTP-PWIs were 
matched up with the histological slices to establish the reference slab. Using anatomical 
features, the MR-DWI/ADC maps, and 
18
FDG-PET images were registered with the 
CTP-PWI image set and hence the CTP functional maps as well.  
The PWIs were used to exclude cerebrospinal fluid and cranium from analysis as 
well as to produce a gray and white matter anatomical mask based on the Hounsfield Unit 
differences between the two tissue types. The critically hypoperfused area was defined as 
relative Tmax > 2 
2
. Gray and white matter CTP thresholds, derived from human studies 
(see Appendix D), were used to delineate the PIV volume on CBF, CBV and CBF•CBV 
functional maps, while blinded to MRI, PET, and histological results. CBF, CBV and 
CBF•CBV product infarct thresholds were 10.1 ml·min-1·(100g)-1, 1.9 ml·(100g)-1, and 
26.0, respectively, for gray matter and 7.4 ml·min
-1
·(100g)
-1
, 1.25 ml·(100g)
-1
, and 9.9, 
respectively, for white matter (Appendix D). The volume of each voxel was determined 
as (120 mm/512 pixels)
2 
x 5 mm. For each animal, total infarct volume (cm
3
) was 
calculated by multiplying the number of infarct positive voxels (gray plus white matter) 
with the voxel volume.   
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As a secondary analysis, the histologically defined TIV was superimposed onto 
CTP-CBF and CBV functional maps to determine perfusion values within gray and white, 
and mirrored contralateral regions.  Pixels with a CBF > 100 ml·min
-1
·(100g)
-1
 or CBV > 
8 ml·(100g)
-1
 were excluded from the region of interest to remove influence of large 
vessels on parenchymal perfusion
27
. Animals were classified as having CBF/CBV 
mismatch (complete or partial) or CBF/CBV matched decrease (Table 4.2). We define 
mismatch as an increase in CBV, from within the superimposed TIV, greater than the 
average plus one standard deviation of the CBV value obtained from the contralateral 
mirrored region of interest (ROI) for each animal.  
MR-derived PIV was defined as the abnormal hyperintense (exceeding the DWI 
signal intensity of the contralateral hemisphere by more than three standard deviations) 
and hypointense (ADC signal < 85% of contralateral hemisphere) areas on DWI and 
ADC maps, respectively, while blinded to CTP, PET and histological results, as described 
previously
28, 29
. The volume of each voxel was determined as (220 mm/128 pixels)
2 
x 5 
mm slice thickness. Total number of voxels in all slices were determined and scaled by 
the voxel volume to obtain the total infarct volume (cm
3
). 
We visually assessed uptake of the 
18
F-FDG semi-quantitatively within 
superimposed TIV as defined by TTC staining by categorizing the regional uptake as 
increased, decreased, or similar to uptake in the contralateral hemisphere. Core, periphery 
and peri-infarct uptake were assessed (Figure 4.2).  Core was defined as very low uptake 
[Standard uptake value (SUV) < 50% of contralateral hemisphere SUV] within the 
superimposed TIV. Periphery-TIV is the total TIV less the core-TIV area. All ROIs were 
mirrored into contralateral hemisphere. 
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Figure 4.2 Assesement of glucose metabolism with 
18
FDG-PET 
 
 
 
TTC-stained excised brain with TIV delineated and corresponding 
18
FDG uptake with 
superimposed TIV (solid black lines), core ROI (solid white), peri-TIV (dashed white).  
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4.2.6 Statistical analysis 
The statistical package, SPSS 15.0 (SPSS Inc., Chicago, IL), was used for all analyses. 
Differences were considered significant at p < 0.05. All data sets were checked for 
normality with the Shapiro-Wilk test prior to analysis with the appropriate parametric or 
non-parametric tests. 
The relationship between the PIV as defined by CTP and MRI parameters and 
TIV from TTC-histology was evaluated for agreement with: 1) percent difference, 2) 
linear regression and 3) Bland-Altman analysis between PIV and TIV. The last analysis 
determined the systematic error (bias) and the 95% limits of agreement, defined as the 
mean and ± 1.96 times standard deviation of the individual differences respectively. 
Pearson correlation was applied to 2), while pairwise multiple comparisons using 
ANOVA with Tukey correction was applied to 1). Also, a paired student t-test was used 
to compare average CBF and CBV values from within superimposed TIV and mirrored 
contralateral TIV. Differences were considered significant at p < 0.05.  
 
4.3 RESULTS 
For all imaging parameters, a significant correlation (p < 0.05) was observed between the 
PIV and TIV (Figure 4.3). The CTP-CBF parameter had the highest R
2
 value and slope 
closest to unity, while the CTP-CBV had the lowest R
2
 value and slope furthest away 
from unity. The CTP-CBF•CBV parameter had a higher R2 value, but lower slope than 
both MR parameters.   
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Figure 4.3 Regression of imaging defined PIV versus TTC defined TIV 
 
 
Scatterplots for predicted infarct volumes (PIVs) as defined by A) MR-DWI, B) MR-
ADC, C) CTP-CBF, D) CTP-CBV, E) CTP- CBF•CBV versus the true infarct volume 
(TIV), defined on TTC-stained excised brain (n=10). Graphs are plotted with linear 
regression fit (solid line) and 95% confidence intervals (dashed lines). Adjusted R
2
 
values, p-values and slopes of regression lines are also shown. Significance was classified 
as p < 0.05.   
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The 95% limits of agreement from the Bland-Altman analysis were as follows: 
MR-DWI = [8.7, -11.5], MR-ADC = [11.1, -12.7], CTP-CBF = [4.7, -6.8], CTP-CBV = 
[23.0, -9.1], CTP-CBF•CBV = [14.4, -5.6]. The best agreement was observed with CTP-
CBF. The limits of agreement for MR-DWI and CTP- CBF•CBV were closely matched 
(Figure 4.4).   
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Figure 4.4 Bland-Altman plots  
 
 
Bland-Altman plots for predicted infarct volumes (PIVs), as defined by A) MR-DWI, B) 
MR-ADC, C) CTP-CBF, D) CTP-CBV, E) CTP- CBF•CBV, and the true infarct volume 
(TIV), defined on TTC-stained excised brain (n=10). For all plots, the y-axis depicts the 
difference between the PIV and TIV, while the x-axis depicts the mean of both PIV and 
TIV values. Also shown are the mean differences (dotted line) ± 95% limits of agreement 
(solid lines).  
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PIV from MR-DWI, ADC and CTP-CBF overestimated the TIV defined with 
histology (Table 4.1). The percent difference between CTP-CBF defined PIV and TIV 
was significantly lower than those for CTP-CBV and CTP-CBF•CBV defined PIVs  (p < 
0.05). Significant differences were not observed between CTP-CBF, MR-DWI or MR-
ADC defined PIVs   or their percent differences from TIV (p > 0.05).  For all animals, 
mean CBF within superimposed TIV was decreased relative to the contralateral side (p < 
0.05), while CBV was not (p > 0.05). Median (range) values for CBF [ml·min
-1
·(100g)
-1
] 
and CBV [ml·min
-1
·(100g)
-1
] within mirror contralateral TIV ROIs were 42.3 (31.5-64.1) 
and 2.1 (1.9-2.7) for gray matter, respectively, and 28.9 (19.4-38.0) and 1.5 (1.2-2.1) for 
white matter, respectively. A complete CBF/CBV mismatch (hypervolemia without a 
CBV defect), partial mismatch (hypervolemia with a CBV defect) and absent mismatch 
(no hypervolemia) was observed in 3/10 (30%), 3/10 (30%), and 4/10 (40%) of animals, 
respectively (Table 4.2). 
A decrease in glucose metabolism (reduced uptake of 
18
FDG) was observed 
within the core TIV, peripheral TIV, and peri-TIV in 8/10 (80%), 1/10 (10%) and 0/10 
(0%) of animals (Table 4.2).   
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Table 4.1 Infarct volumes from MR imaging, CTP imaging and histology.  
 
Parameter 
Infarct volume  
Median [range] 
(cm
3
) 
% change between PIV & 
TIV 
Mean ± SD (cm
3
)   
MR-DWI 13.9 [3.1-27.1] -31.4 ± 98.5 
MR-ADC 14.1 [2.3-24.3] -31.6 ± 115.4 
CTP-CBF 13.3 [3.8-30.9] -23.3 ± 31.7* 
CTP-CBV  3.2  [0.4-19.6] 42.3 ± 44.1 
CTP-CBF·CBV  6.2  [1.2-21.4] 28.5 ± 31.5 
Histology (TTC) 10.6 [0.7-32.3] N/A 
 
   *Significantly different from the CTP-CBV and CTP-CBF•CBV parameters (p < 0.05).                                                     
TTC = tetrazolium chloride, PIV = predicted infarct volume, TIV = true infarct 
volume, N/A = not applicable 
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Table 4.2 CT perfusion values from within superimposed true infarct volume and 
corresponding glucose metabolism.  
 
Animal 
Perfusion values within TIV 
ROI 
 18FDG-uptake  
Gray matter White matter CBF/CBV 
mismatch 
Core 
TIV 
Peripheral 
TIV 
Peri-
TIV CBF CBV CBF CBV 
1 6.5 1.8 4.3 1.5 Complete ↓ ↑ → 
2 11.6 2.3 7.4 1.9 Complete ↓ ↑ ↑ 
3 7.6 2.0 6.9 1.1 Absent ↓ ↑ ↑ 
4 8.5 1.9 7.5 1.3 Complete ↓ ↑ → 
5 9.1 1.7 5.7 1.2 Partial ↓ → ↑ 
6 12.6 1.1 5.3 1.0 Partial ↓ ↓ ↑ 
7 4.87 1.8 7.2 0.9 Partial → → ↑ 
8 9.1 1.2 5.8 1.1 Absent ↓ ↑ ↑ 
9 5.9 1.4 6.7 0.7 Absent ↓ ↑ ↑ 
10 13.7 2.3 14.7 1.8 Absent → ↑ ↑ 
Mean 8.9 1.8 7.2 1.3 
 
Stdev 2.9 0.4 2.8 0.4 
       
TIV = true infarct volume, ROI = region of interest, Complete mismatch = hypervolemia 
without CBV defect, Partial mismatch = hypervolemia with CBV defect, Absent mismatch 
= no hypervolemia. 
18
F-FDG was categorized as increased (↑), decreased (↓), or similar 
(→) to the uptake in the contralateral hemisphere.  Units for CBF is ml·min-1·(100g)-1 and 
CBV is ml·(100g)
-1 
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4.4 DISCUSSION 
This study used a porcine model of enndothelin-1 (ET-1) induced focal cerebral ischemia 
to compare predicted infarct volume (PIV) with true infarct volume (TIV), defined with 
acute neuroimaging and histology, respectively. We showed that the PIV defined with 
absolute gray and white matter CT-CBF thresholds correlated best with the TIV, and was 
similar to both MR-DWI and ADC defined PIVs. This is contrary to previous results 
which showed that the CBF•CBV product was the optimal parameter for infarct 
delineation in gray and white matter
15, 16
. These studies by Murphy et al. used a shortened 
CTP acquisition of 45 seconds, delay-sensitive CTP software, and defined the final 
infarct volume with a 7 day NCCT, which could be larger than the acute infarct volume 
due to maturation and edema. Herein, we used a 2-phase 120 second CTP acquisition to 
eliminate data truncation, followed by functional map calculation using the newest delay-
insensitive CTP software (GE Healthcare, CT Perfuison 4D), and compared our CTP-
PIVs with both the imaging and histological gold standards
30
.  
 Our result is consistent with the current literature which confirms that CBF is 
superior to CBV and CBF•CBV in defining infarct volume; although consensus on the 
use of relative or absolute CBF thresholds has not been established
31
. Applying an 
absolute CBF threshold can be problematic if CTP image acquisition protocol and 
processing algorithms are not optimized to calculate accurate CBF values. In this study, 
the average CBF gray and white matter  (9.9 and 7.2 ml·min
-1
·(100g)
-1
, respectively), 
from within superimposed TIV, varied only ~8% and ~2%, respectively, from the 
described clinical CBF thresholds, obtained using similar scanning parameters with the 
same post-processing algorithm and image analysis. These CBF values are similar to 
those obtained by Jones et al. (1981) who demonstrated in a primate stroke model, that 
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the CBF threshold for infarction was 10–12 ml·min-1·(100g)-1 for 2–3 hours of occlusion 
which was similar to the time of ischemia in this study 
12
. Conversely, CBV values from 
both gray and white matter were ~17% and ~27% higher, respectively, than human 
thresholds, which is likely due to the varying incidence of hypervolemia at the time of 
CTP imaging.  
 As discussed in chapter 3, the prognostic reliability of the CBV parameter is 
affected by reactive hypervolemia, truncation of ischemic time density curve, and 
recanalization status, all of which will vary between study cohorts. Drawbacks for the use 
of relative to contralateral ‘normal’ region perfusion thresholds include variation in 
gray/white matter tissue distributions, potential underlying vascular pathologies, and 
variable/unstable central hemodynamic status of acute stroke patients at admission. 
Many investigators define the penumbra as hypoperfused (low CBF) tissue with 
hypervolemia (high CBV, relative to the contralateral hemisphere) - the so called 
CBF/CBV mismatch hypothesis
33, 34
. Complete or partial CBF/CBV mismatch was 
observed in 60% of animals, and in all of these cases, a portion of the mismatched area 
occurred within infarcted tissue, defined with histology (Figure 4.5 B & C). As described 
in chapter 3, we speculate that acute increases in CBV may be nutritive or non-nutritive, 
the latter caused by the opening of arteriovenous shunts within areas of considerable 
neuronal death
35
. These mismatched regions were accompanied by varying degrees of 
glucose metabolism, which may indicate whether the CBV increase is futile or not; 
however, increased 
18
F-FDG accumulation could also be due enhanced anaerobic 
glycolysis, activated repair processes (inflammatory phagocytosis and gliosis), and 
neuronal excitation from spreading depolarization
36, 37
. This is one limitation besides 
others (see below) of this study.  
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Both the DWI and ADC defined PIV overestimated the TIV in 60% of animals, by as 
much as 350%. Nonetheless, brain tissue that stains positively for TTC may not 
necessarily be healthy and may yet succumb hours later. TTC staining  relies on the 
ability of mitochondrial dehydrogenase enzyme to react with the tetrazolium salt to form 
the red formazan pigment
18
. Therefore, with mitochondrial breakdown, and subsequent 
dehydrogenase enzyme denaturation, the pro-apoptotic/necrotic factors are released into 
the cell
38
. The DWI and ADC parameters are related to bioenergetic failure in neurons, 
causing cytotoxic edema and reduced water diffusion
39
. Therefore, for tissue with a DWI 
-PIV/TIV mismatch, mitochondria are not producing enough ATP to maintain neuronal 
ionic gradients, but their structural integrity is likely maintained – a borderzone between 
infarct core and penumbra
40
. Timely reperfusion of this tissue region is potential cause for 
the high incidence of DWI reversal in both clinical and experimental studies
5, 41
. 
Similarly, CBF defined PIV overestimate the TIV in 60% of animals by as much as 
~70%.  One possible explanation is that CBF threshold for infarction was derived from a 
prior clinical study in which the infarct size was determined from a 5-7 days post ictus 
NCCT scan. The expansion of infarct between admission and follow-up imaging could 
contribute to a higher CBF threshold for infarct evaluated at admission. 
 
 
 
 
 
 
 
 
 
 
 
 
137 
 
 
 
 
 
Figure 4.5 Examples of imaging and TTC stained brains 
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Coronal sections of (i) TTC stained excised brain, with infarct outlined in white, (ii) MR-
DWI, (iii) MR-ADC, (iv) CTP-CBF, (v) CTP-CBV, (vi) 
18
FDG uptake. Colour maps of 
CBF and CBV are 0-100 ml·min
-1
·(100g)
-1
 and 0-8 ml·(100g)
-1
, respectively.  (A) Animal 
3 shows matched infarct volume defects in all imaging modalities, with a decrease and 
increase in 
18
FDG uptake within core TIV and peri-TIV, respectively, relative to 
contralateral uptake; (B) Animal 4 shows a complete CBF/CBV mismatch in the 
corresponding TTC- and MR-defined infarct volumes, along with a decrease and same 
18
FDG uptake in the core-TIV and peri-TIV areas, respectively, relative to contralateral 
uptake. (C) Animal 6 shows a partial CBF/CBV mismatch, which corresponds to TTC- 
and MR-defined infarct volumes, with a decrease in 
18
FDG uptake within the entire TIV 
and peri-TIV, relative to contralateral uptake. (D) Animal 10, shows MR-defined DWI 
and ADC infarct volumes without corresponding TTC- and CTP-defined infarction, with 
the same and increased 
18
FDG uptake within the core-TIV and peri-TIV, respectively, 
relative to contralateral uptake.  
 
 
 
 
 
 
 
 
 
 
 
 
 
139 
 
 
 
Besides the limitation of the 
18
FDG-PET study, this study has several other 
limitations. First, ET-1 receptors are found on vascular smooth muscle cells (pericytes) 
and, endothelial cells. When ET-1 binds to endothelial receptors, the formation of nitric 
oxide (NO) is stimulated, and in the absence of smooth muscle endothelin receptor 
stimulation, this NO causes vasodilation
42, 43
. Therefore, the hypervolemia, observed in 
the CBF/CBV mismatch of this study, may be mechanistically different than that 
observed in thromboembolic stroke models where presence of arteriovenous shunts 
causing venous filling and capillary compression are expected and can be confirmed with 
scanning electron microscopy. Second, false-negative errors may be caused by partial 
volume effects of neighbouring large blood vessels, masking regions of infarction; this 
may contribute to the high incidence of CBF/CBV mismatch within DWI and TTC 
defects. Third, as mentioned previously, glucose is used for all processes requiring 
energy, including acute inflammation and excitotoxic events, which may mask the 
reduced glucose uptake within infarcted tissue. The use of 
18
F-flumazennil, a central 
benzodiazepine receptor antagonist, would be specific for neuronal death
44
.  Fourth, we 
qualitatively assessed and outlined DWI and ADC defects, which has a high level of 
subjectivity; applying diffusion thresholds may be an objective way to delineate 
infarction, and could improve accuracy in delineating infarct volume. Fifth, PIV can 
underestimate TIV as TTC staining occurred 20-30 minutes after the animal was 
euthanized as time was required to excise the brain; moreover, TIV may also be 
underestimated as the apoptotic cascade may already be initiated within peri-infarct 
tissue.  Lastly, differentiation between gray and white matter is challenging due to limited 
resolution of the CT scanner coupled with the smaller porcine brain compared to humans.  
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4.5 CONCLUSION 
This study determined that the CBF parameter is as good as MR diffusion imaging for 
acute infarct delineation, when CTP functional map calculation and image post-
processing was standardized. We also show that the CBF/CBV mismatch may not 
indicate penumbral tissue in the acute stroke setting. These observations could have 
implications on patient selection for thrombolytic therapy.  
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CHAPTER 5  
Hemorrhagic Transformation of Ischemic Stroke:  
Prediction with CT Perfusion 
 
The contents of this chapter have been adapted from the paper entitled “Hemorrhagic 
transformation of ischemic stroke: prediction with CT perfusion” published in Radiology 
2009;250(3):867-77 by R.I Aviv, C.D. d’Esterre, B.D. Murphy, J.J. Hopyan  B. Buck, G. 
Mallia, V. Li, L. Zhang, S.P. Symons, T.Y. Lee. 
 
5.1 INTRODUCTION 
Hemorrhagic transformation (extravasation of red blood cells through a damaged BBB; 
HT) of acute ischemic stroke is an undesirable complication that occurs with rates 
between 2.2% and 44% in clinical studies and increasing to 70% in pathological studies
1-
5
. Several radiological and clinical parameters including baseline stroke severity, time to 
reperfusion, thrombolytic protocol violations, tissue plasminogen activator (tPA), white 
matter disease burden, aspirin, and heparin use are associated with HT
6-12
. While more 
severe hemorrhage is undisputedly associated with worse outcome, there is controversy 
whether less severe forms of hemorrhage are important
8, 10, 13-17
. Considering that even 
small amounts of hemorrhage may be detrimental, it may be desirable to detect patients 
who are more likely to undergo HT prior to tPA administration. Disruption of blood-brain 
barrier (BBB) integrity, considered focal to the development of HT has been 
demonstrated in animal models as increases in PS, but has not yet been fully elucidated in 
humans
18, 19
. Recently, a small study using dynamic contrast-enhanced MRI with kinetic 
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modeling demonstrated the feasibility of measuring BBB disruption
20
. However, the 
availability, speed, and accessibility of CT are key reasons that it remains the diagnostic 
procedure of choice in initiating thrombolysis. CT is also able to provide physiological 
information regarding the infarct core and tissue at risk, as described in Chapter 1
21-23
. 
This is achieved with a dynamic contrast enhanced CT, or CT perfusion study with a 
duration of 70-90 seconds. By extending the acquisition time window, further information 
relating to the BBB integrity can be calculated
24
. Techniques for the measurement of the 
CTP-permeability surface area product (PS) have been shown to be achievable with CTP 
in animal tumor models and a small human case series, but until recently has not been 
applied to stroke imaging
25-28
.  
 The aim of this study was to determine whether admission CT perfusion–derived PS 
maps differ between patients with HT secondary to ischemic stroke and those without 
HT. We hypothesize that patients with HT will have an increased BBB-PS compared to 
those without HT. 
  
5.2 MATERIALS & METHODS 
5.2.1 Study design and patient cohort  
Patients were prospectively recruited at a regional stroke centre (Sunnybrook Health 
Sciences Center, Toronto, Canada) between January 2006 and October 2007. All study 
procedures and medical chart review were approved by the institutional research ethics 
board
+
. All recruited patients gave signed consent for the study. Inclusion criteria were: 
less than 3 hours of stroke symptoms, full clinical assessment by the on-call neurology  
____________________________________ 
+
 Appendix E – Human Ethics Approval form  
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stroke team, completed CT stroke imaging protocol at admission, as described below; 
completed follow up CT and MRI study (including MR-diffusion weighted and gradient-
echo T2 weighted imaging) 5-7 days after stroke onset to determine final infarct size and 
detect HT. All patients were included, regardless of whether they underwent 
thrombolysis. One of two dedicated stroke neurologists, each with more than 5 years 
stroke experience and certified in National Institutes of Health Stroke Scale (NIHSS) 
score and modified Rankin score assessments, collected baseline patient data (age; 
sex;blood pressure; clotting status; NIHSS score; tPA treatment status, dose, route, and 
administration time; and stroke onset) at presentation and determined the modified 
Rankin score at the 90-day follow-up stroke clinic visit. Intravenous tPA therapy was 
administered up to 3 hours after symptom onset, following the admission CT perfusion 
examination, according to standard clinical practice based on American Heart 
Association–American Stroke Association guidelines29. TPA treatment was administered 
in patients with an Alberta Stroke Program Early CT (ASPECT) score of 5 or higher
30
. A 
modified Rankin score of 2 or lower was considered a good clinical outcome. The data 
were maintained in a database. Patients were excluded if they had contraindications to 
iodinated contrast material injection or MR imaging. Patients who repatriated to a local 
hospital before completing the CT stroke imaging protocol were also excluded. Seventy-
four patients met the study entry criteria. Thirty-three patients were excluded owing to 
repatriation to another hospital before completion of the imaging protocol (n=26), 
intraventricular hemorrhage (n=1), or excessive movement during imaging (n=6). Fourty-
one patients were included in this study. 
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5.2.2 CT and MR imaging protocols 
A CT stroke series was performed at admission using a 64-section scanner (VCT GE 
Healthcare) which included a non-contrast CT (NCCT), contrast-enhanced CT 
angiography (CTA) and CT perfusion (CTP). The NCCT was taken at 120 kVp, 300 mA, 
a 1-second rotation, a 5 mm section thickness. The CTA, from the aortic arch to the 
vertex, was performed with the administration of iodinated contrast material (300 mg of 
iodine per kilogram of body weight; iohexol [Omnipaque], GE Healthcare, Piscataway, 
NJ) to a maximum of 90 mL, a 5–10 second scanning delay, 120 kVp, 270 mA, a gantry 
speed of 1 second per rotation, a 1.25-mm section thickness, and a table speed of 20.62 
mm per rotation. After the CT angiography series, a two-phase CTP examination was 
performed. The first phase involved a 45-second continuous (cine) acquisition 
reconstructed at 0.5-second intervals to produce a series of 90 sequential images of eight 
sections each, encompassing a total of 40 mm from the basal ganglia to the lateral 
ventricles. In the second phase of the CTP exam, images encompassing the same eight 
sections were collected at 15-second intervals for an additional 90 seconds immediately 
after the first phase. The scanning parameters for both phases were 80 kVp, 190 mA, 8x5 
mm collimation, and a gantry speed of 1 second per rotation. A 0.5 mL/kg dose (maximal 
dose, 50 mL) of iohexol was injected at a rate of 4 mL/sec 3–5 seconds before the start of 
the first phase. Follow-up CT and MR examinations were performed for all patients 5–7 
days after stroke onset. NCCT scanning was performed as described above. MR 
sequences were performed as follows: diffusion-weighted imaging (DWI) parameters 
were 8125/minimum (repetition time msec/echo time msec), 26-cm field of view, image 
matrix of 128 x 128 pixels, 5 mm section thickness with no intersection gap;  fast low-
angle inversion-recovery imaging with scanning parameters of 8000/120/200 (repetition 
150 
 
 
 
time msec/echo time msec/inversion time msec), 22-cm field of view, image matrix of 
320 x 224 pixels, 5-mm section thickness with 1-mm intersection gap); and gradient-echo 
T2-weighted (1100/35, 20° flip angle, 24 cm field of view, image matrix of 320 x 224 
pixels, 5 mm section thickness with 1-mm intersection gap)  
 
5.2.3 Image analysis 
Two neuroradiologists with more than 5 years stroke experience and blinded to previous 
examination results used follow-up NCCT and gradient-echo T2-weighted MR images to 
determine HT severity in consensus. Any susceptibility effect–induced area of low signal 
intensity in the ischemic region on a gradient-echo T2-weighted MR image was 
considered HT, even in the absence of a corresponding area of high attenuation on the 
NCCT image. The neuroradiologists did not record the size and location of these areas, 
but they graded the extent of hemorrhage by using an established grading system (6). HT 
was categorized as hemorrhagic infarction (HI) or parenchymal hematoma (PH) 
according to the ECASS criteria
2
. HI was defined as blood petechiae within the infarcted 
area, without space-occupying effect, while PH was defined as blood clot with space-
occupying effect. ASPECT scores were assigned by one experienced neuroradiologist 
with 5 years of experience. One operator with 2 years of experience used commercially 
available software (CT Perfusion 4; GE Healthcare Waukesha, Wis) to calculate 
parametric maps of cerebral blood flow (CBF), cerebral blood volume (CBV), mean 
transit time (MTT), and PS from the first- and second-phase CT perfusion data (Appendix 
F). Arterial input and venous output functions were derived from the ipsilateral anterior 
cerebral artery and the superior sagittal sinus, respectively. We corrected partial volume 
averaging of the arterial input curve by scaling the curve with the ratio of the area under 
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the venous output curve to the area under the arterial input curved. Maps were calculated 
by means of deconvolution of the arterial input curve and the tissue curves from 3 x 3 
pixel blocks of CT images with use of the Johnson-Wilson model
31
. In addition to CBF, 
CBV, and mean transit time maps, perfusion-weighted and PS maps were calculated. 
Although we calculated the perfusion-weighted maps by averaging the images acquired 
over the duration of the first phase, calculation of the PS maps required use of the data 
from the second phase of the two-phase CT perfusion examination. The PS is used to 
assess the rate of contrast material extravasation from the intravascular to the 
extravascular space through a disrupted BBB
26
. Extravasation of contrast material leads to 
prolonged enhancement of the tissue beyond the intravascular (first) phase, which can 
only be properly characterized with a two-phase CTP acquisition. One author with 2 years 
of experience analyzed the parametric maps by using custom software (IDL v6.1; 
Research Systems, Boulder, Colorado). To reduce bias, all components of the analysis 
were performed with the author blinded to the other study data - the HT status in 
particular. As depicted in figures 5.1 and 5.2, imaging data for all patients was analyzed 
by: 1) a CBF threshold of 25 ml·min
-1
·(100g)
-1
 was applied to delineate an ischemic 
region of interest (ROI) on the admission CBF map, 2) this ROI was superimposed onto 
the  admission PS and CBV functional maps, 3) a mirror ROI was created by reflecting 
the ischemic ROI across the hemispheric midline. To minimize the contribution of large 
vessels, any pixel with CBF > 100 ml·min
-1
·(100g)
-1
  or a CBV > 8 ml·(100g)
-1
 was 
excluded from the mean ROI value calculations
23
. Finally, CBF and CBV defect volumes 
were calculated by using a CBF threshold of 25 ml·min
-1
·(100g)
-1
 and a CBV threshold of 
2 ml·(100g)
-1
 on the corresponding maps
22, 23
.  
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Figure 5.1 CT images for patient with small leakage in ischemic region 
 
 
 
(A) Admission CT perfusion– derived CBF map of 5 mm thick brain section displayed 
with color scale from 0 (dark blue) to 150 (red) ml·min
-1
·(100g)
-1
. (B) Corresponding 
CBF map shows ischemic ROI outlined with help of a yellow overlay of pixels with CBF 
of less than 25 ml·min
-1
·(100g)
-1
. (C) PS map corresponding to (A) shows superimposed 
ischemic ROI and mirrored ROI in contralateral hemisphere. PS values in ischemic and 
mirrored ROIs are 0.17 and 0.038 ml·min
-1
·(100g)
-1
, respectively. (D) Corresponding 
delayed (7 day) NCCT scan of same section shows infarct and HT (arrow). 
 
 
153 
 
 
 
 
Figure 5.2 CT images for patient with large leakage in ischemic defect 
 
 
(A) Admission CT perfusion– derived CBF map of 5 mm thick brain section displayed 
with color scale from 0 (dark blue) to 150 (red) ml·min
-1
·(100g)
-1
. (B) Corresponding 
CBF map shows ischemic ROI outlined with help of a yellow overlay of pixels with CBF 
of less than 25 ml·min
-1
·(100g)
-1
. (C) PS map corresponding to (A) shows superimposed 
ischemic ROI and mirrored ROI in contralateral hemisphere. PS values in ischemic and 
mirrored ROIs are 0.40 and 0.122 ml·min
-1
·(100g)
-1
, respectively. (D) Corresponding 
delayed (5 day) NCCT scan of same section shows infarct (hypoattenuation) and HT 
(arrows). 
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5.2.4 Statistical analysis 
Quantitative variable results were expressed as mean ± standard deviation or median with 
corresponding interquartile ranges, and categorical results were expressed as proportions. 
All data was checked for normality to determine if parametric or non-parametric tests 
should be performed. An unpaired Wilcoxon rank sum, or Fisher exact test was used to 
compare differences in demographic data and CTP variables between the HT and non-HT 
groups, and between the tPA and non-tPA groups. Age, NIHSS score, time to treatment, 
HT type were compared between these groups. PS, CBF and CBV values from within 
ipsilateral and contralateral ROIs, as well as CBF and CBV defect size were compared 
between groups. Associations between PS and both demographic and CTP parameters 
were tested at univariate and multivariate logistic regression analyses. The odds ratio for 
PS-based prediction of hemorrhage extent and the corresponding 95% confidence interval 
(CI) were estimated at logistic regression analysis. Receiver operating characteristic curve 
analysis of the PS values for prediction of hemorrhage extent was then performed, and the 
area under the receiver operating characteristic curve, sensitivity, specificity accuracy, 
positive and negative predictive values, and positive likelihood ratio were determined. 
Results were considered significant at p < 0.05. 
 
5.3 RESULTS 
The 41 patients (26 men, 15 women) included in the study had a mean ± standard 
deviation age of 70.3 years ± 15.4. The median NIHSS score at presentation was 15 
(interquartile range, 7–20). The mean ± standard deviation time from stroke symptom 
onset to CT scanning was 125 ± 46 minutes. The MR and CT follow-up examinations 
were performed a median of 3 days (interquartile range, 2–6 days) after the initial CT 
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examination. Twenty-two (54%) patients received tPA, which was administered both 
intravenously (IV) and intra-arterially (IA) in two patients and IV only in 20. The mean ± 
standard deviation tPA dose was 61 ± 12mg. Twenty three (56%) patients had a HT: 15 
(37%) with HI and eight (20%) with PH. The data obtained at both baseline and discharge 
was dichotomized according to presence of HT (Table 5.1). Patients with hemorrhage 
were more likely to have a higher NIHSS score at presentation (p < 0.01), receive tPA (p 
< 0.01), have a lower baseline ASPECT score (p < 0.05), and have a worse outcome (p < 
0.01)) compared with patients without HT. There was no significant difference in time to 
tPA treatment between the two groups (p = 0.65). At presentation, defect volumes 
obtained with CBF and CBV ischemic thresholds were larger for the HT group, but not 
significant (p > 0.05; Table 5.1).  
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Table 5.1 Baseline and follow-up patient data dichotomized according to presence of 
HT 
 
Characteristic HT  
(n = 23) 
No HT  
(n = 18) 
P-
value 
Female patients 10 (44) 5 (28) 0.30 
Age (y)
* 
74 (58-83) 72 (64-81) 0.67 
Mean arterial blood pressure > 120mm Hg 7 (30%) 2 (11) 0.25 
International normalized ratio
†
 1.04 ± (0.10) 1.02 ± (0.07) 0.99 
NIHSS at presentation 19 (13-20) 10 (7-15) 0.005 
Time to imaging (min)
 † 
124 ± 765 125 ± 118 0.37 
ASPECT score
* 
6 (5-7) 10 (8-10) 0.02 
Volume with CBF defect (cm
3
)
†
 63±31 52±21 0.17 
Volume with CBVdefect (cm
3
)
† 
48±24 31±13 0.11 
TPA given number (%) 17 (74%) 5 (28%) 0.005 
Time to TPA (mins) 143 (27) 135 (31) 0.65 
TPA dose (mg) 62±13 57±10 0.43 
90 day modified Rankin score mRS 4 (2-6) 1 (0-2) 0.001 
 
Unless otherwise noted, data are numbers of patients, with percentages in parentheses. P 
values were obtained with unpaired t, Wilcoxon rank sum, or Fisher exact testing. P < 
0.05 was considered to indicate a significant difference. 
* Data are median values, with the interquartile range in parentheses. 
† Data are mean values ± the standard deviation. 
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The mean ± standard deviation PS within superimposed ischemic ROIs for patients with 
and without HT was 0.49 ± 0.3 ml·min
-1
·(100g)
-1
 and 0.09 ± 0.10 ml·min
-1
·(100g)
-1
. 
These were significantly different (p < 0.01; Figure 3A). No significant differences in 
CBF within the ischemic ROI were observed between the HT [15.6 ± 6.8 ml·min
-
1
·(100g)
-1
] and non-HT [18.0 ± 5.9 ml·min
-1
·(100g)
-1 
(p > 0.05). Similarly, no significant 
differences in mean CBV were observed between patients with HT [1.0 ± 0.38 ml·(100g)
-
1
] and patients without [1.0 ± 0.40 ml·(100g)
-1
] (p > 0.05). For patients with HT, mean ± 
standard deviation PS values within the contralateral ROI [0.17 ± 0.15 ml·min
-1
·(100g)
-1
]  
was significantly different than ipsilateral values [0.49 ± 0.3 ml·min
-1
·(100g)
-1
] (p < 
0.05). For patients without HT, no significant difference was observed between ipsilateral 
[0.09 ± 0.10 ml·min
-1
·(100g)
-1
] and contralateral ROIs  [0.06 ± 0.04 ml·min
-1
·(100g)
-1
] (p 
> 0.05). The mean PS for the contralateral ischemic ROI was significantly different for 
patients with and without HT (p < 0.05). Subgroup analysis revealed no significant 
differences in PS, CBF, or CBV between the patients with HI and those with PH; 
however, significant differences in PS, but not in CBF or CBV, were observed between 
patients with HI, PH, and non-HT groups (p > 0.05; Table 5.2, Figure 5.3b).  
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Table 5.2 Mean PS, CBF and CBV values for ischemic ROIs in patients 
dichotomized according to HT type and presence 
 
 PH (n=8) HI (n=15) Any HT (n=23) No HT(n=18) 
PS [ml•min-1•(100g)-1] 0.51 ± 0.39 0.48 ± 0.27 0. 49 ± 0.3 0.09 ± 0.10 
CBF [ml•min-1•(100g)-1  15.67 ± 5.6 15.6 ± 7.6 15.62 ± 6.8 18.01 ± 5.9 
CBV ml•(100g)-1  1.00 ± 0.38 0.98 ± 0.39 1.00 ± 0.38 1.00 ± 0.40 
 
Data are mean values ± the standard deviation. P < 0.0001 for difference between PS and 
CBF in parenchymal hematoma (PH), hemorrhagic infarction (HI), and any HT groups 
compared with those in no HT group. P = 0.97 to P = 0 .99 for PS, CBF, and CBV in PH 
group compared with those in HI group. 
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 Compared with the patients who were treated with tPA, non-tPA treated patients 
were older (p = 0.03), tended to have a higher baseline NIHSS (p = 0.06), arrived at the 
hospital later (p = 0.04), and were less likely to have HT (p = 0.005). The patients treated 
with tPA had smaller CBF and CBV defect volumes, although neither parameter was 
significantly different between the two groups. Among the patients treated with tPA, PS 
values were higher in those with HT [0.47 ± 0.33 ml·min
-1
·(100g)
-1
] than in those without 
HT [0.13 ± 0.13 ml·min
-1
·(100g)
-1
] (p < 0.05). A similar finding was seen for non-tPA 
patients with and without HT [0.56 ± 0.24 vs. 0.07 ± 0.07 ml•min-1•(100g)-1; p < 0.05]. 
No PS difference was found between tPA and non tPA patients with HT (0.47 ± 0.33 vs. 
0.56 ± 0.24 ml•min-1•(100g)-1; p=0.49) and without HT (0.13 ± 0.13 vs. 0.07 ± 0.07 
ml•min-1•(100g)-1; p > 0.05). The PS value of tPA treated patients with HT was not 
different from that of all hemorrhage patients (p > 0.05; Table 5.3). 
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Table 5.3 Baseline and follow-up patient data dichotomized according to tPA 
treatment status 
 
Characteristic tPA  (n=22) No tPA (n=19) P-value 
Age (y) 66.86 ± 14.98 76.56 ±11.85 0.03 
Baseline NIHSS score
*
  15.8 (13-21) 8.3 (5.25-16.25) 0.06 
Baseline ASPECT score
* 
6 (6-9) 9 (6-19) 0.13 
Time to treatment (min) 97 ± 49 159 ± 116 0.04 
CBF volume (cm
3
)  59.32 ± 33.02 54.66 ± 20.96 0.90 
CBV volume (cm
3
) 40.52 ± 16.14 45.20 ± 25.75 0.77 
PS [ml•min-1•(100g)-1] 0.28 ± 0.28 0.39 ± 0.33 0.10 
CBF [ml•min-1•(100g)-1] 16.0 ± 6.48 17.39 ± 6.62 0.77 
CBV[ ml•(100g)-1] 0.98 ± 0.32 1.03 ± 0.45 0.77 
HT
† 
17 (77) 6 (31.6) 0.005 
PH
†
 5 (23) 2 (10) 0.42 
 
Unless otherwise noted, data are mean values ± the standard deviation. P values were 
obtained with unpaired t, Wilcoxon rank sum, or Fisher exact testing. P < 0.05 was 
considered to indicate a significant difference. 
* Data are median values, with the interquartile range in parentheses. 
† Data are numbers of patients, with the percentage of patients in parentheses. 
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The patients were subdivided according to hemorrhage status in addition to tPA 
treatment status (Figure 5.4). Although there were overlapping mean PS values within the 
ipsilateral ischemic ROI between the HT and non-HT groups among the patients treated 
with tPA, there was no such overlap in values among the patients who were not treated 
with tPA.  
 Univariate logistic regression analysis demonstrated significance for HT with PS 
(OR 3.5; 95% CI 1.69-7.06, p = 0.001), baseline NIHSS (OR 1.2; 95% CI 1.0-1.3 
p=0.001), baseline ASPECTS (OR 0.5; 95% CI 0.3-0.7; p=0.0007) and tPA 
administration (OR 6.8; 95% CI 1.7-27.5, p=0.007). PS (OR 3.5; 95% CI 1.69-7.06; 
p=0.0007) and baseline ASPECTS (OR 0.4; 95% CI 0.2-0.7, p = 0.002) were the only 
independent variable associated with HT following a stepwise multivariate analysis. 
Receiver operator curve (ROC) analysis demonstrated an optimum PS cutoff value of 
0.23 ml
-1•min-1•(100g)-1, with an AUC of 0.92±0.05 (Figure 5.4). Sensitivity, specificity, 
positive and negative predictive value and positive likelihood ratio was 77% (CI 55-
92%), 93.8% (CI 70-100%), 94% (CI 84-100%), 75% (CI 60-90%) and 4.1 respectively. 
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Figure 5.3 PS values for patients with/without HT, and HT sub-types 
 
 
 
Box plots of PS [ml
-1•min-1•(100g)-1 ] within ischemic ROIS for (A) patients with HT and 
those without HT, and (B) patients with either of two hemorrhage subtypes (HI or PH) 
and  those without HT. In each box, median, 95% CI, and first and third quartile values 
are illustrated. 
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Figure 5.4 Distribution of PS values for tPA treated/non-treated 
 
 
Graph illustrates distribution of mean PS values for ischemic ROIs in patients grouped 
according to tPA treatment status and HT status.  
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Figure 5.5 Receiver Operator Characteristic Curve for the PS parameter 
 
Receiver operator characteristic curve (true positive rate versus false positive rate) of PS 
thresholds to determine HT. Area under the curve (AUC) is shown.   
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5.4 DISCUSSION 
Our study results demonstrate the feasibility of a two-phase protocol for measuring 
hemodynamic parameters and the PS during one CT perfusion examination. The patients 
with HT had a significantly higher PS than did those without hemorrhage. A PS threshold 
of 0.23 ml
-1•min-1•(100g)-1 also enabled the differentiation of patients with HT from those 
without.  
It is important that we identify no significant difference in CBF between the patients with 
and those without hemorrhage. The patients treated with tPA were more likely to have 
HT. However, we observed no significant differences in PS between the tPA-treated and 
non-treated patients. Patients with HT were more likely to have higher admission NIHSS 
scores and poorer clinical outcomes compared with patients without HT. There were no 
significant differences between the patients with HI and those with PH. The limited 
number of patients precluded further stratification of the HT sub-types into HI-1, 2 and 
PH-1,2.   
MR imaging has also been used to study BBB breakdown in patients with acute 
stroke
32-34
. In particular, Warach et al. (2004) found the hyperintense acute reperfusion 
marker (HARM) to be a useful early marker of BBB breakdown in their MR-based 
natural history examination of acute stroke patients
35
. HARM is the hyperintense signal 
observed on fast low-angle inversion-recovery images hours to days after gadopentetate 
dimeglumine administration and is believed to be caused by the accumulation of MR 
contrast material in the cerebrospinal fluid space or ventricles before BBB breakdown. In 
some cases, the HARM signal was not just localized to the ischemic hemisphere; rather, it 
was generalized throughout the brain on the fast low-angle inversion-recovery images, 
signifying more widespread and remote BBB permeability, including that in the 
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contralateral hemisphere. Given that HARM was found to be associated with HT and 
stroke severity, their finding may help to explain our observation that the PS in the 
contralateral mirror ROI in patients with HT was higher than that in patients without HT. 
 HT is common in stroke patients, especially following thrombolytic therapy
9, 36, 37
. 
In our study, HT was associated with PS, NIHSS score, baseline ASPECT score, and tPA 
therapy at univariate analysis; however, the association with tPA was weaker. The 
absence of an independent association between tPA and HT likely reflects the fact that the 
patients were selected for treatment on the basis of their ASPECT and NIHSS scores, 
both of which were independently used to predict HT. Therefore, no additional influence 
of tPA on this outcome could be detected. Our results, like those in most stroke studies, 
could have been affected by the specific inclusion and exclusion criteria that we adopted 
for this study, and by whether the studied cohorts had matched clinical data. Nonetheless, 
our results show that besides the PS parameter and ASPECT score, no other factors (age, 
sex, or baseline NIHSS score) were associated with HT.  
 The prevalence of PH in this study is higher than that of previously published 
randomized studies of thrombolysis
10, 38
. This may have been due in part to the 
classification of hemorrhage at 5–7-day post symptom onset, rather than within the 36-
hour time window used in many other studies
14, 39
. Vasogenic edema and mass effect are 
expected to peak at 3–4 days, which may contribute to the increased number of cases with 
mass effect in our series. An experienced team of stroke neurologists administered tPA by 
following standard thrombolysis guidelines. No tPA dosing errors or protocol violations 
occurred. All patients in this series were classified into hemorrhage and nonhemorrhage 
groups by using gradient-echo T2-weighted MR imaging rather than CT. The superiority 
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of this MR sequence for hemorrhage detection may also account for the higher reported 
prevalence of HT 
40, 41
. 
 Our sample size was too small for us to make any definitive conclusions about the 
effect of tPA treatment on HT; however, tPA may act in concert with ischemic effects to 
render the brain more susceptible to HT as the minimal PS in patients with HT who were 
treated with tPA [0.047 ml
-1•min-1•(100g)-1] was lower than that of patients with 
hemorrhage who were not treated with tPA [0.23 ml
-1•min-1•(100g)-1]. A lower pre-
treatment PS with tPA treatment may be as likely to cause HT as a higher PS without tPA 
treatment.  
 CT is the modality of choice for the initial investigation of acute stroke for 
patients that may require lytic treatment
29
. CT scanners are widely available, accessible, 
and less expensive to operate compared with MR units. Occlusion site and perfusion 
defect size are important considerations in determining the outcome of revascularization 
procedures and defining a target population for treatment
42-44
. Surrogate radiological 
markers of BBB breakdown, including intra-procedural early venous filling and post-
procedural contrast enhancement and extravasation, have been described previously
45, 46
. 
These markers are usually associated with larger volumes of contrast material injected 
over a prolonged period. Until recently, leakage of contrast material volumes used in 
current acute stroke protocols were not detectable with CT
47, 48
. The two-phase perfusion 
CT protocol, described herein, is designed to depict contrast material leakage owing to 
the extension of the acquisition time window of a conventional perfusion CT examination 
by 90 seconds, with six additional acquisitions at 15-second intervals. In this study, CT 
angiography was performed before PS measurement in the two-phase perfusion CT 
protocol. This particular design raises the question of whether residual contrast material 
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from the prior CT angiography examination affects the accuracy of the subsequent PS 
measurement, which itself requires another contrast agent injection. Both the arterial 
input curve and the tissue curve used to calculate the PS with the Johnson-Wilson model 
were generated by subtracting the attenuation of the artery and the tissue before the 
arrival of contrast material from the attenuation after the contrast material arrival. The 
residual contrast material from prior CT angiography would cause the same increase in 
attenuation in the artery and the tissue before and after the arrival of contrast material, and 
the effect of this increase would be eliminated by the subtraction during the generation of 
the arterial input and tissue curves. Therefore, the residual contrast material from prior 
CT angiography would not affect the accuracy of the PS parameter. 
 Our study had several limitations. First, comparisons among the small number of 
patients with HT did not reveal significant differences in PS between the HI and PH 
groups. However, the importance of the HT subtypes is being debated
15, 17-19
. Results of a 
recent study demonstrated that HI is not necessarily benign and is associated with a worse 
clinical outcome compared with that of patients without hemorrhage
18
. Second, six 
patients in our study were excluded because of excessive motion during imaging. This 
number represents 15% (6/41) of the current patient data set, and the exclusion may have 
resulted in an overestimation of the diagnostic accuracy of the technique. Third, the 
sensitivity and specificity of our optimal PS threshold for predicting HT needs to be 
tested prospectively in a larger data set. Fourth, as quantitative permeability 
measurements are uniquely tracer dependent, our specific quantitative results may not be 
generalizable to other contrast agents or other acquisition timing protocols - every 
contrast agent has a different permeability constant, depending on its charge and 
molecular weight. Fifth, we used one threshold value to delineate ischemia, which may 
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have led under/overestimation of the ischemic ROI depending on gray/white matter 
distribution. Sixth, although blood products are easily identified on gradient-echo T2-
weighted MR imaging, this sequence is hindered by susceptibility artifacts that can make 
the area of hemorrhage appear larger than it really is. However, since the PS was 
evaluated within the entire ischemic ROI, defined on CBF maps, overestimation of the 
hemorrhage region volume likely had no substantial effect on the PS calculation. Last, 
although CT perfusion is widely used, it is limited by ionizing radiation, contrast material 
nephrotoxicity, and limited coverage in the z-direction.  
  
5.5 CONCLUSION  
In conclusion, the BBB PS parameter can be measured accurately during the acute stroke 
CT protocol. PS elevation appears to be a promising marker for predicting the risk of HT 
in acute stroke patients. 
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CHAPTER 6 
Early Rate of Contrast Extravasation in ICH Patients 
 
The contents of this chapter have been adapted from the paper entitled “Early rate of 
contrast extravasation in patients with intracerebral hemorrhage” published in the 
American Journal of Neuroradiology, 2011;32(10):1879-84, by: C.D. d'Esterre, T. Chia, 
A. Jairath, T.Y. Lee, S.P. Symons,  R.I. Aviv. 
 
6.1 INTRODUCTION 
As discussed in Chapter 1, primary intracerebral hemorrhage (ICH) accounts for ~23% of 
all strokes, and leads to rapid clinical deterioration
1
. During the first 3 hours of symptom 
onset, early hematoma growth is seen in 18% to 38% of intracerebral hemorrhage 
patients, reducing to 11% thereafter
2-4
. Early hematoma expansion is associated with 
poorer neurological outcome and increased mortality
5
. The cause of early hematoma 
expansion is unknown, but secondary vessel injury and perihematomal ischemia have 
been implicated. Prevention or reduction of secondary bleeding is important when dealing 
with ICH
6
. Recently, administration of recombinant Factor VIIa resulted in the reduction 
of hematoma expansion, without improvement in clinical outcome
7
; however, post hoc 
analysis has suggested benefit in a small sub-group of patients
8
.  
  CT imaging is considered the modality of choice for the acute investigation of 
ICH. Extravasation is demonstrated on CT angiography (CTA) and post contrast CT 
(PCCT) in approximately 40-50% of patients
9, 10
. Several imaging studies have 
demonstrated an association between early contrast extravasation and hematoma 
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expansion
10-13
. A recent study demonstrated that foci of contrast-leakage not discernable 
during the arterial phase of a CTA may be detected on PCCT (PCL)
14
. A further study 
demonstrated that delayed CTA detected other areas of contrast extravasation not seen on 
an early CTA
15
. In both studies, sensitivity to hematoma expansion improved when 
delayed images were considered - it is reasonable to assume that a slower rate of contrast 
extravasation in PCL accounts for the lack of CTA detection, although this has not been 
shown. Further, the etiology and pathophysiological significance of the various 
manifestations of contrast extravasation remain unknown. However, given the association 
between risk of hematoma expansion and poor outcome with the number and density of 
extravasation defects, it is likely that more rapid extravasation, such as that seen on 
arterial phase CTA, may confirm the highest risk
13
.  
 CT perfusion (CTP)-derived permeability surface area product (PS) is a novel 
method of measuring the rate of contrast extravasation from the intra- to extravascular 
compartment
16
. Knowing the rate of contrast extravasation may provide insight into the 
pathophysiology of hematoma expansion by identifying the contributing target 
abnormality. A clinical technique that quantifies this rate provides objective assessment 
of hematoma expansion risk rather than the qualitative approach currently used. Such 
information may become increasingly important as novel ICH treatments, such as focused 
ultrasound coagulation, are developed that will target specific defects
17
.  
 Using the CTP-PS parameter we sought to measure the rate of contrast 
extravasation for CTA-Spot Sign defects and PCCT-PCL defects, respectively. PS values 
from these two abnormalities will be compared to PS values from hematoma volumes 
excluding any extravasation, hematoma volumes in patients without extravasation, and 
contralateral normal tissue. We hypothesize that the rate of contrast extravasation will be 
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highest in CTA Spot Sign defects compared to PCL defects and hematoma regions 
without extravasation.   
 
6.2 MATERIALS AND METHODS 
6.2.1 Patient cohort 
With approval by the local institutional ethics review board
+
, 16 consecutive patients with 
ICH presenting over a 6-month period at a tertiary stroke centre underwent initial non-
contrast CT (NCCT), and CTA upon admission. The imaging was reviewed acutely with 
the patient on the CT table by an attending neuroradiologist with 5 years experience. If 
ICH was identified, a PCCT scan and CT Perfusion (CTP) study was performed 
regardless of the result of contrast extravasation in CTA. Spot Sign and PCL 
extravasation were identified retrospectively by the presence of contrast extravasation on 
the CTA or PCCT, respectively. Of 16 screened patients, 7 demonstrated contrast 
extravasation. Nine foci of contrast extravasation were present on each of the CTA and 
PCCT, respectively, for a total of 18 regions. 
 
6.2.2 Image acquisition 
CT scanning was performed on a 64-slice CT (Lightspeed plus and VCT; GE Healthcare, 
Waukesha, Wis) scanner at admission and 24 hours after presentation in all patients. The 
standard ICH protocol includes a NCCT head followed by a CTA and PCCT. Pre- and 
post-contrast head imaging was acquired from the skull base to vertex with parameters:  
____________________________________ 
+
 Appendix G – Human Ethics Approval form  
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120 kVp; 340 mA; 4 x 5 mm collimation; 1 second/rotation; and a table speed of 15 
mm/rotation. CTA studies were acquired from C6 to the vertex in the helical HS mode 
with parameters: 0.7 ml/kg contrast (to a maximum of 90 ml through an antecubital vein 
via at least an 18 or 20 gauge angiocatheter); 5 to 10 second delay; 120 kVp; 270 mA; 1 
second/rotation; 1.25 mm slice thickness at 0.625 mm intervals, table speed 3.75 
mm/rotation. The CTP study was comprised of 2 phases. The first phase was a 45 seconds 
continuous (cine) scan reconstructed at 0.5 second intervals to produce a series of 90 
sequential images for each of the eight slices, covering a total of 40 mm from the basal 
ganglia to the lateral ventricles. The second phase collected images covering the same 8 
slices over an additional 90 seconds immediately after the first phase at intervals of 15 
seconds. Scan parameters for both phases were: 80 kVp, 190 mA, 8 x 5 mm collimation 
and 1 second/rotation. The dose-length products for NCCT, CTA (intracranial only) and 
CTP components were 1073, 592 and 1804 mGy-cm, respectively. Assuming a 
conversion factor of 0.0021 mSv per mGy-cm, the effective dose was 7.3 mSV.  
Iodinated contrast agent at a dose of 0.5 ml/kg (maximum 50 ml) was injected 3-5 
seconds prior to the start of the first phase at a rate of 4 ml•s-1. A 5 minute post processing 
time is as previously reported
15
. The follow up consisted of an NCCT only. All images 
were viewed on AGFA Impax 4.5 PACS workstation.  
 
6.2.3 Image analysis  
CT Perfusion 4 software (GE Healthcare) was used to calculate parametric maps of PS. 
Arterial input and venous output functions were obtained from the ipsilateral anterior 
cerebral artery and from the superior sagittal sinus, respectively (Figures 6.1 and 
6.2). Partial volume averaging was corrected by multiplying the arterial input function by 
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Figure 6.1 Example of patient with a spot sign and post-contrast leakage 
 
 
 
 
(A) Baseline contrast enhanced source CTP image. (B) Corresponding time-density 
curves (TDC) for the artery (red) and vein (blue; Hounsfield Unit scale: 0-600). (C) TDC 
for Spot Sign (yellow), post contrast-leakage (PCL; green), and contralateral region of 
interest (ROI; purple; Hounsfield Unit scale: 0-30). (D) CTA with Spot Sign visible 
(yellow arrow). (E) Post-contrast enhanced CT (PCCT) showing PCL (green arrow) and 
Spot Sign with extravasation (yellow arrow). (F) Perfusion weighted image and (G) 
permeability surface area product (PS) map. ROIs encircle the contrast extravasation 
(Spot Sign and PCL) on the perfusion weighted image, and entire hematoma excluding 
extravasation and overlap with ventricles (intraventricular hemorrhage). ROIs are 
superimposed onto PS map and reflected about the midline.  
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Figure 6.2 Example of patient without contrast extravasation 
 
 
(A) Baseline contrast enhanced source CTP image. (B) Corresponding time-density 
curves (TDC) for the artery (red) and vein (blue; Hounsfield Unit scale: 0-400). (C) TDC 
for region of interest (ROI) within hematoma (yellow), and contralateral ROI (green; 
Hounsfield Unit scale: 0-16). (D,E) CTA and PCCT with no visible contrast extravasation 
within hematoma. (F) Perfusion weighted image (PWI) and (G) permeability surface area 
product (PS) map. An ROI encircles the hematoma on the PWI. Hematoma ROI is 
superimposed onto PS map, excluding overlap with ventricles, and is reflected about the 
midline.  
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the ratio of the area of venous time attenuation curve to that of the arterial input 
function
18
. Maps were calculated by deconvolution of the arterial input curve and tissue 
curves from 2 x 2 pixel blocks of CT images using the adiabatic approximation to the 
Johnson-Wilson (J-W) model
19
. 
PS, by definition, is the unidirectional rate of contrast extravasation from the 
intravascular to the extravascular space through a disrupted blood-brain barrier
20
. 
Extravasation of contrast material leads to prolonged enhancement of the tissue beyond 
the intravascular (first) phase which can only be properly characterized by a two-phase 
CTP study as previously described
21
.  Parametric maps were analyzed by one author with 
4 years’ experience using custom software (IDL v6.1, RSI Inc, Boulder, Colo. USA). 
Extravasation, observed on CTA and/or PCCT, was located on inherently co-registered 
perfusion weighted images (PWI) from the CTP protocol. Four regions of interest (ROI) 
were superimposed onto co-registered PS functional maps for extravasation positive 
patients: areas of focal contrast extravasation on 1) location of CTA Spot Sign defect 
and/or 2) location of PCL defect, 3) entire hematoma excluding both extravasation and 
overlap with ventricles (IVH), and 4) mirror regions contralateral to extravasation regions 
defined in (1) and (2), (Figure 6.1). For extravasation negative patients, ROIs were placed 
on: 1) entire hematoma volume excluding overlap with ventricles, and 2) mirror regions 
contralateral to region defined in (1) (Figure 6.2). ROIs were superimposed onto cerebral 
blood flow (CBF), cerebral blood volume (CBV) and PS functional maps; pixels with 
values of CBF >100 ml•min-1•(100g)-1 and CBV > 8 ml•(100g)-1 were excluded22. 
Hematoma volumes at presentation and follow up study were calculated blinded to 
extravasation status using Medical Image Processing, Analysis and Visualization (Center 
for Information Technology, National Institutes of Health) Hematoma expansion was 
182 
 
 
 
defined as an increased volume of > 6ml or 30%
11, 23
. Intraventricular hemorrhage (IVH) 
was not considered in the definition of hematoma expansion.  
 
6.2.4 Statistical Analysis 
All analyses were performed with SPSS for windows (v. 16; SPSS Chicago, Ill), and all 
data sets were checked for normality with the Shapiro-Wilk calculation to determine 
whether a parametric or a non-parametric test should be used. The Wilcoxon rank-sum 
test with bonferroni-correction was used to compare all PS values. Significance was 
defined as p < 0.05. Average PS values were compared for: 1) Spot Sign defects only (9 
foci), 2) PCL defects only (9 foci), 3) hematoma excluding extravasation, 4) regions 
contralateral to extravasation, 5) hematoma in patients without extravasation and 6) an 
area contralateral to (5). Unpaired t-tests were used to compare differences in age, time to 
CTA, average arterial pressure, international normalized ratio, partial thrombosplatin 
time, National institute of Health Stroke Scale Score and glucose score, respectively. 
Using the Wilcoxon rank-sum test with bonferroni-correction, the average hematoma 
volume at follow-up (24 hours) was compared with admission hematoma volume within 
extravasation positive and negative groups, respectively.  
 
6.3 RESULTS 
Permeability surface area product (PS) data was acquired for 16 ICH patients (9 males 
and 7 females). Their demographics are listed in Table 6.1. Of the 7 patients with 
extravasation on the admission CTA and/or PCCT imaging, three patients had both Spot 
Sign and PCL defects, three patients had only PCL defects, and one patient had only a  
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Table 6.1 Demographics for extravasation positive and negative groups 
 
 
Patients are dichotomized into contrast extravasation positive (n = 7) and negative (n = 9) 
groups. MAP = average arterial pressure; INR = international normalized ratio; PTT = 
partial thrombosplatin time; NIHSS = National institute of Health Stroke Scale Score. 
Unpaired t-tests are used to compare the data. 
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Spot Sign defect. Nine patients did not present with extravasation on CTA or PCCT. One 
extravasation positive patient received rFVIIa as an off-label treatment. Average PS was 
6.5 ± 1.60 ml•min-1•(100g)-1, 0.95 ± 0.39 ml•min-1•(100g)-1, 0.12 ± 0.39 ml•min-1•(100g)-
1
,0.26 ± 0.09 ml•min-1•(100g)- 1, 0.38 ± 0.26 ml•min-1•(100g)-1 and 0.09 ± 0.32 ml•min-
1•(100g)-1 for 1) Spot Sign defects only (9 foci), 2) PCL defects only (9 foci), 3) 
hematoma excluding extravasation, 4) regions contralateral to extravasation, 5) hematoma 
in patients without extravasation and 6) an area contralateral to (5). PS values from Spot 
Sign defects and PCL defects were significantly different from each other and all other 
regions of interest (p < 0.05; Table 6.2). Average absolute or percent hematoma volume 
increased from 34.1 ± 41.0 ml to 40.2 ± 46.1 ml or 27.8% in contrast extravasation 
positive patients. In extravasation negative patients absolute or percent volume decreased 
from 19.8 ± 31.8 ml to 17.4 ± 27.3 ml, or -1.5% (Table 6.3).  
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Table 6.2   PS values for extravasation positive and negative patients 
 
Permeability surface area product (PS) values (ml•min-1•(100g)-1 ) for patients with (n = 
7) and without (n = 9) contrast extravasation. Sub-groups are based on region of interest 
location. Wilcoxon rank-sum tests with bonferroni-correction were used to compare data. 
*Denotes significantly different (p < 0.05) from all other sub-group mean PS values. 
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Table 6.3 Hematoma expansion data for extravasation positive/negative patients 
 
 
Patients are dichotomized into contrast extravasation positive (n = 7) and negative groups 
(n = 9). Initial and final hematoma volumes were measured at admission and 24 hours, 
respectively. Wilcoxon rank-sum tests, with a bonferroni-correction, were used to 
compare initial and final hematoma volumes within both groups, respectively. 
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6.4 DISCUSSION 
Early CT contrast extravasation [CTA Spot Sign and post contrast-leakage (PCL)] is an 
important predictor for ICH evolution
10, 12, 14, 15
. Size and density of contrast on admission 
CTA reflect the rate of contrast accumulation and have recently been shown to be two of 
three factors associated with hematoma expansion and patient outcome
15
. This study 
utilizes CTP-derived PS measures to quantify the differential rates of contrast leakage in 
contrast extravasation abnormalities observed on admission CTA or PCCT. A technique 
such as CTP that quantifies contrast leakage rate may better define which patients with 
extravasation are at highest risk for expansion. Hematoma volume expansion occurred 
more frequently in patients with extravasation, who also tended to have worse clinical 
outcome.  
 Although the pathophysiological significance of the CTA Spot Sign and PCCT-
PCL defect is uncertain, we have previously suggested that the former may represent the 
primary causative abnormality, whereas the latter may represent secondary vessel injury 
due to hematoma shearing
24
. Although PCL appears to be significant for hematoma 
growth compared to patients with no extravasation, a recent study showed that 40% of 
patients with only the PCL defect did not demonstrate hematoma expansion
14
. As such, 
the clinical effect of PCL appears overshadowed by the presence of the CTA Spot Sign 
where only 4% of Spot Sign positive patients did not undergo hematoma expansion
13
.   
 The rate of contrast extravasation is an important consideration when assessing 
the sensitivity of modalities being used. Slower rates of contrast accumulation will be 
more difficult to detect with early scan techniques if insufficient contrast density has 
accumulated. Two recent studies reported higher rates of extravasation detection using a 
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delayed CTA acquisition (median 113 seconds delay following initial CTA) or PCCT 
(typically performed 3-5 minutes following contrast injection)
14, 15
. Herein, the detection 
of 9 extravasation defects on PCCT, not present on early CTA, is consistent with these 
accounts. Importantly, however, all PCL defects could be visualized as increased PS on 
post processed CTP functional maps. By virtue of a dynamic acquisition lasting 2 minutes 
after contrast injection, CTP appears more sensitive in assessing different contrast leakage 
rates than either CTA or PCCT; however this remains to be confirmed in a larger clinical 
study. CTP has the advantage of not requiring a pre-contrast decision between early and 
late scanning. Further, the overall dose of CTP is similar to a NCCT and avoids 
radiosensitive structures such as the thyroid and orbits. 
Quantification of the rate of leakage provides a unique opportunity to objectively 
study the effect of the rate of contrast extravasation on hematoma expansion for which the 
CTA Spot Sign is currently a surrogate marker. The high PS values obtained in patients 
with the CTA Spot Sign emphasize the rapid rate of contrast extravasation, reinforcing 
the need for a rapid and efficient treatment. Herein, we calculated PS with the Johnson-
Wilson (J-W) distributed parameter model which accounts for: 1) the ‘gradual’ leakage of 
contrast as it travels from the arterial input to the venous output and 2) the clearance 
(backflux) of contrast from the interstitial space into the vascular space. Another tracer 
kinetic model for the calculation of PS is the Patlak model which, unlike the J-W model, 
uses compartments to represent the vascular and interstitial spaces
25
. Therefore, it is 
required that both contrast arrival and leakage through the brain vasculature are 
instantaneous, as opposed to gradual, finite transit. Thus, the Patlak model is not valid 
under conditions when the arterial contrast concentration is changing rapidly, as seen 
during the vascular (first) phase of our data acquisition. This is exemplified by the initial 
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region of non-linearity observed in the Patlak plot, when the first pass data is included
26
. 
Whereas the J-W model can be used to measure PS, CBV and CBF simultaneously, the 
Patlak model provides estimates of PS and CBV but not CBF, which has to be estimated 
separately by using another calculation/model
25
. The Patlak model also assumes that there 
is no clearance (backflux) of contrast from the interstitial space into the vascular space. 
As a result, PS measured with the J-W model, which accounts for backflux, will be higher 
than that derived from the Patlak model.   
Several limitations of this study need to be discussed. First, the case series is 
limited by a small sample size. For practical reasons, patients were recruited by 
supervising neuroradiologists during daytime admissions. Although difficult to achieve 
given the relatively low incidence of ICH admissions and lower incidence of contrast 
extravasation, these results will require validation from larger patient cohorts. The 
influence of systemic and local features such as blood pressure, hematoma location, mass 
effect and shift, respectively, on the rate of extravasation and hematoma growth is 
currently unknown limiting the prediction of potential hematoma volume. Also, because 
the CTA, PCCT and CTP imaging are separated by ~10-15 minutes, PS could 
conceivably change between sequences. The effect of time to scan on presence of 
extravasation is not yet fully understood. Patients with extravasation in this series 
demonstrated a non- significant increased time to scan. Conceivably, increased duration 
from ictus may result in greater opportunity for BBB disruption, re-bleeding and contrast 
extravasation; however, a retrospective series evaluating a longer time to scan interval in 
patients with ICH reported a non- significant trend to lower incidence for expansion 
beyond 3 hours
10
. Similarly a prospective ICH study of 268 patients demonstrated no 
difference in spot sign incidence within the first 3 hours (personal communication: Dr. 
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Andrew Demchuck).  Due to the concurrence of PCCT- PCL and CTA Spot Sign in some 
patients, we were unable to compare hematoma expansion in patients possessing solely 
PCL or Spot Sign; within the same hematoma, the interaction of different coexisting 
patterns of extravasation is uncertain. Finally, PS may be underestimated in the presence 
of higher BBB disruption where increased amounts of blood, with lower Hounsfield unit 
than CT contrast, can leak into the extravascular space during the CTP acquisition.  
 
6.5 CONCLUSION 
In conclusion, the CTP-PS parameter measures different rates of CT contrast 
extravasation for ICH patients with/without CTA-Spot Sign and/or PCL defects. This 
information could be used to guide hemostatic treatment during the acute stroke stage. 
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CHAPTER 7 
Development and Implementation of a Rabbit Model of Middle 
Cerebral Artery Embolic Occlusion: Pre-morbid Cerebrovascular 
Conditioning with Dipyridamole  
 
The contents of this chapter have been adapted from the paper entitled “Dipyridamole 
treatment prior to stroke onset: examining post-stroke cerebral circulation and outcome in 
rabbits”, published in Translational Stroke Research, 2011;2:186-194, by C.D. d’Esterre, 
K.M. Tichauer, R.I. Aviv, L. Morrison, W. Eisert, T.Y.  
 
7.1 INTRODUCTION 
Clinical outcome following embolic stroke depends on a timely maintenance of the 
ischemic penumbra through endogenous regulation and exogenous intervention. Primary 
stroke treatment with intravenous tissue plasminogen activator is the most widespread 
method of restoring blood flow to the ischemic defect; however, it is an aggressive 
approach that can lead to undesirable complications, primarily hemorrhagic 
transformation
1
. For this reason, there is much interest in uncovering novel methods for 
cerebrovascular conditioning before stroke onset.  
Clinical trials have suggested a combination of extended-release dipyridamole 
(DIP) and low dose aspirin, both antithrombotic drugs which limit platelet activation, as a 
cornerstone for reducing stroke incidence in high-risk patients
2
. In addition to its 
antithrombotic ability, DIP offers many pleiotropic, neuroprotective properties and has a 
lower propensity for bleeding when compared to aspirin
3, 4
. DIP conditioning may 
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ameliorate the effects of stroke, if it were to occur; however, clinical observations are 
conflicting regarding this issue
5-7
. Therefore a multi-modal experiment is warranted to 
verify the possible neuroprotective benefit of pre-stroke DIP administration. 
 Pre-clinical animal models of focal ischemia are imperative to evaluate vascular 
changes and outcome throughout the acute ischemic stroke (AIS) setting. Animal models 
have notable advantages over clinical studies: 1) in animals, final infarct volume from 
brain tissue staining can be delineated minutes after euthanasia, limiting infarct expansion 
into penumbral tissue, as opposed to imaging based final infarct delineation in humans; 2) 
when assessing drug efficacy in humans, inconsistent dosing and different baseline 
characteristics (ie. other medications and underlying vascular pathologies) can skew 
clinical results
8
. In comparison, controlled drug administration and baseline homogeneity 
can be achieved non-clinically; 3) Serial imaging is feasible with animal models, as 
radiation dose and/or potential toxicity from contrast is not an issue.  
 Large vessel mechanical- or filament-induced occlusions, thrombotic infusion and 
endothelin-1 induced vasoconstriction have been used successfully to create focal 
ischemic territories; however, these techniques do not completely simulate human AIS 
pathophysiology, posing a problem when establishing neuroprotective treatment 
efficacies. Thus, an AIS induction method which involves embolic occlusion of a large 
vessel, usually the middle cerebral artery (MCA), by an autologous blood clot is an 
appropriate model to investigate the pathophysiology related to thromboembolism. The 
most common thromboembolic MCA occlusion technique, first described in canines, 
involves injection of a fibrin rich autologous blood clot into the internal carotid artery 
(ICA) via a ligated external carotid artery (ECA) in rats
9, 10
. This technique has since been 
applied to rabbits who, unlike rats, have a complete Circle of Willis with anterior and 
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middle cerebral arteries arising from the ICA, similar to that in humans
11
. The rabbit 
embolic large/small clot stroke models were first developed to investigate the effects of 
anticoagulants on cerebral perfusion and intracerebral hemorrhage
12
. Since then, these 
model have been used reliably to examine the efficacy of several AIS treatment 
strategies, including one of the first studies to show benefits of tissue plasminogen 
activator (tPA) administration
13-16
. The models produce a homogeneous stroke, and clot 
placement is easily confirmed with hemodynamic measurements from computed 
tomography perfusion (CTP) or magnetic resonance imaging (MRI). Nonetheless, the 
ligation of the ECA and its branches may cause damage to muscles involved in 
mastication, causing accelerated weight loss and misinterpretation of neurological 
outcome
17
.  
 The purpose of this work was to 1) develop an improved, reproducible rabbit large 
clot embolic model (RLCEM) of focal cerebral ischemia, assessed with the CT perfusion 
(CTP) imaging modality, while maintaining adequate perfusion to extra-cranial 
structures, and 2) implement this modified RLCEM to examine the effect a common 
secondary stroke anti-thrombotic treatment, dipyridamole, on stroke severity.  
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7.2 MATERIALS & METHODS 
7.2.1 Surgical procedures 
Study procedures were approved by our institutional review board
+
. Twenty male New Zealand 
white rabbits (2.7-3.6 kg) were randomized to either DIP treatment (n=10) or saline treatment 
(n=10). Seven days before stroke onset anesthesia was induced with 5% isoflurane, with 
subsequent ‘pedal reflex’ to test for deep pain response. Close monitoring of CO2 levels and 
‘pedal reflex’ response throughout the entire experiment ensured the animal was properly 
anesthetized. A cannula was inserted into a saphenous vein, and a single bolus of 
ketamine/diazepam (3mg/kg, 0.3mg/kg) was administered to maintain anaesthesia during 
intubation. Subsequently the rabbit was ventilated with 4% isoflurane. The right jugular vein 
was exposed, tied off and catheterized at 2cm proximal to the heart. The opposite end of the 
catheter was fed subcutaneously to a battery-powered infusion pump (Med-e-cell, Sandiego, 
CA), fixed behind the head. Pumps were filled with either 5mg/ml pharmaceutical grade DIP 
(Pharmaceutical Partners Canada, Richmond Hill, ON) or 9mg/ml sterile saline. The infusion 
was continued for 7 days at 0.08ml•h-1. At 4 and 7 days after insertion of the infusion pump, 
blood was collected from an ear-artery to determine the plasma concentration of DIP 
spectrofluorometrically (F-7000, Hitachi High Technologies America, Inc., Santa Clara, CA). 
Samples were excited with light at a wavelength of 420 nm and fluorescence spectra were 
recorded in the range of wavelengths from 430-660 nm and compared to standard calibration 
solutions. The calibration solution was made by dissolving 1 mg of DP into 20 ml of alcohol 
with subsequent dilution to 100 ml with water
18
. Sodium hydroxide solution was added as  
__________________________________ 
+
Appendix H – Animal Ethics Approval Form 
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necessary to achieve a physiological pH (Microprocessor pH meter, Hanna Instruments, Ann 
Arbour, MI).   
On the last day of treatment, the left internal carotid artery (ICA) was exposed under 
5% isoflurane and tied off at the common carotid bifurcation. An 18 gauge catheter was 
advanced 1.5cm into the ICA, at which time a baseline CTP scan was acquired under 3% 
isoflurane. Autologous arterial blood was used to fill 3 thrombin-coated capillary tubes 
(Thrombostat; Sigma-Aldrich, St Louis, Mo). A 3 mm autologous arterial blood clot was then 
injected into the left ICA with 2.5ml of saline 
11
. The catheter was removed and ICA was 
repaired with 8-0 suture. Microvascular clips were removed and reperfusion was observed in 
within ICA, ECA and common carotid arteries (Figure 7.1).   
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Figure 7.1 Methodology for blood clot induction with extracranial perfusion 
preservation 
 
Gross anatomy (A) and diagram of left common carotid artery (CCA), external carotid 
artery (ECA), and internal carotid artery (ICA). (B) An 18-gauge catheter was placed into 
the ICA via an incision in the CCA, for injection of an autologous blood clot into the 
middle cerebral artery (MCA). After injection, the catheter was removed and the incision 
was repaired to allow reperfusion of the CCA, ECA and ICA. A small stenosis (black 
arrow) is observed on the contrast enhanced CT angiography 3D rendered image in (C), 
which confirmed reperfusion of these major arteries. Coronal slices of perfusion weighted 
image (D) describing anatomical regions, with corresponding CBF (E), and CBV (F) 
functional maps. An ischemic defect (red arrow) with hypervolemia (yellow arrow), a 
CBF/CBV mismatch, is present within the left hemisphere, while complete reperfusion of 
extracranial vessels is observed. CTP images are coloured according to a rainbow colour 
scale with red and purple representing high and low values, respectively: CBF, 0-180 
ml·min
-1
·(100g)
-1
; CBV, 0-10 ml·(100g)
-1
. 
200 
 
 
 
 
Additional CTP scans were acquired at 10 and 30 minutes after embolization under 3% 
isoflurane. Animals were then recovered with fentanyl (12.5 mcg patch) and buprenorphine 
(0.1ml/kg) and monitored until stable. CTP scans under 3% isoflurane were repeated at 1, 4, 7, 
14, 21, and 28 days post-embolization if possible (some animals were sacrificed prior to the 
end day due to severe neurological deficits). Neurological testing was done on each scanning 
day blinded to the treatment of the animal 
19
. During CTP scanning, rectal temperature was 
maintained between 37ºC and 39ºC and arterial blood pH, partial pressures of O2 and CO2, and 
mean arterial pressure were monitored. Animals were euthanized with potassium chloride 
injection either on day 28 post or when the animal was assessed a neurological score greater 
than 15 (see Neurological Testing section)
19
. Following sacrifice, the brain was removed to 
locate the embolus, and sectioned for histology.  
 
7.2.2 CT perfusion imaging 
Each CTP scan was performed with a Lightspeed Plus 4 section CT scanner (GE 
Healthcare, Waukesha, WI). A preliminary axial CT scan was used to localize four 5 mm-
thick slices in the supply territories of the middle cerebral arteries
11
. Next, a 5ml bolus of 
300mg·ml
-1
 non-ionic, iodinated contrast (Omnipaque, GE Healthcare, Mississauga, 
Ontario) was injected into a saphenous vein at 0.5 ml•s-1. The head was continuously 
scanned for 50 seconds using 80kVp, 80mA and 1s rotation period. From the acquired 
data, 512 x 512 images were reconstructed at 0.5 second intervals.    
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7.2.3 CTP data analysis 
Each CTP study was analyzed by one author for consistency using commercially 
available CT perfusion software (version 4, GE Healthcare, Milwaukee, Wis; Figure 7.2). 
For each CTP imaging data set, time density curves (TDC) for the arterial input function 
(AIF) and venous output functions (VOF) were obtained from the anterior cerebral artery 
and superior sagittal sinus, respectively. Partial volume averaging of the AIF was 
corrected using the VOF-TDC. Perfusion weighted maps were created by averaging the 
cine CT perfusion images over the duration of the first pass of contrast. Parametric maps 
of cerebral blood flow (CBF; ml·min
-1
· 100g
-1
) and cerebral blood volume (CBV; 
ml·100g
-1
) were calculated by deconvolution of tissue TDCs and the AIF. This 
hemodynamic functional map calculation method has been described previously 
20
. 
Functional maps were further analysed by custom software developed in our lab using 
IDL v6.2 (ITT Visual Information Solutions, Boulder, CO). For each slice, regions of 
interest (ROIs) were manually traced around the ipsilateral and contralateral hemispheres 
using the perfusion weighted functional map, and superimposed onto hemodynamic 
maps. For each ROI, mean CBF and CBV were also determined within the ipsilateral and 
contralateral hemispheres following exclusion of pixels with a CBF > 100 ml·min
-
1
·(100g)
-1
 or CBV > 8 ml·(100g)
-1
 - a technique used to eliminate large vessel 
hemodynamic values, focusing on parenchymal perfusion
21
. 
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Figure 7.2 A typical CT perfusion study and corresponding excised brain slices.  
 
Four contiguous, coronal CTP-derived functional maps acquired 30 minutes post stroke 
for a saline-treated animal. Infarct region (white) on TTC stained excised brain slices, 
analysed at 7 days post stroke, corresponds to the initial ischemic defect shown on the 
CBF [ml·min
-1
·(100g
-1
)] and CBV [ml·(100g
-1
)] maps. Within tissue that is destined to 
infarct, CBV in various regions is still within the normal physiological range. CTP 
images are coloured according to a rainbow colour scale with red and blue representing 
high and low values, respectively: CBF, 0-180 ml·min
-1
·(100g
-1
); CBV, 0-10 ml·(100g
-1
) 
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7.2.4 Neurological testing 
One blinded individual performed all neurological assessments. Spontaneous behaviour, 
reaction to handling, posture, gait, limb hypertonia, righting reflexes, limb reflexes, and 
feeding behaviour were scored separately: 0, normal; 1, mild; 2, moderate; and 3, 
severely impaired, and all scores summed, and averaged for each group
19
. 
 
7.2.5 Post-mortem analysis 
Brain tissue from up to one week post stroke onset was analysed histopathologically 
(Figure 7.3). Minutes after brain excision, brain tissue was cut into coronal sections 
corresponding to the CT scan slice locations and stained with 2,3,5-tetrazolium chloride 
(TTC) to quantify the extent of infarcted tissue – the entire brain was  used for this 
quantification. Additionally, presence, location, and length of emboli were noted. Brain 
tissue was fixed in 10% buffered paraformaldehyde solution for 24 hours, then stored in 
Dulbecco’s phosphate buffered saline (1X) for future histolopathological staining. 
Regions of interest from three tissue types were selected from: i) within the TTC-defined 
infarct, ii) 1.5 mm from the TTC-defined infarct volume (peri-infarct penumbral region), 
and iii) normal tissue contralateral to the infarct. These tissue fragments were embedded 
in paraffin, cut into 5μm thick sections and stained (H&E) to quantify hemorrhage; to 
determine the extent of peri-infarct inflammation with leukocyte quantification; and to 
quantify the extent of peri-infarct apoptosis with caspase-3 staining. All quantification 
was performed by a single individual in a blinded manner. To quantify hemorrhage, each 
section was analysed at a magnification of 100x for the number of visible areas of 
extravascular red blood cells. One and two points were given for each localized and 
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confluent area, respectively, to a maximum of 10 (most severe). Scored sections were 
averaged and used to give an average hemorrhage score for each group. Apoptosis 
quantification was done using an apoptotic index (AI). Sections at 400x magnification 
were used to create digital images, on which apoptotic cells were manually counted, using 
point counting. The AI was calculated, using the entire field of view, as: the total number 
of apoptotic cells / the total number of nuclei. To quantify inflammation, 3 random 2mm2 
areas were chosen for each tissue type, from each section. Each area was given a score 
based on the following criteria: 0 = minimal leukocyte infiltration, 1 = mild, 2 = 
moderate, and 3 = severe. An average leukocyte infiltration score was calculated from all 
sections for each group.  
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Figure 7.3 Examples of histology 
 
Histopathological staining of healthy tissue (A-C), and infarcted tissue from DIP- (D-F) 
and saline-treated (G-I) animals. Column 1, 2, and 3 show hemorrhage (100x 
magnification), leukocyte infiltration (200x magnification), and caspase-3 staining (400x 
magnification), respectively. Column 4 shows excised brain slices for i) normal brain (no 
stroke), ii) saline- and iii) DIP-treated animals.  
 
 
 
 
1 2 3 4
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7.2.6 Statistical Analysis 
The statistical package, SPSS 15.0 (SPSS Inc., Chicago, IL), was used for all analyses. 
Differences were considered significant at p < 0.05. Repeated measures analysis of 
variance was used as an omnibus test to identify significant differences between the DIP- 
and saline- treated groups for all physiological parameters, data collected from CTP 
imaging, and neurological scoring. Differences in mortality were analysed using Fisher 
exact test. Mann-Whitney, non-parametric comparison was used to analyse all 
histopathological data. Linear regression was used to determine the relationship between 
CTP-defined ischemic defects at time of sacrifice and excised brain infarct volumes for 
each animal.  
 
7.3 RESULTS 
Twelve of the twenty animals studied were included in the results (6 DIP, 6 saline; 
average weight: 3.1 ± 0.3 kg). Animals were excluded from the study if there were 
problems in the embolization procedure, or if blood plasma DIP concentrations were not 
therapeutic (< 1 µg/ml plasma)
22
. No differences were observed between the 
physiological parameters of the treated and non-treated groups on any scan day. At 10 
minutes post-embolization, mean arterial pressure (MAP) in both groups increased 
significantly from their respective baseline values (p < 0.05); for the remainder of the 
experiment, average MAP of both groups returned to baseline levels. At 28 days post 
embolization, 66% of the DIP-treated animals survived compared to 0% of the saline-
treated. All saline-treated animals had to be sacrificed on or before day 7 post-
207 
 
 
 
embolization due to severe neurological deficit. The survival times between the groups 
were significantly different (p < 0.05).   
 Figure 7.4 compares mean neurological scores collected from DIP- and saline-
treated animals before each CTP scan. On days 4 and 7, the average neurological score of 
the DIP group was significantly lower than the saline-treated (p < 0.05). On days 14, 21, 
and 28, the average neurological score of the DIP-treated group dropped to below 5 and 
was significantly less than one day post stroke (p < 0.05). 
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Figure 7.4 Neurological Scoring 
 
 
 
Mean neurological scores (mean+SD) for dipyridamole- and saline-treated groups. 
Significant differences were observed between groups on days 4 and 7 (*p < 0.05). 
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 Cerebral emboli were found in 3 of 6 DIP-treated animals and 4 of 6 saline-treated 
animals. Average length of emboli in DIP and saline treated groups were 1.6 ± 0.5 and 
2.3 ± 0.2 mm, respectively. The average percent volumes of infarcted tissue in the 
hemisphere ipsilateral to the stroke were 31 ± 7% and 69 ± 10% for the DIP- and saline-
treated groups, respectively (p < 0.05).  
 Average baseline CBF values for both DIP- and saline-treated groups were 72.9 ± 
3.6 and 74.32 ± 4.9 ml·min
-1
·(100g)
-1
; these were within the normal CBF physiological 
range of 45-75 ml·min
-1
·(100g)
-1
, and similar to values previously reported in our group 
23, 24
. A significant decrease in average CBF was found at 10 and 30 minutes for both 
DIP- and saline-treated animals compared to their respective baseline values (p < 0.05). 
Comparing DIP- and saline-treated animals, average CBF was significantly different on 
days 1 and 4 (p < 0.05). For the DIP-treated group, values on days 4 to 28 were 
significantly higher than values at 10 and 30 minutes post embolus induction (p < 0.05). 
Contralateral hemisphere CBF, averaged over the entire study, for DIP- and saline-treated 
groups was 67 ± 5.2 and 69 ± 4.1 ml·min
-1
·(100g)
-1
 (p > 0.05). There were no significant 
differences in average CBV within the ipsilateral hemisphere within or between groups 
throughout the study (p > 0.05). For both groups, CBV was slightly elevated at 10 and 30 
minutes post stroke. The mean CBV for DIP- and saline-treated, averaged over the entire 
study was 2.5 ± 0.2 and 2.4 ± 0.2 ml·100g
-1
 within ipsilateral hemisphere, and 2.4 ± 0.7 
and 2.3 ± 0.4 ml·100g
-1
 in the contralateral hemisphere, respectively. These values were 
slightly higher than CBV values previously obtained from our group using a microsphere 
technique
25
.  
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Figure 7.5  CTP-defined ischemia versus TTC-defined infarction 
 
 
CT perfusion-defined ischemic defect volume (number of pixels with CBF < 25 
ml·min
−1
·(100g)
−1
 in 4 × 5-mm slices
11
) on the day of sacrifice versus the ratio of TTC-
defined infarct volume/ ipsilateral hemisphere total tissue volume. A positive correlation 
was observed (R
2
 = 0.81) 
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Figure 7.6 Ipsilateral CBF and CBV values  
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(A) Ipsilateral hemisphere mean CBF (ml·min
-1
·100g
-1
). Significant differences (p < 
0.05) were found at 10 and 30 minutes for both DIP treated (#) and saline treated (%) 
animals compared to their respective baseline values. Significant differences (p < 0.05) 
occurred between DIP- and saline-treated animals on days 1 and 4 (*). For the DIP-treated 
group, values on days 4 to 28 were significantly higher (p < 0.05) than values at 10 and 
30 minutes post embolus (ε). (B) Ipsilateral hemisphere mean CBV [ml·(100g)-1]. No 
significant differences were observed within or between time points for both groups (p > 
0.05). CBV was slightly elevated at 10 and 30 minutes post stroke. All values are mean ± 
standard deviation. 
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Figure 7.7 depicts the hemorrhage scores and apoptotic indices for infarct, peri-
infarct and contralateral hemisphere brain tissue. Hemorrhagic infarction was 5 fold 
greater in saline-treated animals (p < 0.05). For both groups, hemorrhage was minimal in 
peri-infarct and contralateral tissue regions. For both groups, apoptosis was significantly 
higher in peri-infarct tissue, compared to infarct and contralateral regions (p < 0.05). 
Within peri-infarct tissue, apoptosis was elevated in saline-treated animals (p < 0.05).  
Comparing DIP- and saline-treated groups, respectively, inflammatory scores 
(median [range]) for infarct, peri-infarct and contralateral tissue were: 2[1-3] and 2[2-3]; 
2[1-2] and 2[1-2]; 0[0-1] and 0[0-1]. Inflammation was significantly lower in 
contralateral tissue for both groups (p < 0.05). Inflammation, within infarct and peri-
infarct regions, was not significantly different within or between groups. 
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Figure 7.7 Hemorrhage and apoptosis indices 
 
 
 
Hemorrhage scores and apoptotic indices for infarct, peri-infarct and contralateral 
hemisphere brain tissue for DIP- and saline treated animals. Hemorrhagic infarction was 
fivefold greater (p < 0.05) in saline-treated animals (asterisk). For both groups, apoptosis 
was significantly higher (p < 0.05) in peri-infarct tissue (number sign). Within the peri-
infarct tissue, apoptosis was elevated (p < 0.05) in saline-treated animals (%). All values 
are mean + standard deviation 
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7.4 DISCUSSION 
This study investigated how dipyridamole (DIP), an antithrombotic drug with antiplatelet 
(AP) properties, improves cerebral circulation and long-term outcome in a modified 
rabbit embolic stroke model. The model is an improvement on the RLCEM, allowing 
reperfusion to the extracranial vasculature. Cerebral hemodynamics were investigated 
using serial CTP imaging, neurological deficit was determined by repeated neurological 
testing, and excised brains were analysed with histopathological staining. Animals fared 
better when treated with a therapeutic dose of DIP before stroke onset: on average, they 
scored better neurologically, had more favourable cerebral hemodynamics 1 day after 
embolization, and smaller infarct volume as defined on TTC stained excised brains. 
Additionally, the DIP-treated group had lower incidence of hemorrhage, and were more 
likely to recanalize. 
Activated platelets in the brain play a central role in accelerating the formation of 
thrombi, instigating  progressive tissue injury 
26
. AP agents are routinely used as a stroke-
prevention strategy for at-risk populations, especially post transient ischemic attack (TIA) 
27
. Even with AP therapy, 4–20% of patients with TIA will have a stroke within 90 days 
of the episode, half of those occurring within the first 48 hours 
28
. As such, exploring the 
potential of AP agents to minimize stroke severity is necessary. DIP has been shown to 
have numerous benefits, which could aid with vascular maintenance/recovery during an 
ischemic episode 
29
. DIP attenuates platelet aggregability through several mechanisms. 
DIP inhibits thromboxane synthase, limiting the conversion of prostaglandin to 
thromboxane, an inducer of platelet aggregation and vasoconstrictor
30, 31
.  Also, by 
limiting adenosine uptake into platelets, DIP initiates the buildup of intraplatelet cyclic 
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adenosine monophosphate (cAMP), blocking the platelet response to ADP 
22
. Adenosine 
has also been shown to promote nitric oxide (NO) production by vascular endothelial 
cells 
32
. NO is a potent vasodilator and inhibitor of platelet activation in its own right 
33
. 
The overall reduction in activated platelets limits both platelet/fibrinogen bridging and 
platelet plugging. These mechanisms may help conserve collateral flow to the ischemic 
tissue periphery, limiting infarct expansion into the penumbra. In this study, average 
ipsilateral CBF in the DIP-treated group returned to pre-stroke levels 24 hours post 
embolus induction. This hemodynamic recovery could be attributed to platelet effects, but 
may also result from an increase in circulating plasmin - DIP has been shown to promote 
plasminogen activator release by endothelial cells, which would encourage fibrinolysis of 
the induced blood clot
34
. On that note, DIP-treated animals had a relative reduction in clot 
size within excised brains compared to the saline-treated counterparts. Still, it is not 
known whether portions of the clot broke off to create downstream microemboli, or the 
fibrin mesh was disentangled by way of plasmin interaction.   
Interestingly, an increased propensity to hemorrhage, which may be expected with 
the use of antithrombotic therapy, was not observed in the DIP-treated animals. This 
result is supported by the European Stroke Prevention Study (ESPS-2), which showed no 
increases in bleeding with the addition of DIP to aspirin treatment compared to aspirin 
alone
2
. In fact, we showed minimal hemorrhagic infarction in DIP-treated animals. 
Although not measured in this study, DIP can decrease the expression of matrix-
metalloproteinase-9 (MMP-9), an enzyme implicated in blood brain barrier (BBB) 
breakdown and inflammation
35
. An increase in reactive oxygen species, especially during 
ischemia, is also a major culprit of BBB dysfunction; when ROS concentrations get too 
high, apoptosis is triggered
36, 37
. DIP can potentially minimize neuronal damage caused 
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by reactive oxygen species (ROS) through prevention of membrane lipid peroxidation, 
and by stimulating the vessel wall’s ROS scavenging capability38, 39. As such, the DIP 
ROS scavenging ability could decrease ROS-induced apoptosis throughout the ischemic 
defect. DIP-treated animals had slightly lower concentrations of cells undergoing 
apoptosis within the peri-infarct regions. Overall, the neuroprotective benefits offered by 
DIP could have important implications for BBB stability and the prevention of 
hemorrhagic transformation, edema and cell death. 
Innate inflammation, beginning at stroke onset, can exacerbate the ischemic defect 
through the interaction of platelets, leukocytes and thrombotic moderators 
26
. Initial 
neutrophil infiltration can obstruct microvascular blood flow via capillary plugging, as 
well as increase vascular permeabililty 
40, 41
. Additionally, ROS and cytokine release from 
neutrophils can cause extravascular parenchymal damage
42
. An increase in adenosine 
levels have been shown to inhibit neutrophil activation by reducing the expression of 
neutrophil adhesion molecules
43
. Although DIP causes intravascular increases in 
adenosine, as described herein, we did not observe a difference in leukocyte infiltration 
between DIP- and saline-treated animals. Given that DIP was administered only prior to 
stroke onset, we can speculate that DIP blood concentrations, around the time of 
euthanasia, were too low to cause inter-group differences in adenosine concentrations, 
and subsequent reductions in neutrophil deactivation.  
There are study limitations which warrant discussion. First, it was difficult to 
obtain accurate cerebral blood volume (CBV) measurements since isoflurane, a potent 
vasodilator, was used as the anaesthetic during all CT perfusion scanning
44
. For both 
groups, a slight increase in mean CBV at 30 minutes post stroke was observed; this could 
be related to the autoregulatory vasodilation phenomenon that occurs during the hyper-
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acute stroke phase, causing a mismatch between CBF and CBV in the ischemic tissue
11
. 
Nonetheless, we did not observe CBV differences within or between groups. Second, 
neurological assessment may have been skewed due to variations in the extent of surgical 
trauma between animals – internal carotid anatomical variability contributed to increased 
surgery time. Third, our sample size was small relative to other studies using rodents; 
however, our serial in-vivo imaging procedures and neurological testing allowed 
comparisons in the same animal to be made over many days of survival eliminating the 
need to use a larger number of animals to achieve the same statistical power. Lastly, it 
was uncertain whether the emboli found within excised brains were originally injected or 
endogenously produced. Even so, this model examines the animal’s ability to deal with 
the injected embolus and its associated pathological manifestations (ie. microemboli, 
inflammation).   
 
7.5 CONCLUSION 
Dipyridamole is given to patients at increased risk of stroke as it decreases the incidence 
of cerebroembolism. Presumably, if stroke was to occur, the pathways involved in 
secondary stroke prevention may be neuroprotective during an ischemic episode. We 
used a novel animal stroke model to demonstrate that pre-morbid treatment with 
therapeutic concentrations of DIP provides a neurovascular advantage post stroke onset. 
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CHAPTER 8 
Conclusion and Future Work 
 
8.1 SUMMARY 
The introduction of this thesis describes the importance of early treatment strategies to 
promote tissue salvage and maintain neuronal function in the two most common stroke 
sub-types, cerebral ischemia and intra-cerebral hemorrhage (ICH). As discussed in detail 
in the previous chapters, the objective of this thesis was to help with the selection of 
patients who will benefit from acute stroke treatment (thrombolytics, anti-
hypertensive/coagulation drugs, surgical techniques), as well as determine if pre-stroke 
neuroprotection can reduce stroke severity. Specifically, CTP thresholds of hemodynamic 
parameters including CBF, CBV and PS for cerebral tissue and BBB status, as well as the 
neuroprotective benefit of a common secondary ischemic stroke preventative drug, 
dipyridamole, were explored. Patients with thromboembolic cerebral ischemia and 
primary ICH were studied, along with the development and implementation of two 
unique animal models of ischemic stroke.   
 In this final chapter, I will review the major findings of my research and discuss 
the implications of the six studies. The discussion will encompass experimental and 
clinical relevance of the methods and results, as well as important areas that require 
further investigation. Although we were successful in demonstrating the ability of CTP 
imaging to verify drug efficacy and monitor stroke progression, considerable work is still 
required before the goal of an individualized stroke treatment is realized. Therefore, an 
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outline of the possible investigations that should follow this work will be included.  
Finally, the major conclusions obtained from this work will be summarized. 
 
8.1.1 Prediction of acute tissue viability for ischemic stroke 
Although much research has gone into the management of acute ischemic stroke (AIS), 
treatment remains limited to revascularization with either intravenous tPA or 
endovascular strategies (including intra-arterial tPA). The use of either treatment depends 
on time since stroke onset, the amount of brain tissue involved, location and size of the 
blood clot, and robust collateral circulation. In general, small and more distal clots which 
are not amenable to mechanical removal, and present less than 4.5 hours from symptom 
onset, are treated with intravenous tPA, while larger and more proximal clots are treated 
up to 8 hours with endovascular techniques. For revascularization to proceed, whether the 
benefit of tissue salvage outweighs the risk of reperfusion injury, particularly 
intracerebral hemorrhage (ICH), is an important consideration. To address this concern, 
we need to know if the infarct is too large such that benefits from tissue salvage may be 
too small in light of possible hemorrhagic transformation, worsening clinical outcome. 
Chapters 2, 3 and 4 address the importance of predicting infarct volume during the AIS 
setting. Using both human and animal studies, we determined that the acute CBF/CBV 
mismatch may, at times, represent tissue that is not salvageable, even upon reperfusion. 
This goes against the central dogma which asserts that autoregulatory maintenance, as 
observed by the increase in CBV, represents electrically silent yet viable tissue. 
Subsequently, we showed that the CBF parameter was optimal for predicting final 
infarction in a retrospective analysis, and also best delineated the hyper-acute infarct core, 
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as defined by MR-diffusion weighted imaging and TTC-histology, in a novel porcine 
model of ischemic stroke.  
 
8.1.2 Role of the CTP-PS parameter in acute stroke 
The CTP-blood brain barrier permeability surface area product (BBB-PS), which 
quantifies the leakage rate of CT contrast dye from the intra- to extra-vascular space, has 
the ability to predict clinical and radiological outcome for patients with intracerebral 
hemorrhage (ICH) secondary to cerebral ischemia and for patients with primary ICH.  
 In the risk versus benefit assessment of revascularization in patients with ischemic 
stroke, it is important to recognize that some patients with small infarct volumes may still 
proceed to symptomatic hemorrhagic transformation. On the contrary, patients arriving 
past the thrombolysis treatment window who still have salvageable tissue, irrespective of 
infarct core size, may also be a candidate for tPA. Therefore, assessment of the acute 
infarct core volume, penumbra volume and integrity of the BBB within infarct, penumbra 
and contralateral normal tissue are necessary in the decision of revascularization. In 
patients with secondary ICH from prolonged ischemia with or without reperfusion, 
admission BBB-PS was higher within the ischemic and contralateral regions compared to 
patients without hemorrhage at follow-up. The patients with secondary hemorrhage had a 
significantly higher PS than did those without hemorrhage. A PS threshold of 0.23 ml
-
1•min-1•(100g)-1 also enabled the differentiation of patients with HT from those without. 
 For patients with primary ICH, admission BBB-PS was the highest in patients 
withthe CT angiography (CTA)-Spot Sign compared to those with Post-contrast CT 
Leakage (PCL) and those without CT contrast extravasation. Moreover, increased BBB-
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PS was correlated with hematoma expansion. Measuring the rate of leakage provides a 
quantitative method to study the degree of BBB derangement on hematoma expansion. 
The high PS values obtained in patients with the CTA Spot Sign emphasize the rapid rate 
of contrast extravasation, reinforcing the need for a rapid and efficient treatment in this 
subgroup of patients.       
 These two acute stroke studies were the first to use quantitative CTP-BBB PS 
parameter to predict clinical and radiological outcome in patients with primary and 
secondary ICH. Using the admission BBB-PS parameter can inform treatment decisions 
for both of these stroke sub-types. 
 
8.1.3 Reducing stroke severity with secondary prevention drugs 
Antiplatelet (AP) drugs are universally recognized for their effectiveness in reducing 
recurrent stroke in high risk patients
1, 2
. If stroke does occur, extending the tPA 
therapeutic window and minimizing long term morbidity may be an additional benefit of 
this treatment. Dipyridamole (DIP) is prescribed clinically in extended-release form as a 
secondary stroke treatment, and is primarily recognized as an antithrombotic agent with 
AP properties
3
. DIP offers both platelet and non-platelet neuroprotective benefits and, 
unlike aspirin, has a lower propensity for bleeding
4
. Using a novel rabbit large clot 
embolic model (RLCEM), we found that administration of therapeutic concentrations of 
DIP improved ipsilateral CBF at 24 hours after stroke induction. The RLCEM mimics the 
clinical situation in which a patient would take DIP as a secondary treatment and still 
suffer a stroke thereafter. The antithrombotic action of dipyridamole seems to be 
mediated by two complementary mechanisms: i) an anti-platelet action, which reduces 
thrombi formation, and ii) induced tPA release by endothelial cells, which breaks down 
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established thrombi through plasmin activation, and subsequent fibrinolysis. As such, DIP 
has implications for both primary and secondary stroke prevention. 
 Anti-platelet drugs are now emerging as potential treatments of the inflammatory 
response of ischemic stroke. Adenosine level increases, initiated by DIP, have been 
shown to inhibit neutrophil activation via reduction in expression of neutrophil adhesion 
molecules
5
. There was an increase in H&E stained neutrophils throughout the ipsilateral 
cerebral parenchyma of non-treated animals out to 7 days – DIP treated animals had 
minimal neutrophil staining at that time. Neutrophils are generally associated with acute 
inflammation; therefore their presence during the sub-acute stroke stage would suggest 
acute inflammatory processes are continuing to occur and that DIP may reduce the 
inflammatory processes initiated by neutrophils during the sub-acute stroke stages. 
      Dipyridamole (DIP) is given to patients at increased risk of stroke as it 
decreases the incidence of cerebroembolism. Presumably, if stroke was to occur, the 
neuroprotective pathways involved in secondary stroke prevention may be of benefit 
during an ischemic episode. These neuroprotective pathways are linked to suppression of 
inflammatory processes, which have direct and indirect effects on thrombus formation 
and vascular endothelium. As such, acute stroke interventions should implement anti-
inflammatory mediators, which include anti-platelet drugs, into practice.  
 
8.2 EXPERIMENTAL & CLINICAL RELEVANCE 
The studies described in this thesis contribute important information for the advancement 
of acute stroke diagnosis and treatment.  The animal studies described in Chapters 4 and 7 
employed two clinically relevant models of acute ischemic stroke that reproduces a 
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number of important features of the human disease.  These models allowed us to monitor 
infarct expansion by making consecutive CTP measurements over the first few hours 
following stroke; this information is not readily obtained in the clinical setting.   
 One of the current problems in acute ischemic stroke care is that the number of 
patients that receive treatment remains very low. Thrombolysis and mechanical clot 
removal are the only two treatments approved for clinical use. Treatment using 
mechanical retrieval is very limited; thrombolysis is more widely available, but it is 
restricted to a small percentage of patients. One of the major limiting factors for 
reperfusion therapy is the narrow 4.5 to 8 hour time window that is mandated for 
thrombolysis and mechanical clot removal, respectively. The use of the admission 
NCCT/CTA can help clinicians make thrombolytic treatment decisions by providing 
evidence of early ischemic changes and vessel occlusion status; however, without 
perfusion data, information on the severity of hypoperfusion is lacking, a critical factor 
when deciding to reperfuse - the rate of neuronal death differs for tissue with a CBF of 5 
ml·min
-1
·100g
-1
 versus 12 ml·min
-1
·100g
-1
 between 1-3 hours; although both CBF values 
will ultimately cause infarction sub-acutely. Moreover, we can observe an unremarkable 
admission NCCT for a patient with infarct core perfusion values because hypoperfusion 
has not been established long enough. Therefore, to improve the thrombolytic selection 
criteria, it is important to include only those patients with a substantial volume of 
penumbra to salvage, for which accurate infarct core delineation is critical. This approach 
could be implemented using CTP imaging and applying the thresholds derived from this 
thesis. 
 A number of important criteria must be satisfied if a technique for improving 
patient selection will gain widespread clinical use. Among the most important 
229 
 
 
 
requirements are: wide availability, minimal cost, rapid and accurate assessment of 
penumbra and infarcted tissue. As we have shown in this thesis, CTP imaging is one 
potential candidate that satisfies most of these requirements.  CT scanners are widely 
available around the clock in most hospitals and relatively inexpensive compared with 
other imaging techniques. CTP imaging requires less than three minutes of scan time and 
the functional maps can be calculated within 5-7 minutes.   
 Another important aspect of the work contained within this thesis was the 
identification of specific thresholds for grey and white matter. Given the different 
metabolic needs, specific thresholds for each tissue type have the ability to improve 
classification of penumbra and infarct. Implications of these tissue-specific thresholds 
extend beyond patient selection for revascularization procedures and may be important in 
future studies of neuroprotection.   
 
8.3 FUTURE WORK 
This thesis addresses many important questions concerning the diagnosis, prognosis, and 
treatment of acute stroke.  However, as is customary in research, for every question 
answered there are a number of new questions raised.  The following section will outline 
potential new directions of research. 
 
8.3.1 Improved calculation of CTP functional maps 
To improve the image quality of the functional maps, we will use a newer iterative CT 
image reconstruction technique and advanced image processing techniques including: 1) 
masked smoothing, where smoothing is guided by a tissue mask derived from the average 
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image of the source CTP images and 2) principal component analysis where the main 
features (components) of all time-density curves from the raw CTP images are extracted 
using a statistical procedure and then individual pixel time-density curves are smoothed 
by reconstituting them with these main components that are not dominated by noise
6
. 
These improvements in processing will be applied to the future studies described below. 
 
8.3.2 Multi-variate prospective study to determine secondary ICH 
To further improve the selection of patients for thrombolytic therapy, a predictive model 
based on the acute infarct volume and BBB-permeability will be established using the 
CTP thresholds obtained in this thesis.  Further, we will investigate whether a second 
(higher) BBB-PS threshold would predict symptomatic versus non-symptomatic 
hemorrhage – it is speculated that less severe forms of hemorrhage may not be clinical 
relevant and represent different pathogenesis
7
.   
 
8.3.3 Minor stroke and transient ischemic attack 
Patients with transient ischemic attack (TIA) and minor strokes are often excluded from 
revascularization treatment because their neurological deficits are transient or mild; 
however, these patients can often have subsequent stroke
8
. TIA confers a 10% risk of 
stroke within 30 days, one half of these occurring within 48 hours; a proportion of these 
sub-acute episodes are simply due to worsening of initial minor stroke
9
. Further, long 
term disability has been shown to occur in patients with mild symptoms at presentation 
and without recurrent events
8
. In these patients, cerebral perfusion pressure (CPP) may 
have fallen to a level that needs to be corrected promptly to prevent an impending stroke. 
Knowledge of CPP, along with basic clinical parameters, may be used to guide treatment 
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and predict clinical outcome. CPP is inversely related to the tissue mean transit time 
(MTT) which measures the time required for blood/contrast to traverse the tissue 
vasculature under prevailing CPP. A related parameter to MTT is Tmax which is the sum 
of MTT and the time blood requires to reach the local tissue distal to an obstruction via 
collaterals. Determination of the optimal MTT (Tmax) threshold may predict impending 
disabling stroke in patients with TIA/minor stroke (NIHSS <4).  
 
8.3.4 Voxel based classification 
An inherent limitation of the studies described in this thesis is the region of interest 
analysis that was used to derive the hemodynamic thresholds. The thresholds derived 
from this method depend on the mean value of the regions; therefore, the true thresholds 
for infarction and BBB permeability may be different than those identified in this study. 
To more accurately determine the thresholds, independent of the mean regional values, 
voxel or pixel based thresholds can be applied.  These thresholds could be derived in a 
similar manner to the region of interest thresholds by obtaining hemodynamic values 
from all voxels within the ischemic region.  Voxels could then be classified, based on 
delayed imaging.  
 
8.3.5 Comparing AIS therapeutics 
Using the RLCEM developed in this thesis, anti-thrombotic therapeutics in the AIS 
setting can be compared. One treatment regimen, Clopidogrel monotherapy, has been 
shown to reduce recurrent stroke, but may not improve the functional severity post stroke 
onset, and has a propensity to cause intracranial bleeding
10
. This secondary stroke 
preventative agent is typically given as an alternative to Aspirin or Dipyridamole
11, 12
. 
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Using a similar methodology as described in chapter 7, investigation and comparison of 
the effect of pre-morbid administration of anti-thrombotic drugs, which have anti-platelet 
and pleiotropic properties, in the setting of embolic ischemic stroke are possible.  
 
8.3.6 
18
F-Flumazenil imaging in porcine AIS model  
To determine the volume of acute infarct core the use of the 
18
F-flumazenil tracer, a 
central benzodiazepine receptor antagonist, could be utilized in the porcine model of AIS 
developed in this thesis
13
. Using a similar methodology as described in chapter 4, a 
comparison of infarction volume, as defined by contemporaneous CTP imaging, MR-
DWI and PET imaging, is possible. Moreover, an attempt to determine hemodynamic 
thresholds for penumbral tissue using the CTP-CBF/Tmax mismatch, while comparing 
the predicted infarct core to final infarct volume, defined using TTC histology can be 
achieved. Moreover, infarct core and penumbra volumes derived from CTP imaging 
could be compared with MR-perfusion weighted imaging as well as MR-arterial spin 
labeling sequences.  
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8.4 CONCLUSION 
In summary, the significant findings in this thesis include: 
 
1. As shown in the clinical studies and study with a novel porcine model of ischemic 
stroke, very low CBV is indicative of infarct core, while acute and sub-acute 
hypervolemia may be nutritive or non-nutritive. Moreover, the CBF parameter 
was optimal for prediction of infarct volume. 
 
2. Blood brain barrier integrity within the first few hours of stroke onset can be 
measured with the CTP-PS parameter. PS values can predict radiological and 
clinical outcome in the primary and secondary ICH stroke sub-types.  
 
3. Pre-morbid administration of dipyridamole, a common secondary preventative 
drug, may extend the tPA treatment window and reduce stroke severity.  
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Appendix D 
Method to determine the optimal CT perfusion hemodynamic thresholds 
for gray and white matter in the setting of acute stroke 
 
Patients and Imaging 
 Twenty-one patients, from the analysis in Chapter 5, had CTA confirmed full 
recanalization at 24 hours, confirmed with the modified TIMI score
1
. All imaging was as 
described in Chapter 5. Briefly, the CTP study scanned eight 5 mm thick sections of the 
brain in 2 phases together with contrast injection via an antecubital vein at a rate of 2-4 
ml/s. The first phase was a 45-second continuous (cine) acquisition reconstructed at 0.5-
second intervals to produce a series of 89 sequential images for each section. The second 
phase followed 15 seconds after the completion of the first phase and scanned the same 
eight sections at 15-second intervals for an additional 90 seconds. CBF, CBV, Tmax, a 
special ‘Time-density curve (TDC) truncation’ functional maps and a perfusion-weighted 
map were calculated from the acquired 2-phase contrast enhanced dynamic images as 
described previously
2
.  
 
Image Analysis  
CTP functional maps of CBF, CBV, Tmax, and perfusion weighted images (PWI) were 
calculated with CT Perfusion 4D, delay insensitive software (GE Healthcare), as 
described in Chapter 1. Using custom software (IDL v6.2, RSI Inc.), follow-up images 
from 5-7 day post stroke were registered to baseline images to adjust for movement 
between the scans. The PWIs of the CTP studies were used to segment gray and white 
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matter based on Hounsfield Unit thresholds. The resulting gray and white matter masks 
were applied to the admission CBF and CBV maps to obtain average gray and white 
matter values for infarcted tissue - pixels with CBF > 100 ml∙(100g)-1∙min-1 or CBV > 8 
ml∙(100g)-1 were excluded and not used in calculating average CBF and CBV values for 
regions of interest (ROI) to remove contributions from large vessels. Final infarction was 
outlined on the registered 5-7 day follow-up imaging. These infarct ROIs were 
superimposed onto the admission CTP functional maps. The critically hypoperfused tissue 
(relative Tmax > 2), if present, was outlined on the admission Tmax map, and the 
gray/white matter mask was applied
3
. The area outside of the infarct ROI and within the 
area of critical hypoperfusion was operationally defined as penumbra. Logistic regression 
analysis was performed using all data points. Gray and white matter CBF, CBV, and an 
interaction term CBF·CBV were included as potential predictors in the regression model.  
Sensitivity and specificity for infarction were calculated from the resulting regression 
model.  
 
Statistical Analysis 
 Logistic regression analysis was performed on functional data of all infarct and 
penumbra. Gray and white matter CBF, CBV, and an interaction term CBF·CBV were 
included as potential predictors of infarct vs penumbra in the regression model.  
Sensitivity and specificity for infarction were calculated from the resulting regression 
model. All statistical analyses were performed using SPSS 13 for Windows (SPSS for 
Windows, SPSS Inc.). 
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Results  
Gray matter thresholds 
Average CBF and CBV gray matter tissue that was infarcted on the 5-7 day NCCT was 
5.60 ± 2.63 ml∙(100g)-1∙min-1 and 1.68 ± 0.82 ml∙(100g)-1, respectively. Average CBF and 
CBV values for ischemic regions on the admission CTP that were not infarcted on the 5-7 
day NCCT (Penumbra) were 20.10 ± 4.41 ml∙(100g)-1∙min-1, and 1.68 ± 0.82 ml∙(100g)-1. 
Contralateral CBF and CBV values were 29.64 ± 9.53 ml∙(100g)-1∙min-1 and 2.75 ± 0.63 
ml∙(100g)-1. Univariate logistic regression using admission CBF, CBV or CBF*CBV as 
predictor was performed. Optimal gray matter CBF, CBV and CBF•CBV product 
thresholds to separate penumbra from infarct were 10.1 ml·min
-1
·(100g)
-1
, 1.9 ml·(100g)
-
1
, and 26.0, respectively. The regression model using the CBF parameter resulted in the 
highest sensitivity (95.2%, 20/21) and specificity (95.2%, 20/21) for infarction, with an 
overall accuracy of (95.2%, 40/42) of tissue types classified correctly (Figure A1). 
   
White matter thresholds 
Average CBF and CBV gray matter tissue that was infarcted on the 5-7 day NCCT was 
5.86 ± 1.32 ml∙(100g)-1∙min-1 and 1.04 ± 0.61 ml∙(100g)-1, respectively. Average CBF and 
CBV values for ischemic regions on the admission CTP that were not infarcted on the 5-7 
day NCCT (Penumbra) were 12.27 ± 3.26 ml∙(100g)-1∙min-1, and 1.70 ± 0.61 ml∙(100g)-1. 
Contralateral CBF and CBV values were 21.18 ± 6.89 ml∙(100g)-1∙min-1 and 1.33 ± 0.50 
ml∙(100g)-1. Univariate logistic regression using admission CBF, CBV or CBF*CBV as 
predictor was performed.  Optimal white matter CTP-CBF, CBV and CBF•CBV product 
thresholds to separate penumbra from infarct were 7.4 ml·min
-1
·(100g)
-1
, 1.25 ml·(100g)
-
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1
, and 9.9, respectively. The regression model using the CBF•CBV product resulted in the 
highest sensitivity (93.8%, 15/16) and specificity (87.5%, 14/16) for infarction, with an 
overall accuracy of (90.6%, 29/32) of tissue types classified correctly (Figure A1).  
 
 
 
Figure A1 Thresholds for infarction for gray matter CBF, CBV and CBF·CBV 
 
 
Gray matter values for all Infarct (n=21) and Penumbra (n=21) regions of interest with the 
solid line representing the optimal threshold to separate infarct from penumbra, the upper 
and lower dashed lines represent the 5% and 95% probability for infarction, derived from 
univariate logistic regression with A) CBF, B) CBV, and C) CBF·CBV product as 
predictor. CBF provided the best classification of penumbra and infarct regions with a 
sensitivity of 95.2%, (20/21) regions), and specificity of 95.2%, (20/21 regions), and 
overall accuracy of 95.2% (40/42).  
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Figure A2 Thresholds for infarction for white matter CBF, CBV and CBF·CBV 
 
 
 
White matter values for all Infarct (n=16) and Penumbra (n=16) regions of interest with 
the solid line representing the optimal threshold to separate infarct from penumbra, the 
upper and lower dashed lines represent the 5% and 95% probability for infarction, derived 
from univariate logistic regression with A) CBF, B) CBV, and C) CBF·CBV product as 
predictor. The CBF·CBV parameter provided the best classification of penumbra and 
infarct regions with a sensitivity of 93.7%, (15/16 regions), specificity of 87.5%, (14/16 
regions), and overall accuracy of 90.6% (29/32 regions).   
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Appendix F 
Tracer Kinetic Modeling 
 
The Johnson and Wilson model used in this study is a refinement to compartmental 
models which have previously been used to measure PS  in the context of tumors
1,2
. 
Because contrast agents are not metabolized in tissue and excluded from cell entry, the 
modeling of contrast agent distribution calls for only two compartments, the plasma and 
interstitial space, with bidirectional exchange via passive diffusion between the 
compartments. Groothuis et al. were the first to apply compartmental models in CT 
scanning to measure this parameter
3,4
.  Compartmental models can only measure PS and 
CBV, not CBF, because when PS is much smaller than CBF, contrast distribution in the 
brain is only determined by diffusion.  The Patlak approach simplifies the compartmental 
model by assuming the absence of contrast agent backflux from the interstitial to the 
intravascular space
4,5
. Under the Patlak assumption, the normalized tissue concentration is 
linearly related to the normalized integral of the artery input function with the slope and 
intercept of the linear regression equal to PS and CBV
5
.  Notably, the Johnson and 
Wilson model used in this study does not require us to invoke the Patlak assumption, 
which is likely not valid for contrast agent behavior in the brain with a ‘leaky’ BBB. 
Unlike compartmental models, it also allows CBF to be estimated together with CBV and 
PS. Kinetics of contrast distribution in the brain using the Johnson and Wilson model  
applies to the entire brain independent of whether the blood-brain barrier is intact. 
 The model divides the brain into two principal spaces: the intravascular space 
(IVS) and the extra-vascular space (EVS), separated by a capillary endothelium of 
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variable permeability and therefore applies to both leaky and non-leaky blood-brain 
barrier. Three basic assumptions concerning contrast kinetics in the brain were made in 
the model
6
. First, the permeable capillary endothelium allows bidirectional diffusion of 
contrast between EVS and IVS. Second, there is an axial contrast concentration gradient 
in the capillaries but the radial concentration gradient is assumed to be negligible. Third, 
within the EVS, the tracer concentration is assumed to have a homogeneous spatial 
distribution. St Lawrence and Lee had derived the adiabatic approximation solution which 
simplifies the calculation of parametric maps with the Johnson and Wilson model
7
. The 
adiabatic approximation assumes that the EVS contrast concentration is changing slowly 
(i.e. in a quasi-steady state) relative to the rate of change of concentration in the IVS 
(capillaries). Under this approximation, the impulse residue function, H(t), can be 
represented simply as: 
 
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where cT  is the capillary mean transit time (MTT) and F is cerebral blood flow (CBF), so 
that cerebral blood volume (CBV) is F·Tc according to the Central Volume Principle
8
. E 
is the contrast extraction fraction  and eV  is the EVS contrast distribution volume. E 
relates to the PS of brain capillaries (blood-brain barrier) via the following relationship: 
[2]                                                                                  e1E F
PS







  
If Ca(t) is the arterial input function to the brain, then the measured brain tissue  curve, Q 
(t), can be calculated as the convolution of Ca(t) and H(t): 
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where * is the convolution operator and To is the appearance time of brain contrast 
relative to that in the input artery. The validity of Equation 3 assumes that brain blood 
flow is constant and Q (t) is linear with respect to Ca(t). With Q(t) and Ca(t) measured in 
a CT Perfusion study, CT Perfusion 4 (GE Healthcare) estimates the parameters: CBF, 
CBV, MTT, PS and To by iteratively changing their values until an optimum fit to Q(t) is 
achieved via Equations 1-3. 
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